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General introduction  
and background

Chap te r  1
Introduction, scope and 




The prevalence of obesity (body mass index, BMI>  30 kg/m2) and morbid obesity 
(BMI> 40 kg/m2) is increasing across the globe 1­2. Mexico and the US seem to deal with 
the highest obesity prevalence rates among adults, 32% and 35% respectively 1, 3, while 
the estimated obesity prevalence rates for 2013 show that >50% of the women in Kuwait, 
Libya and Qatar are obese 4. The average prevalence of obesity in Europe is estimated 
between 18­21% in 2013. In the Netherlands approximately 35% of the population is 
overweight (BMI>25 kg/m2) and 13% obese 5. Numbers of morbid obesity in Europe 
are lacking, but are estimated to range between 1­7% depending on the country 5­8. A 
global analysis of overweight and obesity prevalence rates suggests that in developed 
countries the increasing obesity trend has attenuated over the past 8 years, while in the 
developing world the trend seems to continue to increase 4.
With obesity and morbid obesity, physiologic parameters may alter. These patients 
are reported to have a lower percentage of fat free mass and water relative to their total 
body weight 9­10, while absolute values of cardiac output and blood volume are increased 
in comparison to non­obese subjects 11. Concerning liver function, non­alcoholic 
steatohepatitis is highly associated with morbid obesity patients and histological liver 
abnormalities such as fatty infiltration are present in approximately 90% of the livers of 
this population 12­13. Furthermore, liver perfusion may be altered due to a combination 
of ballooning of hepatocytes (due to fatty infiltration) and narrowing of the peripheral 
hepatic micro vessels, the sinusoids 14. For renal function, it seems that in obese subjects 
creatinine clearance increases with fat free mass 15 and glomerular filtration is increased 
in overweight and obese subjects compared to non­obese subjects 16­17.
In addition, it has been reported that obese patients have an increased risk to develop, 
among others, thrombosis 18, cardiovascular disease 19, cancer 20, and infections, includ­
ing surgical site infections and other nosocomial infections as well as to develop serious 
complications of common infections21. The underlying causes of this increased risk are 
thought to be related to the metabolic syndrome and the increased inflammation status 
which are both highly prevalent among subjects with (morbid) obesity 22­24.
The physiological changes in obese and morbidly obese patients mentioned 
above may impact the pharmacokinetics and pharmacodynamics of drugs. Therefore 
evidence­based dosing guidelines in the (morbidly) obese population are needed, as 
this population deserves to receive effective and safe pharmacotherapy as much as any 
other patient group. In particular, in view of the increased risk of obese patients to seri­
ous comorbidities, evidence­based dosing is necessary. To reach this goal, knowledge 
on the extent into which these physiologic changes influence absorption, metabolism, 
distribution and elimination of drugs is essential. Ultimately also the influence of obesity 
on the pharmacokinetic­pharmacodynamic relationship should be evaluated.
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In the past decades a substantial number of studies have aimed to evaluate how the 
pharmacokinetics of certain drugs change in obese patients. However, it seems that in 
the vast majority of these studies only overweight (BMI> 25 kg/m2) and obese (BMI> 30 
kg/m2) subjects were included, while today morbidly obese patients (BMI> 40 kg/m2) are 
not uncommon in the daily practice of physicians and pharmacists. In this respect, there 
is a strong need for pharmacokinetic studies after both intravenous and oral drug ad­
ministration in morbidly obese patients to establish evidence­based dosing guidelines 
for this special population.
bArIAtrIC surGerY
Bariatric surgery or weight loss surgery is considered the most effective treatment 
option for morbid obesity 25­26 and results, among other factors, in long term weight 
loss, reduction in overall mortality and remission of type 2 diabetes 26­27. Adult patients 
with a BMI> 40 kg/m2 or with a BMI>35 kg/m2 with a severe obesity­related co morbid 
condition such as hypertension, impaired glucose tolerance, diabetes mellitus, hyperlip­
idemia, or obstructive sleep apnea qualify for a bariatric surgery procedure 28­29. Bariatric 
surgery comprises of many different types of surgery of which the Roux and – Y gastric 
bypass (RYGB, 47% in 2011) and sleeve gastrectomy (SG, 28% in 2011) are currently 
most performed worldwide, while the adjustable gastric banding procedure has not 
been performed much in recent years (18% in 2011) 30. During a Roux and – Y gastric 
bypass the stomach is reduced to a small pouch and the duodenum and initial part of 
the small intestine are bypassed 31­32. For a sleeve gastrectomy a large portion of the 
stomach along the greater curvature is removed resulting in a tube like structure along 
the smaller curvature 33. The prevalence of bariatric surgery is increasing, with more 
than 340,000 bariatric surgeries performed worldwide in 2011 30. For the Netherlands, 
the media reported a significant increase in bariatric surgeries from 4,000 in 2011 to an 
estimate of 10,000 in 2013 34.
Bariatric patients present physicians and pharmacists with many challenges regarding 
safe and effective drug therapy, as bariatric procedures may impact a drug’s pharma­
cokinetics both due to the anatomical changes made to the gastro­intestinal tract and 
the induced loss in body weight. These anatomical changes may cause an increase in 
stomach pH, an increase in gastric emptying time, and a decrease in the surface area 
of absorption 31, 35, thus potentially affecting a drug’s rate and extent of oral absorption. 
In addition to these anatomical alterations, bariatric patients may lose a substantial 
percentage of their body weight (a mean of 32% of total body weight 0.5­2 years after 
bariatric surgery 26) which may have a major impact on the distribution and clearance 
of a drug 36.
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While case reports have reported a decrease in oral drug exposure of certain drug in 
patients after bariatric surgery (e.g tamoxifen 37, phenytoin 38, imatinib 39), sofar only 17 
clinical studies have aimed to evaluate how a bariatric procedure alters the pharmaco­
kinetics of approximately 25 drugs 31, 36, 40. The results of this limited number of studies 
show a large variation. For some drugs, mean oral absorption remains unchanged 
after a gastric bypass as measured by the oral AUC (e.g. atorvastatin 41, furosemide and 
omeprazole 42), while others, including erythromycine 43, tacrolimus and sirolimus 44 and 
tolbutamide 42, showed a substantial reduction in AUC after an oral dose. In contrast, for 
metformin an increase in oral AUC was reported in 16 patients after RYGB 45. In summary, 
there seems to be a large variation in how bariatric surgery influences drug exposure 
after oral administration 36, whereas it seems that this variation cannot be related to 
the Biopharmaceutics Classification System (BCS) 46. Alternatively, the impact of bariatric 
surgery on the absorption of a specific drug may be predicted based on the type of sur­
gery and knowledge of the involved absorption processes of the drug (e.g. availability of 
transporters, bile salts, main oral absorption site, CYP3A substrate, etc.). However, due to 
the small number of studies, the limited number of patients included, the large variation 
in compounds studied and types of bariatric surgery included in these studies, no such 
conclusion can be derived yet.
Finally, information on how loss in body weight in morbidly obese patients after 
bariatric surgery affects the pharmacokinetics of drugs has only been studied for 8 
drugs 42, 45, 47­48, while it is known that increase in body weight greatly affects clearance 
and particularly distribution of drugs.
the objeCtIve of thIs thesIs
There is a strong need for knowledge on safe and effective pharmacotherapy in morbidly 
obese patients and in addition, in patients which have undergone a bariatric procedure.
As a first step towards evidence­based dosing strategies in morbidly obese patients, 
Chapter 2 presents an overview of studies on drug pharmacokinetics including both 
obese and non­obese subjects, sorted by metabolic or elimination pathway of the drug. 
This overview shows that the impact of obesity on drug metabolism and elimination 
seems to differ greatly between drugs and depends on the metabolic or elimination 
pathway primarily involved in the clearance of a drug. In addition, obesity may also 
impact oral absorption, oral bioavailability and the volume of distribution of drugs. 
Chapter 3 provides an overview of the impact of obesity on absorption, distribution, 
metabolism and elimination of drugs as well as perspectives for future research into the 
influence of obesity on pharmacokinetics. It shows that (morbid) obesity may largely 
impact volume of distribution, while the magnitude and direction of change are difficult 
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to predict, while changes in clearance may be smaller than those on volume of distribu­
tion and may be predictable on the basis of the elimination pathway involved. Lastly, 
it describes that very little is known about the influence of obesity on oral absorption.
The clinical studies presented in this thesis focused on two drugs, i.e. cefazolin and 
midazolam. In Chapter 4 a study is presented which aimed to evaluate the influence 
of morbid obesity on cefazolin pharmacokinetics and penetration into the subcu­
taneous tissue using clinical microdialysis techniques. Cefazolin is a first generation 
cephalosporin antibiotic which is widely applied for the prevention of surgical site 
infections during many types of surgical interventions, including bariatric surgery 49 
and is eliminated completely by glomerular filtration and active tubular excretion 50. It 
was studied because in morbidly obese patients there seem to be more surgical wound 
infections, while cefazolin plasma concentrations seem to reach adequate levels 21, 51. It 
was unknown whether cefazolin reaches adequate levels at the target site, which is the 
subcutaneous adipose tissue around the surgical wounds, in morbidly obese patients..
Chapter 5 presents a study of midazolam population pharmacokinetics in mor­
bidly obese patients. Midazolam was studied because it is the best Cytochrome P450 3A 
(CYP3A) substrate currently available and preliminary evidence indicates that absolute 
clearance of CYP3A substrates is lower in obese patients (Chapter 2) 52. Midazolam is a 
widely applied drug for sleeping disorders, (pre)anesthesia and sedation in the Intensive 
Care. It is metabolized into 1­OH­midazolam by the CYP3A enzyme and is considered a 
model probe for the activity of CYP3A 53­54. CYP3A is an important enzyme system that is 
involved in the metabolism of 25% of all clinically used drugs 55, including many drugs 
that are relevant for obese patients, such as statins, cardiovascular drugs, antipsychotics 
and oncolytic drugs 56. A potentially reduced absolute clearance is highly relevant, be­
cause it may result in prolonged effect of the drug with increased risk of adverse events 
particularly upon prolonged use. As the CYP3A enzyme is located in the liver as well 
as in the gut wall, it determines both systemic clearance and oral drug bioavailability 
of CYP3A substrates including midazolam. For this reason a semi­simultaneous dosing 
design was applied in this study, in which patients first received an oral dose followed by 
an intravenous dose approximately 150 minutes later. This design allowed for both the 
evaluation of systemic midazolam clearance as well as midazolam oral bioavailability.
The influence of bariatric surgery on the pharmacokinetics of midazolam was studied 
in Chapter 6. In this study, eighteen patients of the morbidly obese patients who partici­
pated in the study of Chapter 5 were restudied one year post bariatric surgery using the 
same study design. Midazolam systemic clearance and oral bioavailability were closely 
studied in view of anticipated weight loss together with the anatomical changes to the 
gastro­intestinal tract, respectively.
To further investigate the CYP3A mediated metabolism of midazolam into 1­OH­
midazolam, in Chapter 7 we used midazolam and 1­OH­midazolam data and semi­phys­
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iologically based PK modeling to quantify the influence of bariatric surgery on CYP3A 
activity in the gut wall and liver separately. This evaluation required a more advanced 
model in which also presystemic metabolism of midazolam into 1­OH­midazolam could 
be accounted for.
In Chapter 8, the outcomes of the Chapters 4­7 are summarized and interpreted. 
In addition, perspectives on future studies and directions for evidence­based dosing 
guidelines in morbidly obese and bariatric patients are provided with the latter being 
particularly of relevance for clinical practice. Finally, the relevance of these findings for 
other drugs which share the same elimination pathway are discussed.
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AbstrACt
The prevalence of obesity in adults and children is rapidly increasing across the world. 
Several general (patho)physiological alterations associated with obesity have been de­
scribed, but the specific impact of these alterations on drug metabolism and elimination 
and its consequences for drug dosing remains largely unknown.
In order to broaden our knowledge of this area, we have reviewed and summarized 
clinical studies that reported clearance values of drugs in both obese and non­obese 
patients. Studies were classified according to their most important metabolic or elimina­
tion pathway. This resulted in a structured review of the impact of obesity on metabolic 
and elimination processes, including phase I metabolism, phase II metabolism, liver 
blood flow, glomerular filtration and tubular processes.
This literature study shows that the influence of obesity on drug metabolism and 
elimination greatly differs per specific metabolic or elimination pathway. Clearance of 
cytochrome P450 (CYP) 3A4 substrates is lower in obese as compared with non­obese 
patients. In contrast, clearance of drugs primarily metabolized by uridine diphosphate 
glucuronosyltransferase (UGT), glomerular filtration and/or tubular­mediated mecha­
nisms, xanthine oxidase, N-acetyltransferase or CYP2E1 appears higher in obese versus 
non­obese patients. Additionally, in obese patients, trends indicating higher clearance 
values were seen for drugs metabolized via CYP1A2, CYP2C9, CYP2C19 and CYP2D6, 
while studies on high­extraction­ratio drugs showed somewhat inconclusive results. 
Very limited information is available in obese children, which prevents a direct compari­
son between data obtained in obese children and obese adults.
Future clinical studies, especially in children, adolescents and morbidly obese indi­
viduals, are needed to extend our knowledge in this clinically important area of adult 
and paediatric clinical pharmacology.
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IntroduCtIon
Currently more than 30% of the US population is obese (Body Mass Index (BMI) >30 kg/
m2) 1­2, while approximately 5% have been reported to be morbidly obese (BMI >40kg/
m2) 3. In Europe the prevalence of adult obesity ranges from 9­29% depending on the 
country 4 and increases every year. Also for children strong upward trends are observed. 
According to the national health and nutrition examination survey, conducted in 
2007 – 2008, 17% of US children are obese 5. Upcoming economies, such as China and 
India, also show an alarming increase of obesity in both adults and children with more 
than 30% of Chinese adults being overweight 6. If current trends persist, there will be 
2.16 billion overweight and 1.12 billion obese individuals worldwide in 2030 as com­
pared with 388–405 million obese individuals in 2005 7.
In view of this trend, it is important to understand the impact of obesity on drug 
metabolism and elimination and its consequences for drug dosing in the (morbidly) 
obese population. Obesity and morbid obesity are associated with several (patho)
physiological changes that may influence the pharmacokinetics of drugs. Among other 
factors, obese patients have relatively more fat and less lean tissue per kilogram of total 
body weight than non­obese individuals 8­9. Blood volume is observed to be increased, 
particularly in the morbidly obese 10­11. In addition, studies have confirmed that obese 
patients suffer from low­grade inflammation 12, which is probably the underlying cause 
of the high prevalence of non­alcoholic steatohepatitis (NASH)13­14. NASH has been 
reported to either increase or decrease drug metabolizing enzyme activity 15­18. The net 
effect of obesity on drug metabolism is also influenced by cardiac output and liver blood 
flow, both of which are shown to be increased in obese patients 19. Concerning renal 
function, a state of glomerular hyperfiltration similar to the condition seen in early­stage 
diabetic nephropathy and sickle cell disease has been reported in obese individuals 20­21. 
Until now, the influence of obesity on tubular processes has been unknown.
In summary, many (patho)physiological alterations associated with obesity have been 
described in the literature, yet the impact of these alterations on specific drug metabolic 
and elimination pathways has not been clearly summarized. Numerous publications 
have described obesity­related alterations in all aspects of drug pharmacokinetics, 
including absorption, distribution, metabolism and elimination of drugs 9, 22­30. In addi­
tion, several publications have tried to provide practical guidelines for dosing in this 
population 9, 23­28. In recent publications, the influence of obesity on drug metabolism 
and renal elimination was stated to be inconclusive and inconsistent, with drug clear­
ance being the most important pharmacokinetic parameter for maintenance dosing 
regimens 9, 22, 24, 27, 30. In some cases, results from animal or in vitro studies have been 
used to fill the knowledge gaps 27, 30. So far, many pharmacokinetic studies have been 
performed in obese patients and these studies may represent a wealth of knowledge 
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on clearance of specific drugs in obesity. In this review our goal was to order and sort 
pharmacokinetic studies by their primary drug metabolic or elimination pathway to 
gain insight into how these pathways change with obesity. Therefore, drugs representa­
tive for a specific pathway were included in the review, in order to generate knowledge 
on obesity­related changes in the most important metabolic and elimination pathways 
in humans. As such, this review provides insight into how obesity affects specific drug 
metabolism and renal elimination pathways in both obese adults and obese children, on 
the basis of results of pharmacokinetic studies in obese and non­obese individuals. For 
this purpose, a direct comparison between drug clearance in obese and non­obese in­
dividuals is necessary: therefore, clinical trials that included both obese and non­obese 
individuals were reviewed in this analysis.
seArCh strAteGY And seleCtIon CrIterIA
Approach
We studied individual drug metabolism and elimination processes by using drug clear­
ance values as surrogate markers for these processes. To allow for direct comparisons 
between obese and non­obese individuals, clinical studies that investigated drug 
pharmacokinetics in both obese and non­obese patients were collected. The drugs re­
ported in these clinical studies were categorized by their currently known rate­limiting 
clearance processes, and absolute clearance values were summarized in tables, which 
is an approach that has been applied before 29. In addition, weight­normalized clear­
ance values were added to provide information on the weight­normalized changes in 
clearance values between non­obese and obese individuals. These weight­normalized 
clearance values were either directly extracted from the original publication or derived 
by dividing mean clearance by mean total body weight. As an alternative to total body 
weight, consideration was given to normalizing clearance values for lean body weight, 
as this parameter is often proposed as a body size descriptor for obese patients 27, 31. Un­
fortunately, this parameter was reported in only very few studies included in this review; 
therefore, it was not possible to report clearance values adjusted for lean body weight.
Clearance processes were divided into metabolism and renal elimination. For drug 
metabolism, phase I metabolism, phase II metabolism and liver blood flow were consid­
ered. Drugs for which information about the rate­limiting cytochrome P450 (CYP) pro­
cess was inconclusive were included in the Other Phase I Metabolism section. For renal 
elimination, two processes involved in drug elimination by the kidneys were identified: 
glomerular filtration and tubular processes (tubular secretion and tubular reabsorption).
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Inclusion criteria
Papers from the international peer reviewed literature reporting drug pharmacokinetics 
in obese and normal­weight adults or children were eligible for inclusion. Drugs were 
included if cleared by a specific metabolic or renal elimination pathway, as reported in 
international peer reviewed literature. This reference about the drug’s main metabolic or 
elimination route was included in the tables.
search terms and search results
The PubMed database was used for the search for papers in which the pharmacokinet­
ics of a drug were studied in both an obese and non­obese population. The following 
search terms were used:
­ (Clearance[All Fields] AND (‘obesity’[MeSH Terms] OR ‘obesity’[All Fields])) AND 
(controls[All Fields] OR normal[All Fields] OR healthy[All Fields]), yielding 562 results 
on 2 March 2011.
­ ‘[Substrate]’ and ‘obesity’ and ‘pharmacokinetics’. Substrates mentioned in Cyto­
chrome P450 Drug Interaction Table were used 32. A total of 91 (CYP3A4), 10 (CYP2E1), 
35 (CYP2D6), 43 (CYP1A2), 23 (CYP2C19), 14 (CYP2C9), 1 (CYP2C8), 7 (CYP2B6) papers 
of interest were found between March and May 2011.
­ ‘[Kidney process]’ and ‘obesity’ and ‘pharmacokinetics’. A total of 18 (glomerular), 5 
(tubular secretion) and 2 (tubular reabsorption) papers of interest were found be­
tween May and June of 2011.
Additionally, references in the selected articles were checked for additional publications 
to include in this review.
exclusion criteria
From studies investigating pharmacokinetics of drugs in both obese and non­obese 
patients, the following studies were excluded: studies on drugs for which the metabolic 
or renal elimination pathway was reported to be miscellaneous, unknown or inconsis­
tent, as concluded from peer reviewed literature; studies investigating endogenous 
substances (including insulin); pharmacodynamic studies; animal studies; case reports; 
and in vitro studies.
druG MetAbolIsM
Drug metabolism predominantly occurs in the liver through enzymes responsible for 
the modification of functional groups (phase I reactions) and the conjugation of endog­
enous substituents to drugs to make them even more polar (phase II conjugation) 33.
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In 90% of obese patients, histologically proven liver abnormalities as fatty infiltration 
are present 34. Non­alcoholic fatty liver disease (NAFLD) may range from simple liver ste­
atosis without inflammation to non­alcoholic steatohepatitis (NASH) with active hepatic 
inflammation. NASH prevalence is difficult to assess, because the diagnosis can only be 
confirmed using a liver biopsy. However, it is estimated that up to 20% of the obese 
population and up to 50% of morbidly obese patients have NASH 35, and its incidence 
correlates with BMI (kg/m2) 36. While fatty infiltration of the liver may result in altered 
enzyme activity of phase I or II systems, this enzyme activity may also be subject to 
changes caused by other obesity­associated (patho)physiological changes such as the 
chronic state of inflammation 12, 16.
To describe the enzyme activity of phase I and II systems in obesity, we provide in 
this section an overview of clinical studies investigating drugs of which clearance is 
dependent on phase I or II reactions or liver blood flow and which were studied in both 
obese adults or children and non­obese adults or children in one report.
Phase I metabolism
Phase I enzymes catalyse the modification of functional groups of a substrate (i.e. oxi­
dation, reduction and hydrolysis), and the majority of these enzymes consist of CYPs. 
CYPs are predominantly located in the endoplasmatic reticulum of hepatocytes. Other 
sites include the gastro­intestinal tract, where significant amounts of gene expression 
of various CYP isoforms have been detected 37­38. CYP enzyme metabolism contributes 
to approximately 75% of all drug metabolism 39. In this section, we provide an updated 
review of all studies that have investigated phase I­mediated drug clearance in both 
obese and non­obese patients in one report.
Cytochrome P450 (CYP) 3A4
CYP3A4 is involved in the phase I metabolism of approximately 50% of all drugs 40. In 
table I, an overview of the studies comparing clearance of CYP3A4­metabolized drugs 
in both obese and non­obese individuals is presented. The pharmacokinetics of ten 
CYP3A4 substrates in obese versus non­obese subjects have been reported, including 
alfentanyl, midazolam, triazolam, alprazolam, cyclosporine, carbamazepine, docetaxel, 
taranabant, trazodone and N­methyl­erythromycin.
As an in vivo probe of CYP3A4 activity, N­methyl­erythromycin, midazolam, triazolam, 
alprazolam and cyclosporine are widely applied 41­46. In this respect, it was reported that 
obesity was significantly associated with lower metabolism of [14C]­N­methyl­eryth­
romycin, measured as exhaled 14CO2 in both men and women (r2= 0.91 and r2 =0.90, 
respectively) 41­42, indicating reduced CYP3A4 metabolic activity. Similarly, triazolam 
clearance was significantly lower in obese patients 47. For midazolam 48, alprazolam 47 
and cyclosporine 49­50, clearance values were reported to be lower in obese versus non­
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obese individuals, though this was not statistically significant, potentially because of the 
limited power of these studies.
A trend towards lower CYP3A4 activity associated with obesity was also found for 
other major CYP3A4­cleared drugs. Carbamazepine clearance in non­obese versus 
obese patients was only marginally higher 51. Upon major weight loss, carbamazepine 
clearance in six obese patients was significantly increased 52. As an explanation, it has 
been suggested that a fatty liver, as observed by abdominal ultrasound, may hinder car­
bamazepine metabolism either by inhibition of important biochemical reactions or by 
reduction in liver blood flow. After weight loss, ultrasound images showed a disappear­
ance of fatty changes, in line with an increase in carbamazepine clearance. Clearance of 
alfentanil, which is also predominantly metabolized by CYP3A4 53, was almost halved 
in obese as compared with non­obese patients 54. The pharmacokinetics of taranabant, 
primarily metabolized by CYP3A4 55, were studied using data from 12 phase 1 clinical 
trials and one phase 2 study, including 385 obese individuals (BMI range 30­43 kg/m2) 56. 
While the authors found a lower estimated oral clearance in obese individuals, they at­
tributed this result to either increased protein binding or a decrease in CYP3A activity.
For two CYP3A4 substrates no difference in clearance was reported in obese versus 
non­ obese patients. Trazodone, for which CYP3A4 is the major isoenzyme involved in 
the formation of its metabolite 57­58, showed no difference in clearance between obese 
and non­obese patients. Furthermore, docetaxel clearance values of adults patients 
were not significantly different between non­obese, obese or morbidly obese adults 59.
In studies of patients before and after gastric bypass surgery an increase in activity 
of CYP3A4 metabolism in obese individuals was reported. Cyclosporine requirement in 
patients after gastric bypass surgery was significantly increased from 1.8 to 3.5 mg/kg/d 
(p= 0.02,) in order to maintain similar cyclosporine trough levels 60. Similarly it was re­
ported that higher, tacrolimus, sirolimus (CYP3A4 61­62) and mycophenolic acid (CYP3A4, 
CYP2C8 63) doses were needed in transplant recipients with a gastric bypass to ensure 
exposure similar to that in a non­bypass patient 64. In contrast, atorvastatin bioavail­
ability 3  –  6 weeks after gastric bypass surgery was found to be both increased and 
decreased as compared with before surgery 65­66. The observations made in these gastric 
bypass studies seem to reflect an increase in CYP3A4­mediated clearance in after weight 
loss. However, these observations may also be explained by the surgical procedures or 
an increase in activity of CYP3A4 located in the intestines, both causing reduced absorp­
tion of oral drugs. Finally, it could be a combination of the factors mentioned. To our 
knowledge, no studies have investigated the oral bioavailability of CYP3A4 substrates 
in obese (gastric bypass) patients versus non­obese patients, and as such, we cannot 
distinguish between these factors.
In summary, 7 out of 13 studies presented in Table 1 show a significantly lower clear­
ance of CYP3A4 substrates in obese patients and 4 studies show non­significantly lower 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































absolute clearance values. Body weight­normalized clearance values, as depicted in Ta­
ble 1, show that drug clearance per kilogram body weight is halved in obese individuals. 
The underlying mechanism of impaired CYP3A4 metabolism and the potential conse­
quences for CYP3A4 drug­drug interactions in obese patients are unclear and should be 
subjects of future research. Furthermore, it should be noted that the majority of patients 
included in these studies were mildly obese, while only a few morbidly obese patients 
(BMI >40 kg/m2) were included. To date, the pharmacokinetics of CYP3A4­metabolized 
drugs have not been studied in obese children or adolescents.
CYP2E1
Although CYP2E1 metabolism represents only about 5% of phase I drug metabolism39, 
the impact of obesity on CYP2E1 activity has been the subject of several studies, in which 
also a significant proportion of morbidly obese patients were included. Chlorzoxazone, 
enflurane, sevoflurane and halothane represent the four model drugs for CYP2E1 activ­
ity reviewed here, of which the results are summarized in Table 2.
Chlorzoxazone pharmacokinetics were studied in several clinical trials, as this drug 
is a highly selective probe of CYP2E1 metabolism 67. In women, it was shown that 
morbid obesity is associated with increased 6­hydroxylation of chlorzoxazone, which is 
consistent with induction of CYP2E1 68. For obese patients, with or without non­insulin­
dependent diabetes mellitus, it was found that CYP2E1 activity was 40% higher as 
compared with non­obese subjects 67, 69.
More recently, CYP2E1 activity in obesity was further studied by Emery et al. 18. Un­
bound oral clearance (CLunbound/F) of chlorzoxazone was approximately 3­fold higher in 
morbidly obese compared with non­obese individuals (p<0.001). Six weeks and 1 year 
post­weight­reducing surgery, chlorzoxazone CLunbound/F in patients was reduced. The 
authors suggest a causal relationship between the induction of CYP2E1 activity and 
hepatic fatty infiltration, based on liver biopsy assessment. They found a trend towards 
higher CLunbound/F with increasing severity of liver fatty infiltration or steatosis (P=0.06). 
More specifically they showed that CLunbound/F was significantly higher among subjects 
with steatosis involving  >50% of hepatocytes, compared with those with steatosis 
in ≤ 50% of hepatocytes (p=0.02) 18.
Volatile anesthetics, including enflurane, sevoflurane and halothane, are partly metabo­
lized by CYP2E1. Ionic fluoride is formed by CYP2E1 oxidation of enflurane and sevoflurane, 
and therefore represents a reliable marker of CYP2E1 metabolism70­71. A third volatile anes­
thetic, halothane, undergoes CYP2E1 biotransformation, which results in trifluoro­acetic 
acid72. After a similar dose of enflurane maximal ionic fluoride concentrations were found 
to be significantly higher in obese compared with non­obese patients 73­74. A similar result 
was seen for sevoflurane in obese versus non­obese patients 75. A second sevoflurane 
study did not find a significant difference in ionic fluoride concentrations between obese 
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and non­obese patients 76. After similar doses of halothane, significantly higher trifluoro­
acetic acid concentrations in obese patients at 1 and 3 hours after dosing were found 77.
The studies summarized in Table 2 show a consistent and significant increase in clear­
ance of different CYP2E1 substrates in obese as compared with non­obese subjects, 
indicating induction of CYP2E1 activity in obesity. When normalized for body weight, 
clearance values are more or less equal among obese and non­obese individuals, which 
indicates that CYP2E1 activity increases with body weight. As an explanation, liver 
fatty infiltration, which is expected to increase with increasing body weight, may be the 
underlying cause of the CYP2E1 enzyme activity increase with body weight 18. In obese 
children, no studies on CYP2E1­metabolized drugs have been performed yet.
With regard to the higher CYP2E1 activity observed in obese patients, it can be an­
ticipated that caution should be practiced when using paracetamol (acetominophen) 
in obese patients, as CYP2E1 catalyses the formation of the toxic metabolite N­acetyl­
p­benzo­quinone imine (NAPQI). Two studies have looked into paracetamol pharmaco­
kinetics in both obese and non­obese patients 78­79. Both studies are discussed in the 
Phase II metabolism section, because 90% of paracetamol is conjugated via phase II 
metabolism and only 5–10% of paracetamol is metabolized by CYP2E1 80. Moreover, one 
study 79 did not report metabolites, but only paracetamol clearance values, while the 
other did not measure NAPQI or the metabolites formed after NAPQI (APAP­C or APAP­
M) 78. Therefore, the above­stated warning may be considered somewhat speculative, 
and further studies are needed to assess the role of CYP2E1 in paracetamol metabolism 
and toxicity in both obese adults and children − in particular, given the importance of 
paracetamol in paediatric therapeutics.
CYP2D6
CYP2D6 metabolism represents about 10­15% of phase I drug metabolism in humans 40. 
The activity of this CYP isoform may differ greatly between individuals depending on 
its genetic polymorphisms 81­82. Two CYP2D6 substrates, dexfenfluramine and nebivolol, 
have been subjects of pharmacokinetic studies in obese and non­obese individuals, as 
shown in Table 3.
For dexfenfluramine metabolism, there was a trend towards higher dexfenfluramine 
clearance and higher metabolite/parent ratio in obese versus non­obese subjects 83. 
Nebivolol clearance was significantly a higher in obese subjects as compared with 
non­obese individuals 84. As nebivolol clearance is relatively high (>1L/min), it may be 
more dependent on liver blood flow than on intrinsic CYP metabolism. However, as 
the CYP2D6 phenotype has been found to influence the clearance of nebivolol, it was 
included in this section 85.
In summary, these few studies indicate trends towards increased CYP2D6­mediated 
metabolism in obese versus non­obese patients.
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CYP1A2
CYP1A2 metabolism represents a small part (~5%) of total phase I drug metabolism. 
Smoking has an inducing effect on CYP1A2 activity 86. Caffeine and theophylline have 
been indicated as CYP1A2­specific probes 87­88 and have been studied in obese versus 
non­obese populations by different research groups (Table 4).
In adults, caffeine clearance was not significantly different between non­smoking 
obese and non­smoking non­obese patients and between obese patients before and 
after weight loss 89. Two earlier caffeine studies in adult obese and non­obese subjects 
also did not show a significant difference in caffeine clearance 90­91.
In children aged between 6 and 10 years, Chine et al. evaluated oxidative enzyme ac­
tivity of CYP1A2, using the urinary metabolic ratio of caffeine metabolites 92. The authors 
observed non­significantly lower CYP1A2 enzyme activity in obese as compared with 
non­obese children.
Theophylline clearance showed a significant decrease in 16 obese women after a 6.2 
(1.5) kg weight loss 93. In a study with 200 individuals, no significant difference in the­
ophylline clearance between moderately obese and non­obese subjects was found 94. 
However, after correcting for the influence of smoking, higher total body clearance 
associated with obesity was found for a select group of young non­smoking subjects 
(p<0.025). In a third study, it was shown that theophylline clearance correlates with total 
body weight and not with ideal body weight 95.
In summary, trends of higher clearance values in obese as compared with non­obese 
patients indicate a slight increase in CYP1A2 activity. When corrected for body weight, 
clearance values showed both higher and lower clearance values for obese individuals 
as compared with non­obese subjects (Table 4).
CYP2C9
CYP2C9­mediated metabolism represents about 10% of phase I drug metabolism in 
humans. For this review, four CYP2C9 substrates (ibuprofen, phenytoin, glimepiride and 
glipizide) were identified and are presented in Table 5.
Phenytoin and ibuprofen are widely accepted CYP2C9 substrates 96­97. Phenytoin 
and ibuprofen clearance showed a trend towards higher 98 and significantly 99 higher 
clearance in obese patients, respectively. Non­significantly higher CYP2C9 activity in 
obese subjects was also seen for glimepiride and glipizide. Glimepiride is metabolized 
primarily by CYP2C9 to the active M1 hydroxy metabolite, the cyclohexyl hydroxymethyl 
derivative 100. Glimepiride clearance of the parent drug and of the CYP2C9­dependent 
metabolite M1 were not significantly different in obese versus non­obese type­2 diabe­
tes patients. However, the cumulative urine excretion of M1 over 24 hours post dose was 
30% (p < 0.05) higher in obese versus non­obese subjects, while both groups received 
equal doses 101. For glipizide (a CYP2C9 substrate 102), clearance was slightly higher, 
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which was not statistically different in obese as compared with non­obese subjects, 
though the difference in body weight was rather limited 103.
In summary, these studies indicate slightly increased CYP2C9­mediated clearance in 
obese as compared with non­obese patients. Body weight­normalized clearance values 
show a slight decrease in CYP2C9­mediated clearance per kilogram of total body weight 
(Table 5).
CYP2C19
CYP2C19 biotransformation is involved in approximately 5% of all phase I drug me­
tabolism. As for CYP2D6 and CYP2C9, the activity of this isoform may largely differ 
depending on genetic polymorphisms 104. Only one clinical study, which is presented in 
Table 6, investigated the pharmacokinetics of CYP2C19 probes, i.e. diazepam and methyl 
diazepam 104­105. Diazepam clearance was higher in the obese group, and no difference in 
desmethyl diazepam clearance in obese versus non­obese individuals was found 106­107. 
Body weight­normalized clearance values show a slight decrease in CYP2C19­mediated 
clearance for obese individuals (Table 6).
Other phase I metabolic enzymes
Xanthine oxidase
Besides CYP enzymatic pathways, there is a wide variety of other enzymes contributing 
to phase I metabolism of drugs. However, often no appropriate substrate for a particular 
enzyme has been identified 108. We have identified two studies in children, investigating 
the pharmacokinetics of the xanthine oxidase­metabolized compounds mercaptopu­
rine and caffeine (Table 7).
Mercaptopurine undergoes extensive biotransformation by xanthine oxidase 109. In 
children, mercaptopurine clearance values were found to be higher in overweight or 
obese children as compared with non­obese children. In addition, a significant cor­
relation between drug exposure and fat body mass, expressed by the weight/height 
percentile, was demonstrated 110.
Xanthine oxidase also mediates the biotransformation of the caffeine metabolite 
1­methylxantine into 1­methyluric acid, which can be measured in urine. The metabolic 
ratio for xanthine oxidase, measured using the metabolites in urine, was higher in obese 
children than in non­obese children between 6 and 10 years of age 92. Obese children 
also showed elevated interleukin­6, C­reactive protein, and leptin levels, whereas 
adiponectin levels were decreased as compared with the non­obese children 92. It was 
suggested that these pro­inflammatory cytokines and adipokines upregulate xanthine 
oxidase gene expression and activity. Another explanation for the increase in xanthine 
oxidase activity may be the increase in liver volume associated with obesity.





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In conclusion, xanthine oxidase­mediated clearance was significantly increased 
in obese versus non­obese children in both studies. To our knowledge, no studies on 
xanthine oxidase in adults have been performed.
Miscellaneous phase I metabolism enzymes
In addition to typical substrates for phase I drug metabolic enzymes, there are many 
other drugs that undergo hepatic biotransformation by a combination of phase I and 
phase II enzymes. As a result, even when the exact share of each involved enzyme is 
known, it is difficult to predict into what extent drug clearance will be affected in obese 
adults and children. In Table 8 we have summarized all studies in obese and non­obese 
patients that have investigated the pharmacokinetics of drugs in which multiple en­
zymes are involved. Here we will only discuss antipyrine, while for the outcomes of other 
drugs, we refer to Table 8.
Antipyrine (phenazone) is widely used as a model drug in the assessment of hepatic 
oxidative capacity in humans, as more than 99% of a given dose is excreted into urine 
as metabolites. The major metabolic routes are N­demethylation to norphenazone 
(CYP2C8, ­2C9, ­2C18, ­1A2), 4­hydroxylation (CYP3A4, ­1A2, ­2B6) and 3­methylhy­
droxylation (CYP1A2, ­2C9), which together account for 50% − 80% of the dose111. Two 
antipyrine studies reviewed here did not find significantly different clearance values 
between the obese and non­obese patient groups 106, 112.
The outcomes of the antipyrine studies are representative for the general conclusion 
from the studies in Table 8. In summary, 8 out of 13 studies did not show significantly dif­
ferent clearance values in obese versus non­obese subjects. Of the 5 studies that did find 
a difference in clearance values, obese clearance values were either higher (doxorubicin, 
ethinyl­estradiol and bisoprolol 113­115) or lower (amiodarone and doxorubicinol 116­117) as 
compared with clearance values in the non­obese group. Per kilogram of body weight, 
all clearance values were lower in obese as compared with non­obese individuals. 
The limited influence of obesity on these particular clearance values may in part be 
explained by compensating mechanisms among the different enzymatic pathways 
involved. However, it should be noted that the differences in body weight between the 
obese and non­obese subjects in all of the studies in Table 8 are relatively small. As this 
is a mixed group of drugs, it is difficult to generalize the results.
Summary of phase I metabolism
In summary, phase I enzymatic processes showed higher, lower or similar activity in 
obese as compared with non­obese subjects, depending on the enzymatic pathway. 
CYP3A4 mediated clearance was consistently lower, while CYP2E1­mediated clearance 
showed higher activity among obese versus non­obese adults. For CYP2E1, it has been 
demonstrated that an increase of CYP2E1­mediated clearance is correlated with both 
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total body weight and the degree of liver steatosis, supporting the concept that liver 
fibrosis and inflammation associated with the increase in body weight are the underly­
ing cause of increased CYP2E1 enzyme activity.
Clearance mediated by phase I metabolizing enzymes (CYP1A2, CYP2C9, CYP2C19 and 
CYP2D6) showed trends of higher clearance values in obese versus non­obese subjects, 
although in the majority of studies, this was not statistically significant, and the number 
of studies was limited. In contrast, CYP1A2 activity in children was non­significantly 
lower in obese versus non­obese children. Xanthine oxidase activity was significantly 
higher in obese as compared with non­obese children. Overall, the differences in body 
weight between obese and non­obese individuals were relatively small, and few or no 
morbidly obese patients were included in these studies.
Phase II metabolism
Phase II metabolic processes include glucuronide­, N­acetyl­, methyl­, gluthatione­ and 
sulfate­ conjugation of substrates. Uridine diphosphate­glucuronosyltransferase (UGT) 
enzymes catalyze the conjugation of various endogenous substances and exogenous 
compounds, and are by far the most important phase II processes for metabolism of 
drugs (~50%) 40.
Uridine Diphosphate Glucuronosyltransferase (UGT)
The human UGT superfamily is comprised two families (UGT1 and UGT2) and three sub­
families (UGT1A, UGT2A, and UGT2B). Many of the individual UGT enzymes are expressed 
not only in the liver but also in extrahepatic tissues, including the gastrointestinal tract, 
adipose tissue and kidneys, where the extent of glucuronidation can be substantial 118. 
As the liver is the main UGT enzyme organ, it is suggested that liver disease or increased 
organ size, often co­occurring with obesity, is somehow correlated with UGT activity. 
The expression of specific UGT enzymes in visceral and subcutaneous adipose tissue 
may also provide an explanation for increased UGT in activity in obesity 119.
Here we will discuss studies of four drugs that primarily undergo UGT conjugation, 
i.e. paracetamol, garenoxacin, oxazepam and lorazepam. The studies are summarized 
in Table 9. In contrast to CYP isoforms, individual UGT enzymes responsible for specific 
drug biotransformation processes were mentioned in an additional column of Table 9 .
Paracetamol is extensively metabolized by UGT enzymes 120­121. In both adult men 
and women, significantly higher clearance values were found in obese compared with 
non­obese individuals 79. Between adolescents with and without NAFLD, no difference 
in total body weight­normalized clearance was found, indicating higher absolute clear­
ance values in obese adolescents 78. Furthermore, the ratio of paracetamol/paracetamol­
glucuronide metabolite in urine was significantly increased in obese adolescents, 
indicating increased UGT metabolism.
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In a population pharmacokinetic analysis of garenoxacin (a major UGT substrate 122), 
it was found that clearance values increased with total body weight. In the final phar­
macokinetic model, an obesity factor (>130% ideal body weight) used as a covariate for 
clearance significantly improved the model 123.
For both oxazepam and lorazepam, it was found that clearance values were signifi­
cantly higher in obese as compared with non­obese control subjects 124. A determinant 
role of UGT in the metabolism of both compounds has been shown in the literature 120, 125. 
On the basis of the differences in oxazepam and lorazepam clearance values, the authors 
concluded that obesity is associated with an increased conjugating capacity and that 
this increase is in proportion to total body weight. It should be noted that many subjects 
in this study received more than one study drug, which may limit the interpretation of 
these results.
In conclusion, all studies show a significantly increased clearance in obese as com­
pared with non­obese subjects. As a consequence, body weight­normalized clearance 
values were equal or only slightly lower for obese as compared with non­obese indi­
viduals, except for oxazepam clearance, which showed a significant increase in body 
weight­normalized clearance.
Other metabolic phase II routes
Apart from UGT, the pharmacokinetics of N­acetyltransferase (~5% of phase II drug 
metabolism) and glutathione S­transferase­metabolized drugs have been investigated 
in obese versus non­obese subjects. Caffeine, procainamide and busulfan have been 
indicated as substrates, as presented in Table 10.
N­acetyltransferase is responsible for the N­acetylation of procainamide 126. Procain­
amide plasma clearance was slightly higher in obese as compared with non­obese 
adults, although this was non­significant 127. In obese children, a 5­fold increase in the 
metabolic ratio of the N­acetyltransferase pathway of caffeine was observed when com­
pared with non­obese children 92, when only considering the slow­acetylator genotype.
For busulfan, both obese (BMI between 27 and 35 kg/m2) and severely obese patients 
(BMI > 35 kg/m2) showed significantly higher oral clearance values as compared with non­
obese patients 128. Per kilogram of body weight, clearance was significantly lower in obese 
versus non­obese patients. This was confirmed in a more recent trial with busulfan in 
obese and non­obese adults 129. While CYP3A4 involvement is suggested 130, the glutathi­
one S­transferase A1­1 isoform is the major and possibly determinant pathway of busulfan 
metabolism 131. In obese children (aged 0 − 21 years) busulfan clearance per kilogram of 
body weight after a test dose and a regular dose was lower than in non­obese children 132.
In conclusion, other type phase II­metabolized substrates show higher absolute clear­
ance values in obese as compared with non­obese adults and children, while weight­
normalized clearance values were lower in obese as compared with non­obese patients.
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Summary of phase II metabolism
For glucuronidation processes, all studies in Table 9 show a significant increase in UGT 
biotransformation in obese as compared with non­obese subjects. Weight­normalized 
UGT clearance values were equal to or only slightly lower in obese as compared with 
non­obese patients. However, the number of studies with UGT­metabolized drugs is 
small. The underlying mechanism of this phenomenon remains unsolved, although 
NAFLD was demonstrated to be associated with higher paracetamol clearance values 
in adolescents 78.
N­Acetylation catalyzed by N­acetyltransferase shows a significant increase in obese 
children and a non­significant increase in adults. Glutathione transferase of busulfan in 
obese children and adults was lower in non­obese adults and children when normalized 
for body weight.
liver blood flow
High­extraction­ratio drugs are rapidly metabolized and therefore sensitive to changes 
in liver blood flow, but are relatively insensitive to changes in enzyme activity and are 
thus a potential marker of liver blood flow. The influence of obesity on liver blood flow is 
not fully specified. NASH increases fat deposition in the liver, causing sinusoidal narrow­
ing and altered functional morphology of the liver 133. In contrast, because of increased 
blood volume and cardiac output, liver blood flow is not necessarily reduced in obese 
subjects 19.
In Table 11, studies of eight high extraction ratio drugs in obese and non­obese sub­
jects are summarized and include propofol, propanolol, labetalol, verapamil, lidocaine, 
fentanyl, sufentanil and paclitaxel.
Propofol is extensively metabolized by various UGT enzymes 118 and its clearance 
is limited by liver blood flow 134. Van Kralingen et al. 135 and Cortinez et al. 136 studied 
propofol pharmacokinetics in a wide range of body weights and found that total body 
weight as a covariate for clearance significantly improved the predictive performance of 
the population pharmacokinetic model.
Four different studies reported propranolol clearance values in obese versus non­
obese patients. Three studies did not show altered clearance values between obese and 
a The references mentioned with the substrate (first column) refer to literature in which the appropriate­
ness of the particular drug as a NAT2 or GSTA1 probe was confirmed.
b Unless otherwise specified, mean values (standard deviation).
c See section Approach for calculation of weight­normalized clearance values.
d Values are expressed as range.
AIBW  =  adjusted ideal body weight; BMI  =  body mass index; %BMI  =  BMI percentile (used in children); 
CL  =  clearance; CL/F  =  oral clearance; GSTA1  =  glutathione S­transferase A1; IBW  =  ideal body weight; 
IV = intravenously; NA = not available; NAFLD = non­alcoholic liver fatty disease; NAT2 = arylamine N­acet­
yltransferase type 2; PO = orally; TBW = total body weight.






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































non­obese patients 137­139, and one study found significantly lower propranolol clear­
ance values in obese versus non­obese patients 140. Propranolol clearance is strongly 
determined by liver blood flow as it approaches liver blood flow values 141. On the 
other hand, propranolol tends to decrease liver blood flow by ~20­30% by blocking the 
beta­adrenoreceptor, explaining the relative lower clearance value seen for propranolol 
compared with other drugs in Table 11 141.
Labetalol clearance in obese patients showed a trend towards being increased 138. 
For verapamil and lidocaine, no difference in clearance between obese and non­obese 
was found 142­143. As lidocaine clearance is determined mainly by liver blood flow 144, the 
authors concluded that extreme total body weights did not change liver blood flow.
Sufentanil and fentanyl are predominantly metabolized by CYP3A4 145, but their total 
clearance is mainly determined by liver blood flow 146­147. Sufentanil showed higher 
clearance values in obese versus non­obese patients; however, this difference was not 
statistically significant 148. The difference in body weight between the two groups studied 
was small (90 versus 74 kg). The pharmacokinetics of fentanyl were studied in a popula­
tion with a wide range of total body weights, showing a non­linear positive correlation 
between total body weight and fentanyl clearance 149. Reported paclitaxel clearance val­
ues in obese and non­obese patients are extremely high (291 − 431 L/h), indicating liver 
blood flow­dependent clearance 150. Clearance values for paclitaxel in obese patients were 
higher than values of non­obese patients; however, this was not statistically significant 59.
In conclusion, only a few high­extraction­ratio drug studies in Table 11 showed altered 
clearance values in obese versus non­obese adults. Body weight­normalized clearance 
values show a large decrease in clearance per kilogram. For instance, the clearance 
per kilogram values of propranolol and lidocaine are almost halved. A straightforward 
conclusion from these studies is complicated because of the heterogeneity of the drugs. 
Liver blood flow is about 2–2.5 L/min, while clearance values of some drugs listed in 
table XI are less than 1 L/min, obscuring the justification of their role as a model drug 
for liver blood flow. When considering drugs with clearance values of more than 1.5 L/
min (propofol, sufentanil and paclitaxel), all studies show higher clearances in obese 
patients. Propanolol was excluded from this comparison, as this drug shows high vari­
ability in drug clearance values among studies (Table 11). The observation of increased 
clearance is not statistically significant for sufentanil and paclitaxel, probably because of 
the small difference in total body weight in these studies. Unfortunately, the data from 
these studies did not allow comparison of weight­normalized clearance values.
summary of liver blood flow
According to the results of propofol, sufentanil and paclitaxel studies, liver blood flow is 
likely to be increased in obese patients. However, only a few (very) high­extraction­ratio 
drugs have been studied and the difference in body weights between patients groups 
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was limited for sufentanil and paclitaxel. To our knowledge, no studies have investigated 
the pharmacokinetics of high­extraction­ratio drugs in children.
renAl elIMInAtIon
The kidneys are the primary organs involved in the elimination of drugs. The processes 
involved in drug elimination through the kidneys include glomerular filtration, tubular 
secretion and tubular reabsorption. The exact effect of obesity on these functions is not 
clear 25. Renal function seems to be affected, as obese patients showed a 62% increase in 
the mean estimated glomerular filtration rate (eGFR) 151. This finding was observed, irre­
spective of the presence of hypertension by an increase of renal blood flow 152. Obesity is 
related to a state of glomerular hyperfiltration, which resembles that seen in early­stage 
diabetic nephropathy and sickle cell disease 20­21, 153. It has been argued that overweight 
may ultimately lead to end­stage renal disease, because focal glomerular sclerosis and/
or diabetic nephropathy have been observed in a small study in 17 morbidly obese 
patients who presented with proteinuria 154. In obese children, it was found that the 
glomerular filtration rate increases with BMI 155. In contrast to obese adults, obese chil­
dren showed a higher degree of albuminuria, a marker for glomerular dysfunction 156­157. 
Therefore, it was concluded that albuminuria indicates early renal glomerular dysfunc­
tion as a consequence of childhood obesity 156. However, obese children compared with 
non­obese children did not differ in their glomerular filtration rates, as no overt changes 
in eGFR were detected 157.
The influence of obesity on renal tubular secretion and renal tubular reabsorption is 
not well known, and no objective clinical measure of these drug clearance pathways 
presently exists 151. Tubular dysfunction can be defined as the presence of at least two of 
the following criteria: nondiabetic glycosuria, urine phosphate wasting, hyperaminoac­
iduria, beta­2­microglobulinuria, and increased fractional excretion of uric acid 158­159. For 
obese children, an increased degree of beta­2­microglobulinuria, suggesting increased 
tubular dysfunction, has been described 156.
In this section, we will provide an overview of clinical studies investigating drugs that 
are primarily eliminated renally and were studied in both non­obese and obese adults 
and children.
Glomerular filtration
In Table  12, an overview of studies comparing clearance of drugs that are mainly ex­
creted by glomerular filtration in obese and non­obese individuals is presented. These 
drugs include vancomycin, daptomycin, carboplatin, low­molecular­weight heparins 
and cimetidine.
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Vancomycin clearance in morbidly obese patients is reported to increase with total 
body weight, compared with non­obese patients 160. No significant increase of dapto­
mycin clearance was described in obese patients with a mean total body weight of 114 
kg 161. However, in patients with a higher mean total body weight (126 kg), significantly 
higher daptomycin clearance was reported 162. Carboplatin is mainly eliminated by glo­
merular filtration and partly by tubular secretion 163. Both a linear increase of carboplatin 
clearance with total body weight 164 and ideal body weight 165 have been described. A 
comparison of carboplatin clearance values between obese and non­obese patients 
showed no significant difference 59. The low­molecular­weight heparins enoxaparin, 
tinzaparin and dalteparin show higher total drug clearance in obese patients compared 
with non­obese patients (166­168). Studies on the influence of obesity on drug clearance 
mediated by glomerular filtration in obese children are very limited. In obese children, 
lower anti­Xa levels after the same dose of enoxaparin were reported, suggesting higher 
enoxaparin clearance in obese children166. In contrast to these studies, total clearance 
of cimetidine was not altered in obese patients compared with non­obese patients 167.
In conclusion, the majority of these studies show higher clearance values with 
increasing body weights, indicating increased glomerular filtration in obese patients. 
Weight­normalized clearance values did not show a consistent trend for the influence of 
overweight on glomerular filtration, as normalized clearance values were either equal or 
lower in obese as compared with normal­weight patients.
tubular secretion
Drugs that are (partly) eliminated by tubular secretion and have been investigated in 
obese patients are summarized in Table  13 and include procainamide, ciprofloxacin, 
cisplatin, topotecan and digoxin.
Approximately 50% of administered procainamide is eliminated as unchanged drug 
by glomerular filtration and active tubular secretion 168. Renal procainamide clearance 
was shown to be higher in obese patients because of elevated tubular secretion, as 
no significant difference in 24­hour creatinine clearance was observed between obese 
and non­obese patients 127. Significantly higher clearance values were also reported 
for cisplatin and ciprofloxacin, which are eliminated by tubular secretion 59, 169­171. For 
both topotecan and digoxin, there was a trend towards higher drug clearance in obese 
patients, which is assumed to result from increased tubular secretion 59, 172. For tubular 
secretion, normalized clearance values per kilogram were equal or slightly lower in 
obese as compared with non­obese patients.
In conclusion, these studies indicate higher tubular secretion in obese as compared 
with non­obese individuals. To date, no information is available on the impact of obesity 
on the tubular secretion of drugs in children.

















































































































































































































































































































































































































































































































































































































































































































Studies on the influence of obesity on the tubular reabsorption of drugs are scarce 
(Table 14). Tubular reuptake of lithium in obese patients was reported to be lower, as 
lithium clearance was significantly increased in obese patients and glomerular filtration 
did not differ between these obese and non­obese patients 173. In contrast, proximal 
tubular reabsorption of sodium in obese patients is reported to be increased because of 
glomerular hyperfiltration 174.
summary of renal elimination
The reviewed studies show that clearance of renally eliminated drug is higher in obese 
patients because of increased glomerular filtration and tubular secretion. The influence 
of obesity on the tubular reabsorption is unknown, as there is a lack of evidence on this 
topic.
dIsCussIon And ConClusIons
In this review, we have summarized the effects of obesity on drug metabolism and 
elimination. Studies that investigated pharmacokinetics of drugs in both obese and 
non­obese individuals were classified according to the drug’s most important metabolic 
or elimination pathway. This allowed us to structurally review the influence of obesity on 
each individual metabolic or elimination pathway. Metabolic processes were subdivided 
into phase I metabolism, phase II metabolism and liver blood flow­dependent metabo­
lism. Renal elimination was subdivided into glomerular filtration and tubular processes.












































p = 0.005 0.31 vs 0.37 
mL/min/kg
173
a The references mentioned with the substrate (first column) refer to literature in which the appropriate­
ness of the particular drug as a tubular reabsorption probe was confirmed.
b Unless otherwise specified, mean values (standard deviation).
c See section Approach for calculation of weight­normalized clearance values.
CL = clearance; mEq = milliequivalents; TBW = total body weight.
2 | 59
The reviewed studies show that the impact of obesity on drug metabolism and 
elimination differs greatly, depending on the metabolic or elimination pathway primar­
ily involved in the handling of the investigated drug. In particular, CYP3A4­mediated 
drug elimination was found to be consistently lower, while UGT­, CYP2E1­, arylamine 
N­acetyltransferase type 2­ and xanthine oxidase­ mediated drug metabolism was 
consistently higher among obese as compared with non­obese subjects. Clearance me­
diated by phase I metabolizing enzymes CYP1A2, CYP2C9, CYP2C19 and CYP2D6 show 
trends towards higher clearance values in obese individuals.
Studies on drug clearance mediated by liver blood flow are somewhat inconclusive, 
although, on the basis of a few highly extracted drugs, an increase in liver blood flow can 
be noted in obese patients.
Regarding drug elimination, the reviewed studies show an increase of glomerular 
filtration and tubular secretion in obese patients. The influence of obesity on tubular 
reabsorption is unknown.
Many of the observed trends were also reflected in weight­normalized clearance val­
ues, which were halved (e.g. CYP3A4), almost equal (e.g. CYP2E1) or slightly decreased in 
obese as compared with non­obese individuals (e.g. CYP2C9 and tubular secretion). For 
other drug clearance pathways, trends in body weight­normalized clearance were not 
as pronounced (e.g. the glomerular filtration rate and CYP1A2). It should be emphasized 
that these body weight­normalized clearance values may provide information on quan­
titative differences in clearance values but do not explain the relationship between total 
body weight and drug clearance values.
The large number of studies included in this review shows that there is a substantial 
amount of information available on the impact of obesity on drug metabolism and 
elimination. However, in many of these studies, the difference in body weight between 
obese and non­obese subjects is rather small. More specifically, the obese subjects 
included in the reviewed studies are not as obese as the patients currently seeking 
medical care. From this perspective, information on drug metabolism and elimination in 
morbidly obese patients (BMI >40 kg/m2) and super­obese patients (BMI >50 kg/m2) is 
largely lacking and requires future research.
Regarding obesity in children, only five studies investigated pharmacokinetics of a drug 
in obese versus non­obese children, of which four were recently published 78, 92, 117, 132. Re­
garding renal elimination, no pharmacokinetic studies of obese versus non­obese chil­
dren were found. Extrapolation of results from studies in obese adults to obese children 
is widely applied because often no clinical studies in obese children are available 24, 175. 
For the UGT mediated metabolism of paracetamol this may be justified, as paracetamol 
clearance in both adolescents 78 and adults 79 was increased. This strong similarity in 
results was not seen for other drugs that were studied in both adults and children such 
as caffeine 92. Moreover, the expression and activity of enzymatic pathways in children 
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may be different compared with adults and are dependent on maturational status (age). 
In addition, obesity may influence the maturation process(es) itself, and the starting 
point of weight gain may also influence the maturation process(es), representing ad­
ditional factors of variability in drug metabolism and elimination among obese adults 
and children. Taking this into consideration, extrapolation from adult observations may 
give false predictions of clearance values in children (and vice versa) and should be 
performed with care.
While it is impossible to study and assess the pharmacokinetics of every drug in obese 
subjects, future clinical trials should aim to quantify the impact of obesity on specific 
drug elimination pathways and on the underlying associated mechanisms (e.g. steatosis 
and inflammation). In this approach, study outcomes can be extrapolated to other drugs 
eliminated by the same pathway. This extrapolation can be achieved by using model 
drugs and within the context of a multidisciplinary research team including physicians, 
pharmacists, pharmacologists and pharmacometricians. Primarily, future research 
in this area should focus on individual metabolic and elimination pathways in adults 
and children that show increasing or decreasing trends in activity among obese versus 
non­obese individuals. As concluded from this review, these pathways include CYP3A4, 
CYP2E1, xanthine oxidase, UGT, N­acetyltransferase, glomerular filtration and tubular 
processes. Mainly, CYP3A4 deserves immediate research attention. Finally, particularly 
obese children and adolescents, and morbidly obese (BMI >40 kg/m2) and super­obese 
patients (BMI >50 kg/m2) should be included in these studies.
In conclusion, this systematic review of pharmacokinetic studies in obese and non­
obese patients shows that the impact of obesity on drug metabolism and elimination 
greatly differs per drug metabolic or elimination pathway. However, the clinical trials 
reviewed here often only included overweight to moderately obese patients. As the 
prevalence of obesity and total body weights of both children and adults are still increas­
ing and this trend will persist, future studies assessing the impact of morbid obesity on 
specific drug elimination pathways in both children and adults are warranted.
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AbstrACt
Obesity and morbid obesity are associated with many physiological changes affecting 
pharmacokinetics, such as increased blood volume, cardiac output, splanchnic blood 
flow, and hepatic blood flow. In obesity, drug absorption appears unaltered, although 
recent evidence suggests that this conclusion may be premature. Volume of distribution 
may vary largely, but the magnitude and direction of changes seem difficult to predict, 
with extrapolation on the basis of total body weight being the best approach to date. 
Changes in clearance may be smaller than in distribution, whereas there is growing 
evidence that the influence of obesity on clearance can be predicted on the basis of re­
ported changes in the metabolic or elimination pathways involved. For obese children, 
we propose two methods to distinguish between developmental and obesity­related 
changes. Future research should focus on the characterization of physiological concepts 
to predict the optimal dose for each drug in the obese population.
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IntroduCtIon
Obesity represents a serious and increasing health problem worldwide. In the United 
States in 2009–2010, the prevalence of obesity (body mass index (BMI)  >  30 kg/m2) 
was 35.9%, and the prevalence of morbid obesity (BMI > 40 kg/m2) was 6.3% (8.2% for 
women and 4.4% for men) 1. Alarmingly, the prevalence of overweight and obesity in 
children is also increasing. According to the most recent National Health and Nutri­
tion Survey (2009­2010) 31.8% of US children and adolescents (age 2­19 years) are 
overweight (≥85th percentile of BMI for age), 16.9% are obese (≥95th percentile), and 
12.3% are morbidly obese (≥97th percentile) 2. Worldwide prevalence rates for obesity 
in adults and overweight and obesity rates in children are also high, exceeding 24% in, 
for instance, Canada, Spain, the United Kingdom, Greece, Mexico, Saudi Arabia, Egypt, 
Australia, New Zealand, and some parts of South America 3.
Obesity increases the risk of many diseases and health conditions, such as hyperten­
sion, cardiovascular disease, dyslipidemia, type 2 diabetes, cancer, and osteoarthritis, 
thereby diminishing average life expectancy 4. In addition, obese individuals are also 
more likely to suffer from chronic pain 5­6 and nosocomial infections 7­8. Because these 
comorbidities often require pharmacotherapeutic or surgical and anesthetic treatment, 
an important question is how to optimize the dose of drugs, particularly in light of the 
fact that the morbidly obese patient group is increasing. In this respect, specific attention 
should be paid to obese children, who are likely to become obese adults. Comorbidities 
associated with childhood obesity are hypertension, obstructive sleep apnea, diabetes 
mellitus, and coronary artery disease, necessitating pharmacotherapeutic or even surgi­
cal or bariatric treatment 9­10. Furthermore, obese children are also more likely to de­
velop asthma or severe asthma 11, but their response to inhaled steroids is decreased 12. 
Moreover, overweight and obesity have been reported as independent predictors of 
the relapse risk of acute lymphoblastic leukemia 13. It cannot be excluded that these 
differences result from changes in the pharmacokinetics of chemotherapeutic agents in 
overweight or obese children. Therefore, it is of utmost importance to gain insight into 
how to adjust the dose of drugs in obese and morbidly obese children and adolescents. 
This issue should be viewed through the perspective of the fact that even in nonobese 
children, 37­80% of drugs are prescribed in an off­label or unlicensed manner 14­16.
In this review, we provide an overview of the current knowledge on changes in drug 
disposition in obese patients in relation to physiological changes associated with obe­
sity. Our ultimate goal is to direct future research aiming for individualized dosing in this 
growing and heterogeneous patient population. We pay specific attention to changes in 
drug disposition in obese children.
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PhYsIoloGICAl ChAnGes AssoCIAted WIth obesItY
Obesity is associated with many physiological and pathophysiological changes that 
may affect drug disposition. Obesity and morbid obesity are not only associated with 
an increase in fat but also in lean body weight (LBW), which is the weight devoid of all 
adipose tissue. The percentage of fat mass per kilogram of total body weight increases 
more than LBW in obese patients, with, for instance, an increase in LBW representing 
20–40% of total excess of weight in morbidly obese patients 17­18.
To supply the excess body mass with oxygen and nutrients, blood volume, cardiac 
output, and capillary flow increase substantially in obese and, in particular, morbidly 
obese individuals 19­22. Serum albumin and total protein concentrations are reported 
to be comparable in lean and obese subjects, even though concentrations of alpha­
1­acid glycoprotein are increased 23. In the cardiovascular system, the increased blood 
volume and cardiac output eventually leads to systemic hypertension, left and right 
ventricular hypertrophy, and an increased risk for sudden cardiac death due to conduc­
tion disorders 24­25. Pulmonary function is uniformly altered in obesity, with reduced lung 
volumes 26 and a higher incidence of obstructive sleep apnea syndrome 27.
Nonalcoholic steatohepatitis and histological abnormalities such as fatty infiltration in 
the liver are very common in morbidly obese patients 28­29. Because of the accumulation 
of fat in the liver of obese individuals, functional morphology may be altered owing 
to sinusoidal narrowing 30­31. However, because of increased blood volume and cardiac 
output, liver blood flow is not necessarily reduced in obese subjects 32. Although liver 
volume is reported to be increased in obese individuals 33, the results of studies on the 
influence of obesity on expression and function of CYP enzymes are inconclusive, with 
the exception of CYP3A and CYP2E1; the expression and function of these enzymes have 
been reported to be decreased and increased, respectively 34.
There are conflicting data on alterations in renal function. Irrespective of the pres­
ence of hypertension, investigators have reported increases in glomerular filtration rate 
and effective renal plasma flow 35­37. However, there is also evidence of unaltered renal 
function 38. In studies in Zucker rats with genetic obesity, researchers found that, after 
an initial increase in glomerular filtration rate, this rate normalized and subsequently de­
creased in the later stages of obesity, ultimately leading to end­stage renal disease 39­41. 
In morbidly obese patients who presented with proteinuria, one study reported focal 
glomerular sclerosis, diabetic nephropathy, or both 42. In addition, estimates of the cre­
atinine clearance from standard formulas tend to be inaccurate in obese patients 43­45. 
Even though obesity­associated renal damage may be unpredictable, the available 
evidence indicates that it is best to use LBW in the Cockroft­Gault formula for estimation 
of creatinine clearance in obese patients 44,46.
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With respect to the functioning of the gastrointestinal tract, studies in obese sub­
jects have found accelerated gastric emptying of solids 47­50, high splanchnic blood 
flow 19, and increased gut wall permeability 51­52. Because studies on the influence of 
obesity on intestinal transit time and motility have shown contradictory results, the 
exact impact of obesity on drug or nutrient absorption remains unclear 50,53­54. Wisén 
& Johansson 54 found that obese subjects had significantly higher absorption in the 
proximal small intestine. Studies on the influence of obesity on enterohepatic recircu­
lation are lacking.
MeAsures to quAntIfY bodY sIze And overWeIGht
BMI is the international metric recommended by the World Health Organization to clas­
sify obesity 55. A BMI value between 18.5 and 25 kg/m2 is considered healthy. BMI values 
greater than 30 and 40 kg/m2 indicate obesity and morbid obesity, respectively 55. As 
BMI does not differentiate adipose tissue from muscle mass, BMI should be considered 
a descriptor of body shape instead of a measure of body composition 56­57. For a child’s 
weight status (2–18 years), an age­ and sex­specific percentile for BMI (BMI­for­age) is 
used because children’s body compositions vary as they age and between boys and 
girls 58­59. For children younger than 2 years, weight­for­length charts are used. Over­
weight is defined as a BMI between the 85th and 95th percentile and obesity above the 
95th percentage for children of the same age and sex 60.
The value of the ideal body weight (IBW) parameter is most commonly calculated us­
ing the equation by Devine 61. Similar to BMI, this measure is rarely used as the basis for 
the individualization of drug dosage in obese patients, except for some specific drugs 
such as muscle relaxants 62­64 and remifentanil 65. This measure may lack predictive value 
for the dose adjustment of other drugs because it is based on height and sex only and 
does not consider body weight in any way 56. Adjusted body weight is an empirical, IBW­
based metric with different correction factors (0.14­0.98) that was developed after the 
discovery that IBW was a suboptimal parameter for drug dosing in obese subjects 66, but 
very little evidence supports using this as a guide for dosing 67.
Body surface area (BSA) is mainly used for dosing of anticancer drugs, a practice that 
has a historical rather than scientific basis. BSA can be calculated using the equations by 
Dubois and Dubois 68 or Mosteller 69. The equations are based on the theory of Euclidean 
geometry and account for height and weight 66. Remarkably, recent reports have shown 
that there is no evidence to reduce the dose or dose capping when BSA­adjusted doses 
are used in obese or morbidly obese cancer patients 70­71. These results may be explained 
by the nonlinear relation of BSA with total body weight (Figure 1), reducing the absolute 
increase in dose in relation to the increase in body weight.
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Because of the drawbacks of the previous measures, researchers have proposed us­
ing lean body weight (LBW) as a measure of body composition 73. Information on body 
weight as well as height and gender are required to calculate LBW (Figure 1). LBW repre­
sents the weight of bones, muscles, tendons, and organs without body fat (i.e., fat­free 
mass). The most recent LBW equation, proposed by Janmahasatian et al. 72, provided 
good predictions of the fat­free mass as measured with bioelectrical impedance analysis 
or dual­energy X­ray absorptiometry. The exact value of LBW as a predictor for dosing 
remains to be established. In this respect, it is important to note that in pharmacometric 
studies, this parameter was not always identified as the best predictor 67,74­75. Peters et 
al. 76 proposed a new formula to calculate LBW in children. However, researchers have 
very limited experience with this measure as a predictor for dosing drugs in obese 
children 77.
In general, actual body weight should be used with caution as a body­size descriptor 
in obesity because its value is influenced by factors such as age, sex, height, muscle 
mass, and obesity. Nevertheless, nonlinear functions of total body weight (TBW) show 
good performance as predictors of clearance in several pharmacokinetic studies cov­
ering wide ranges in body weight 74­75,78. Similarly, in a large study on the variation in 
clearance and volume of distribution of 12 different drugs, total body weight appeared 
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figure 1 Lean body weight 72 (a) and body surface area 68 (b) versus total body weight for males of various 
heights.
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the InfluenCe of obesItY on orAl bIoAvAIlAbIlItY And AbsorPtIon 
rAte
Only six studies have directly compared the oral bioavailability and absorption rate of 
drugs between obese and nonobese subjects on the basis of both oral and intravenous 
administration 80­85. For propranolol, clearance (CL) after an intravenous dose was not 
different between six obese (136 ± 36 kg) and six control (67 ± 5 kg) subjects. However, 
oral clearance (CL/F) was lower in obese patients, indicating that the bioavailability (F) of 
propranolol was slightly higher for obese subjects (35 ± 4% versus 27 ± 2%, p > 0.05) 80. 
In the discussion of their article, the authors point out that the slightly higher bioavail­
ability reported for propranolol may also be applicable for triazolam 80,86. Unfortunately, 
in the study on triazolam, there were no observations after intravenous administration 86, 
which makes it impossible to draw conclusions on an eventual difference in absolute 
bioavailability. For midazolam, no difference in bioavailability was found between 
normal­weight volunteers (66 ± 2 kg, n = 20) and obese volunteers (117 ± 8 kg, n = 20) 
(40 ± 3% versus 42 ± 4%, p> 0.05, respectively), nor was a difference found in time of 
maximum concentration (Tmax) or maximum concentration (Cmax) itself 81. Similarly, no 
difference in bioavailability or oral absorption rate was found for trazodone, cyclospo­
rine, dexfenfluramine, and moxifloxacin between obese and nonobese subjects 82­85.
In view of the limited number of studies on oral absorption, we most recently stud­
ied midazolam bioavailability in 20 morbidly obese patients (mean body weight 144 
kg (112­186 kg) and mean BMI 47 kg/m2 (40­68 kg/m2)) and 12 healthy volunteers (76 
kg (63­93 kg) and mean BMI 22 kg/m2 (19­26 kg/m2)) (http://clinicaltrials.gov/show/
NCT01519726). For this study, a semisimultaneous oral and intravenous administration 
design was chosen in which morbidly obese patients received 7.5 mg of midazolam 
orally followed by a 5 mg intravenous bolus dose after 159 ± 67 min. Healthy volunteers 
received 2­mg oral and 1­mg intravenous midazolam separated by 150 min. This study 
design allowed for the characterization of both clearance and bioavailability in a single 
pharmacokinetic study. Results of this study show an increased bioavailability (60 ± 13% 
versus 28 ± 7%, p < 0.01) and a lower oral absorption rate (0.057 ± 14% min−1 versus 0.13 
± 5 min−1, p < 0.01), but no influence of obesity on systemic clearance in morbidly obese 
patients compared to healthy volunteers 87. Dose simulations of the final population 
pharmacokinetic model showed that after a 7.5­mg oral midazolam, Cmax is only slightly 
lower, whereas Tmax is increased for morbidly obese patients (Figure 2c).
The significant difference in oral bioavailability reported in this study 87 may result 
from the larger body weights of the subjects compared to the previous study by Green­
blatt et al. 81, who reported no difference in bioavailability (mean body weight of 144 kg 
versus 117 kg). The observed higher bioavailability could be explained by an increased 
splanchnic blood flow 19, which may lead to reduced contact between midazolam and 
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intracellular CYP3A enzymes in the gut wall. Also, the increase in bioavailability may be 
explained by increased paracellular absorption through the gut wall, or a combination 
of both 51­52,88­89. The higher midazolam bioavailability found in morbidly obese patients, 
however, does not seem to result in higher Cmax values (Figure 2c); this may be explained 
by the higher volume of distribution 87 which was also reported by Greenblatt et al. 81. 
The lower absorption rate (and therefore increased Tmax) in morbidly obese patients may 
be the result of the difference in midazolam formulation, as healthy volunteers received 
an oral solution and morbidly obese patients a tablet. As midazolam effectiveness is 
determined by the initial midazolam concentrations after an oral dose, this study sug­
gests that the net result of the alterations in the different pharmacokinetic parameters 
is that no adjustments in oral midazolam dose seem necessary for obese individuals. 
However, a different conclusion should be drawn for intravenous administration, given 
the substantially increased volumes of distribution of midazolam in morbidly obese 
patients (Figure 2a, b) 81,87.
There is limited information on the influence of obesity on drug pharmacokinetics 
after oral administration. This is a major limitation, given the fact that most drugs are 
figure 2 Population­predicted midazolam con­
centrations over time based on the final pharma­
cokinetic model in three typical morbidly obese 
patients (112, 145, and 186 kg) and one healthy 
volunteer (76 kg) after (a) a 5­mg intravenous bo­
lus dose (logarithmic scale), (b) a 2.5­mg/h contin­
uous infusion (linear scale), and (c) a 7.5­mg oral 
dose (linear scale). Figure adapted from Reference 
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given orally. From the very small number of studies on drug absorption identified in 
this review, it seems that drug absorption is rather unaltered. However, this may be a 
premature conclusion warranting further systematic evaluations on drug absorption 90. 
Given the reported accelerated gastric emptying of solids 47­50, increased splanchnic 
blood flow 19, and increased gut permeability 51­52 in obese subjects, changes in absorp­
tion rate and oral bioavailability cannot be excluded. The recent study on midazolam 
oral and intravenous pharmacokinetics in both morbidly obese patients and healthy 
volunteers confirms some of these anticipated changes 87. The design of this study may 
be used as an example to study drug absorption because both oral and intravenous 
administration were evaluated within each individual. Investigators analyzing results on 
drug absorption from a study without data after intravenous administration risk being 
unable to distinguish between the influence of obesity on clearance and bioavailability 
(or between volume of distribution and bioavailability). Finally, the consequences of al­
tered absorption rate and oral bioavailability should each be evaluated for their clinical 
relevance and impact on drug dosing in the obese population.
the InfluenCe of obesItY on druG dIstrIbutIon
Volume of distribution is an important parameter that is often substantially altered in 
obese patients 79,90­92. It is particularly important to characterize changes in volume of 
distribution when a rapid onset of the effect is needed as the peak concentration after 
single­dose administration is largely determined by the volume of distribution. The 
same applies for the time to reach steady state and an eventual loading dose as part of 
a continued or repeated administration scheme. A rapid onset of effect may be clinically 
relevant in anesthesia, for anticoagulation, and for antimicrobial drug effects.
In general, drug distribution depends on the physicochemical properties of the drug, 
such as molecular weight, lipid solubility, and protein binding, as well as the properties 
of the biological system 91,93. The latter properties may differ between subjects (obese 
subjects versus healthy volunteers). In obese subjects, changes in volume of distribu­
tion may be expected to result from increased blood volume, increased cardiac output 
and blood flow, increased LBW, increased adipose tissue and reduced tissue perfu­
sion 19­22,91­92, with only a limited influence of changes in blood proteins (i.e., albumin, 
alpha acid glycoprotein) 23,94.
From the available evidence, the values of the volume of distribution appear highly 
variable in obese individuals and more difficult to predict than the values of clearance 79,90. 
While intuitively more influence of obesity on lipophilic drugs than on hydrophilic drugs 
may be expected 93, Jain et al. 90 concluded, on the basis of an overview of the ratios 
of volume of distribution of various drugs in obese versus nonobese individuals, that 
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changes in volume of distribution cannot be predicted on the basis of lipophilicity 
alone. More specifically, they showed that, for lipophilic drugs, the values for volume of 
distribution normalized with body weight may be increased, unchanged, or reduced 90. 
Also, in our experience, volume of distribution is difficult to predict. For instance, no 
influence of obesity on the peripheral volumes of distribution of propofol was observed, 
despite the high lipophilicity of the drug 75,77­78. For hydrophilic drugs, unchanged or 
decreased ratios of volume of distribution normalized with body weight were observed, 
but the magnitude of the effect of obesity was smaller than for lipophilic drugs 90.
Similarly, Mahmood 79 concluded, on the basis of a study on the pharmacokinetics of 
12 different drugs, that predictions of volume of distribution in the obese from the values 
in normal­weight subjects were less accurate than predictions of clearance. Although 
total body weight appeared to be a more consistent and reliable size descriptor than 
other size descriptors for the prediction of volume of distribution 79, as was suggested 
before 56, linear scaling of volume of distribution with body weight was reported to lead 
to overprediction of volume of distribution in the obese for many drugs. Instead, predic­
tion of volume of distribution by an allometric model on the basis of total body weight 
was more accurate. However, for the 12 drugs studied, the exponents of allometric func­
tions were found to vary widely (0.27–2.459), illustrating the variability of changes in 
volume of distribution as a result of total body weight 79. As the allometric models were 
built on data from normal­weight subjects, Mahmood concluded that inclusion of data 
from the obese into these allometric models could lead to better predictions 79.
The relative impact of the obesity­related changes in volume of distribution with 
respect to adjusting the dose in obese individuals is illustrated below in three examples.
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figure 3 Concentrations of (a) subcutaneous interstitial space fluid (ISF) cefazolin and (b) unbound plasma 
cefazolin in morbidly obese (black, n = 7 for panel a and n = 8 for panel b) and nonobese (grey, n = 7 for both 
panels) patients. Figure adapted from Reference 74 (Chapter 4) with permission.
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example 1: Cefazolin
In a clinical microdialysis study, cefazolin concentrations in subcutaneous adipose tissue 
and in plasma were evaluated in morbidly obese and nonobese patients 74. Previously, 
no influence of morbid obesity was found on protein binding or on trough concentra­
tions of cefazolin, whereas a modest influence of obesity was found on cefazolin peak 
concentrations upon an intravenous bolus administration 94. The results of the microdi­
alysis study show that cefazolin penetration into the subcutaneous tissue over 4 h after 
dosing in obese patients was reduced by 30% on average (Figure 3).
These results were explained by reduced distribution of cefazolin to the subcutane­
ous tissue, which was found to depend on body weight, while there was no evidence 
for an increased peripheral volume of distribution represented by the subcutaneous 
tissue compartment 74. Instead, the value of the central volume of distribution was 
found to depend on body weight, and there was no influence of weight on clearance. 
Because time above the minimal inhibitory concentration at the target site is relevant 
for cefazolin prophylaxis, these findings have important consequences for the dosing 
regimen, particularly for the heaviest patients 74. In this respect, it is also important to 
take into account that obesity is an independent risk factor for postoperative surgical 
site infection 7­8,95.
example 2: nadroparin
A second example concerns anti­Xa levels, which Diepstraten et al. 96 measured to 
evaluate the effect of nadroparin in morbidly obese patients (107–260 kg). Prophylactic 
ranges have been defined for anti­Xa levels 4 h after subcutaneous dosing 97­98. Volume 
of distribution is an essential parameter to determine the optimal dose for nadroparin. 
Upon subcutaneous administration, anti­Xa levels correlated best with LBW rather than 
BMI or total body weight, so dose adjustments on the basis of LBW are proposed 96.
An explanation for the finding that LBW should be used to dose low­molecular­weight 
heparins such as nadroparin could be that anti­Xa is a large, hydrophilic molecule that 
mainly distributes over vascular tissue and blood. Investigators have previously reported 
that blood volume increases with body weight in a nonlinear manner 22, which probably 
corresponds to LBW. Also, researchers have proposed to adjust the dose for enoxaparin, 
another low­molecular­weight heparin, in obese individuals on the basis of LBW 99. Opti­
mal dosing of low­molecular­weight heparins in obese individuals is particularly impor­
tant because these individuals are at increased risk for venous thrombosis embolisms 100.
example 3: Atracurium
As a third example, we present a pharmacodynamic study on atracurium in morbidly 
obese patients (BMI > 40 kg/m2, body weight 112–260 kg) 62. Patients were randomized 
to receive atracurium on the basis of IBW or total body weight (TBW). Dosing on the 
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basis of IBW resulted in a predictable profile of muscle relaxation, allowing for adequate 
intubation conditions and recovery of muscle strength within 60 min. In the patients for 
whom the dose was individualized on the basis of TBW, a dose­dependent prolongation 
of action was shown (Figure 4); thus, van Kralingen et al. 62 concluded that atracurium 
should be dosed on IBW.
In this example, changes in both pharmacokinetics (volume of distribution, clear­
ance), and pharmacodynamics may have contributed to these results. Similar results 
have previously been reported for rocuronium 63­64. Remarkably, these results have led 
to an IBW­based dosing advice for rocuronium in the European label, whereas in the 
United States, rocuronium is still advised to be dosed on total bodyweight 90.
From this overview, it seems that the current level of understanding of the com­
prehensive effect of obesity on volume of distribution is limited. Although volume of 
distribution often changes with obesity, the direction and magnitude is not always 
predictable 79,90, despite many efforts to correlate it to physicochemical properties 17,90­92. 
When no information is available, extrapolation on the basis of total body weight with 
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figure 4 Effect of atracurium expressed as time to recovery of the twitch response of the neuromuscular 
train­of­four (TOF) to 5% versus dose for morbidly obese patients dosed 0.5 mg/kg based on ideal body 
weight (grey squares, n = 8) and dosed 0.5 mg/kg based on total body weight (black triangles, n = 9). Figure 
adapted from Reference 62 with permission.
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the InfluenCe of obesItY on druG MetAbolIsM And exCretIon
Typically, there is more attention for the influence of obesity on metabolic and elimina­
tion clearance than on drug distribution 79,101­103. This may be explained by the fact that 
drug clearance is considered the most important pharmacokinetic parameter because it 
determines the maintenance dose of drugs.
A systematic review on reported clearance values of drugs in both obese and non­
obese patients showed that the influence of obesity on drug metabolism and elimina­
tion differs between specific metabolic or elimination pathways 101, even though the 
magnitude of its influence seems relatively small compared to the influence of obesity 
on distribution 79). Overall, the clearance of drugs primarily metabolized through the 
Phase II metabolism enzyme uridine diphosphate glucuronosyltransferase is reported 
to increase with obesity. For drugs that are eliminated through Phase I metabolism, the 
changes may differ depending on the pertinent enzyme. For example, an increased 
CYP2E1 clearance, a lower CYP3A clearance, and a trend toward higher clearance of 
CYP1A2, CYP2C9, CYP2C19, and CYP2D6 substrates have been reported 101. In agreement 
with these literature findings, oral clearances were successfully predicted for eight drugs 
that are primarily cleared by CYP3A, CYP1A2, CYP2E1, and CYP2C9 on the basis of physi­
ologically based pharmacokinetic modeling, in which known alterations in physiology 
resulting from obesity are implemented 103. More specifically, seven out of nine cases 
(involving eight drugs) were within 2­fold of the actual ratio between clearance in obese 
and lean patients 103. Remarkably, in this study, oral clearances of the CYP3A substrates 
alprazolam, midazolam, triazolam, and cyclosporine in the obese were somewhat over­
predicted compared to observed oral clearance values, which were expected to be lower 
in the obese 103. As for midazolam, similar systemic clearance and higher bioavailability 
in morbidly obese patients were recently reported 87; it is emphasized that oral clear­
ance equals CL/F and that reported differences in oral clearance in the obese may result 
from differences in systemic clearance, bioavailability, or both. Therefore, investigators 
should take care to predict systemic clearance on the basis of oral data as long as limited 
information is available on drug absorption in the obese.
With respect to renal clearance, higher values are reported in obese individuals 35,101. 
Recent results on the renally excreted antibiotic cefazolin in morbidly obese patients 
undergoing bariatric surgery did not identify an influence of body weight on cefazolin 
clearance, however 74,94. Even though this finding may be an artifact resulting from the 
relatively short sampling time in the study, a lack of change in glomerular filtration rate 
in obese individuals without microalbuminuria has been reported before 38, emphasiz­
ing that renal clearance of drugs may not necessarily be increased.
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Concerning drug clearance mediated by liver blood flow, higher values were reported 
for a small number of high­extraction­ratio drugs with clearance values of more than 
1.5 L/min 101, which confirm early reports on increased hepatic flow in obese patients 19.
Recently, Mahmood 79 has used an allometric equation to scale the pharmacokinetics 
of 12 drugs that are eliminated through different routes between healthy normal­weight 
subjects and obese patients. The results of this study indicate that clearances of these 12 
different drugs increase in a nonlinear manner with total body weight 79, confirming a 
previous report 56. Clearance in the obese could be predicted with accuracy from normal­
weight subjects using total body weight and simple allometry if an allometric exponent 
was estimated within the normal­weight population 79. In addition, allometric scaling 
with a fixed exponent of 0.75 or 1.0 was found to be inferior to the allometric model in 
which the exponent was estimated. Mahmood 79 also states that obesity may not have 
an impact on clearance at all, as was the case for phenazone, carbamazepine, lithium, 
remifentanil, cefazolin, and theophylline; thus, we emphasize that allometric scaling 
using a fixed exponent of 0.75 or 1.0 on the basis of results from normal­weight patients 
should not be applied unless more data become available. This argument also applies 
to the proposal to scale clearance with LBW with an exponent of 2/3, independent of 
the drug’s primary route of metabolism and elimination 102, as this approach assumes an 
increase in clearance with obesity, which may not be the case for all drugs 79,104.
In conclusion, for clearance, the influence of obesity seems smaller and somewhat 
easier to predict compared to alterations in volume of distribution, even though many 
questions remain on the exact quantification 101. From the results presented here, it seems 
that predictions can be made on the basis of the primary pathway involved 101,103. When 
no information is available, extrapolation on the basis of total body weight with an esti­
mated allometric exponent from results in normal­weight subjects seems preferable 79.
ChArACterIzAtIon of the InfluenCe of obesItY In ChIldren
Despite the increasing numbers of obese and morbidly obese children, very limited 
pharmacokinetic and dosing information in obese children is available 105­107. A specific 
aspect that investigators, regulators, and prescribers should consider when determin­
ing dosing guidelines for obese children and adolescents is that, in general pediatric 
practice, dosing regimens are expressed in mg/kg. This linear mg/kg­based dosing is 
subject to debate even in normal­weight children between 0 and 18 years 108­112, but 
an overdose may be anticipated if the dosing is based on mg/kg total body weight in 
overweight and, particularly, obese and morbidly children. This underscores the need to 
develop dedicated models for obese and morbidly obese children and adolescents 78. 
Performing these studies in the target population of obese individuals is even more 
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relevant given that differences in pharmacokinetics, pharmacodynamics, or even the 
disease itself may exist in this population 12­13.
In view of the limited number of pharmacokinetic studies in obese children 101,113­114, 
we present two pharmacokinetic studies in which data from overweight and obese chil­
dren (and adults) of a large age range, along with their controls, are analyzed. In obese 
children, total body weight can be considered to be composed of both weight resulting 
from growth and development and weight from varying levels of obesity. This raises the 
question of, for instance, whether an obese 9­year­old child weighing 60 kg ­in whom 
part of this body weight is physiological weight, i.e., body weight conforming to his 
age, and the other part is overweight­ should receive the same dose as a normal­weight 
16­year­old individual of the same weight. The distinction between physiological weight 
and overweight should be kept in mind when weight is studied as a covariate in children 
of varying ages and varying degrees of obesity.
example 1: Propofol
For propofol, researchers performed a population pharmacokinetic meta­analysis with 
data from morbidly obese adults, adolescents, and children and their nonobese controls 
(body weight 37–184 kg, age 9–79 years) 77. In this analysis, propofol clearance was 
found to increase with body weight according to a power function. Age was identified 
and implemented as a second covariate using a bilinear function with two distinct 
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figure 5 Individual post hoc propofol clearance estimates versus total body weight for morbidly obese 
adults and their nonobese controls (black circles) and obese adolescents and children and their nonobese 
controls (grey circles) (n = 94). The dashed lines indicate the population clearance values for 15, 41, and 65 
years. Figure adapted from Reference 77 with permission.
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example 2: busulfan
In another study, investigators determined busulfan concentrations from a large popu­
lation of underweight, normal­weight, and overweight children, adolescents, and adults 
(0.1–35 years) 115. This study used a previously derived, body weight–driven, pharmaco­
kinetic model for busulfan in children of all ages 116. The results showed that the derived 
model 116 proved equally predictive in normal­weight, underweight, and overweight 
children 115. In addition, Bartelink et al. developed an exploratory model in which the 
body weight of each patient was considered to be composed of two parts: (a) physi­
ological body weight related to growth (mean body weight­for­age) and (b) overweight, 
i.e., body weight related to under/overweight for a certain age (body weight Z­score) 
(Figure 6). Despite adequate performance of this exploratory model in which weight as 
a result of growth and obesity was disentangled (Figure 6), the model was not superior 
over the simple, weight­based model 115­116.
To capture the entire developmental change in clearance across the pediatric age 
range, this pharmacokinetic analysis of busulfan in over­ and underweight children of 
all ages used an advanced power function based on body weight in which the exponent 
was allowed to change with body weight 116­117. This advanced power function was 
needed because very young infants were also included in the busulfan analysis, whereas 
the propofol analysis did not consider children younger than 9 years of age 77. When this 
function was used for busulfan, the data were adequately described, and no influence of 
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figure 6 Busulfan clearance versus mean body weight­for­age for an exploratory model of overweight and 
underweight for children of all ages. In the model, a function for body weight due to growth (described 
using mean body weight­for­age, black line) and a function for body weight due to under­ and overweight 
(described using the body weight Z­score) were implemented. Grey lines represent body weight Z­scores 
of +1 (dark grey) and +2 (light grey), and broken lines represent body weight Z­scores of −1 (dashed) and −2 
(dotted). Figure adapted from Reference 115 with permission.
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age could be identified. In contrast, for propofol, a bilinear, age­based function with two 
distinct slopes was found (Figure 5) 77. The reason for this difference may be in part that, 
for the busulfan analysis, no patients above 35 years were included 115. For busulfan, these 
results imply that within the ranges of age and weight studied, dosing in children can 
be based on actual body weight, irrespective of the level of over­ or underweight 115­116.
In conclusion, although very limited pharmacokinetic and dosing information is avail­
able in obese children 105­107, we present two approaches on how to analyze data from 
children varying in age and degree of obesity (Figures 5 and 6). Future clinical studies 
should focus on the pharmacokinetics and pharmacodynamics of commonly used 
drugs in obese and morbidly obese children and adolescents to expand our knowledge 
in this clinically important area. Such studies should perform proper evaluations of the 
exact influence of weight resulting from growth, obesity, and age; these evaluations 
may be complicated because of the interrelation between weight and age in different 
manners, and they should use advanced validation frameworks, such as those described 
for pediatric pharmacokinetic analyses 118.
PersPeCtIves
To predict the optimal dose for each drug in the obese, not only well­designed clinical 
studies on drug disposition in obese adults and children upon oral and intravenous 
administration are needed. Future research should also focus on the characterization of 
physiological concepts that can be used across drugs. From this overview, it is clear that 
for none of the parameters bioavailability, volume of distribution or clearance, a general 
covariate model with one size descriptor and one allometric exponent can be defined 
without paying attention to the nature of the compound involved, including the route 
of elimination. In this respect, physiologically based modeling principles that take into 
account both drug characteristics and physiological changes in the obese body are of 
large importance.
For obesity­related changes in clearance, a recently reported, semiphysiological 
approach applied in children, in which information for one drug was used to predict 
changes for another drug sharing the same metabolic or elimination pathway, may 
deserve attention. Using this approach, the maturation function for glucuronidation of 
morphine in young children 119­120 was found to adequately predict the maturation in 
zidovudine glucuronidation in infants 121. As the physicochemical drug parameters were 
not found to affect this maturation profile, researchers concluded that this maturation 
function for glucuronidation can also be used for other substrates of this enzyme 122. 
This approach of between­drug predictions was also applied to renally excreted drugs 
in 0.5–5 kg neonates on the basis of a model derived for amikacin 123. This model has 
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recently been extended to older children and adults 124 to obtain adequate predictions 
for other renally excreted drugs 125­126.
To predict volumes of distribution in the obese, investigators need to take into ac­
count both physicochemical properties and physiological changes in the obese body. 
Most recently, a new covariate relation that integrates body weight and LBW as covari­
ates, with a weighting factor depending on the physicochemical properties of the drug, 
was proposed to predict volume of distribution at steady state 127. Even though this 
approach was applied to only a limited number of obese individuals weighing below 
100 kg, it deserves further exploration in the obese population, particularly because this 
approach to covariate modeling led to similar results as a whole­body, physiologically 
based pharmacokinetic model 127.
ConClusIon
In conclusion, although studies are particularly needed on absorption and distribution 
of drugs in obese individuals, some insight has been gained into changes in important 
metabolic and elimination pathways in obesity. For obese children, investigators need 
to perform clinical studies for which the proposed models 77,115 can be used to analyze 
the data. Future research should focus on the characterization of physiological concepts 
to predict the optimal dose for each drug in the obese.
dIsClosure stAteMent
The authors are not aware of any affiliations, memberships, funding, or financial hold­
ings that might be perceived as affecting the objectivity of this review.
3 | 91
referenCes
 1. Flegal KM, Carroll MD, Kit BK, Ogden CL: Prevalence of obesity and trends in the distribution of 
body mass index among US adults, 1999­2010. Jama 2012; 307: 491­7
 2. Ogden CL, Carroll MD, Kit BK, Flegal KM: Prevalence of obesity and trends in body mass index 
among US children and adolescents, 1999­2010. Jama 2012; 307: 483­90
 3. World, Obes., Fed.: World map of obesity, 2014
 4. Haslam DW, James WP: Obesity. Lancet 2005; 366: 1197­209
 5. Stone AA, Broderick JE: Obesity and pain are associated in the United States. Obesity (Silver 
Spring) 2012; 20: 1491­5
 6. McCarthy LH, Bigal ME, Katz M, Derby C, Lipton RB: Chronic pain and obesity in elderly people: 
results from the Einstein aging study. J Am Geriatr Soc 2009; 57: 115­9
 7. Choban PS, Heckler R, Burge JC, Flancbaum L: Increased incidence of nosocomial infections in 
obese surgical patients. Am Surg 1995; 61: 1001­5
 8. Huttunen R, Karppelin M, Syrjanen J: Obesity and nosocomial infections. J Hosp Infect 2013; 85: 
8­16
 9. Oyetunji TA, Franklin AL, Ortega G, Akolkar N, Qureshi FG, Abdullah F, Cornwell EE, Nwomeh BC, 
Fullum TM: Revisiting childhood obesity: persistent underutilization of surgical intervention? Am 
Surg 2012; 78: 788­93
 10. Schilling PL, Davis MM, Albanese CT, Dutta S, Morton J: National trends in adolescent bariatric 
surgical procedures and implications for surgical centers of excellence. J Am Coll Surg 2008; 206: 
1­12
 11. Black MH, Zhou H, Takayanagi M, Jacobsen SJ, Koebnick C: Increased asthma risk and asthma­
related health care complications associated with childhood obesity. Am J Epidemiol 2013; 178: 
1120­8
 12. Forno E, Lescher R, Strunk R, Weiss S, Fuhlbrigge A, Celedon JC: Decreased response to inhaled 
steroids in overweight and obese asthmatic children. J Allergy Clin Immunol 2011; 127: 741­9
 13. Gelelete CB, Pereira SH, Azevedo AM, Thiago LS, Mundim M, Land MG, Costa ES: Overweight as a 
prognostic factor in children with acute lymphoblastic leukemia. Obesity (Silver Spring) 2011; 19: 
1908­11
 14. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C, Seyberth H, Pandol­
fini C, Raffaelli MP, Rocchi F, Bonati M, Jong G, de Hoog M, van den Anker J: Survey of unlicensed 
and off label drug use in paediatric wards in European countries. European Network for Drug 
Investigation in Children. Bmj 2000; 320: 79­82
 15. Ernest TB, Elder DP, Martini LG, Roberts M, Ford JL: Developing paediatric medicines: identifying 
the needs and recognizing the challenges. J Pharm Pharmacol 2007; 59: 1043­55
 16. t Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN: A survey of the use 
of off­label and unlicensed drugs in a Dutch children’s hospital. Pediatrics 2001; 108: 1089­93
 17. Cheymol G: Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet 1993; 
25: 103­14
 18. Cheymol G: Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmaco­
kinet 2000; 39: 215­31
 19. Alexander JK, Dennis EW, Smith WG, Amad KH, Duncan WC, Austin RC: Blood volume, cardiac 
output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull 
1962; 1: 39­44
3 | 92
 20. Licata G, Scaglione R, Barbagallo M, Parrinello G, Capuana G, Lipari R, Merlino G, Ganguzza A: 
Effect of obesity on left ventricular function studied by radionuclide angiocardiography. Int J 
Obes 1991; 15: 295­302
 21. Herrera MF, Deitel M: Cardiac function in massively obese patients and the effect of weight loss. 
Can J Surg 1991; 34: 431­4
 22. Lemmens HJ, Bernstein DP, Brodsky JB: Estimating blood volume in obese and morbidly obese 
patients. Obes Surg 2006; 16: 773­6
 23. Blouin RA, Kolpek JH, Mann HJ: Influence of obesity on drug disposition. Clin Pharm 1987; 6: 
706­14
 24. Crocker DW: Lipomatous infiltrates of the heart. Arch Pathol Lab Med 1978; 102: 69­72
 25. Bharati S, Lev M: Cardiac conduction system involvement in sudden death of obese young 
people. Am Heart J 1995; 129: 273­81
 26. Jones RL, Nzekwu MM: The effects of body mass index on lung volumes. Chest 2006; 130: 827­33
 27. Rajala R, Partinen M, Sane T, Pelkonen R, Huikuri K, Seppalainen AM: Obstructive sleep apnoea 
syndrome in morbidly obese patients. J Intern Med 1991; 230: 125­9
 28. Guzzaloni G, Grugni G, Minocci A, Moro D, Morabito F: Liver steatosis in juvenile obesity: correla­
tions with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses 
to an oral glucose tolerance test. Int J Obes Relat Metab Disord 2000; 24: 772­6
 29. Moretto M, Kupski C, Mottin CC, Repetto G, Garcia Toneto M, Rizzolli J, Berleze D, de Souza Brito 
CL, Casagrande D, Colossi F: Hepatic steatosis in patients undergoing bariatric surgery and its 
relationship to body mass index and co­morbidities. Obes Surg 2003; 13: 622­4
 30. Ijaz S, Yang W, Winslet MC, Seifalian AM: Impairment of hepatic microcirculation in fatty liver. 
Microcirculation 2003; 10: 447­56
 31. Farrell GC, Teoh NC, McCuskey RS: Hepatic microcirculation in fatty liver disease. Anat Rec (Hobo­
ken) 2008; 291: 684­92
 32. Casati A, Putzu M: Anesthesia in the obese patient: pharmacokinetic considerations. J Clin Anesth 
2005; 17: 134­45
 33. Johnson TN, Tucker GT, Tanner MS, Rostami­Hodjegan A: Changes in liver volume from birth to 
adulthood: a meta­analysis. Liver Transpl 2005; 11: 1481­93
 34. Kotlyar M, Carson SW: Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Phar­
macol Ther 1999; 37: 8­19
 35. Janmahasatian S, Duffull SB, Chagnac A, Kirkpatrick CM, Green B: Lean body mass normalizes the 
effect of obesity on renal function. Br J Clin Pharmacol 2008; 65: 964­5
 36. Ribstein J, du Cailar G, Mimran A: Combined renal effects of overweight and hypertension. Hyper­
tension 1995; 26: 610­5
 37. Marik P, Varon J: The obese patient in the ICU. Chest 1998; 113: 492­8
 38. Anastasio P, Spitali L, Frangiosa A, Molino D, Stellato D, Cirillo E, Pollastro RM, Capodicasa L, Sepe 
J, Federico P, Gaspare De Santo N: Glomerular filtration rate in severely overweight normotensive 
humans. Am J Kidney Dis 2000; 35: 1144­8
 39. O’Donnell MP, Kasiske BL, Cleary MP, Keane WF: Effects of genetic obesity on renal structure and 
function in the Zucker rat. II. Micropuncture studies. J Lab Clin Med 1985; 106: 605­10
 40. Kasiske BL, Cleary MP, O’Donnell MP, Keane WF: Effects of genetic obesity on renal structure and 
function in the Zucker rat. J Lab Clin Med 1985; 106: 598­604
 41. Schmitz PG, O’Donnell MP, Kasiske BL, Katz SA, Keane WF: Renal injury in obese Zucker rats: 
glomerular hemodynamic alterations and effects of enalapril. Am J Physiol 1992; 263: F496­502
3 | 93
 42. Kasiske BL, Crosson JT: Renal disease in patients with massive obesity. Arch Intern Med 1986; 146: 
1105­9
 43. Pai MP: Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv 
Chronic Kidney Dis 2010; 17: e53­62
 44. Demirovic JA, Pai AB, Pai MP: Estimation of creatinine clearance in morbidly obese patients. Am J 
Health Syst Pharm 2009; 66: 642­8
 45. Wuerzner G, Bochud M, Giusti V, Burnier M: Measurement of glomerular filtration rate in obese 
patients: pitfalls and potential consequences on drug therapy. Obes Facts 2011; 4: 238­43
 46. Lim WH, Lim EM, McDonald S: Lean body mass­adjusted Cockcroft and Gault formula improves 
the estimation of glomerular filtration rate in subjects with normal­range serum creatinine. 
Nephrology (Carlton) 2006; 11: 250­6
 47. Cardoso­Junior A, Coelho LG, Savassi­Rocha PR, Vignolo MC, Abrantes MM, de Almeida AM, Dias 
EE, Vieira Junior G, de Castro MM, Lemos YV: Gastric emptying of solids and semi­solids in mor­
bidly obese and non­obese subjects: an assessment using the 13C­octanoic acid and 13C­acetic 
acid breath tests. Obes Surg 2007; 17: 236­41
 48. Tosetti C, Corinaldesi R, Stanghellini V, Pasquali R, Corbelli C, Zoccoli G, Di Febo G, Monetti N, 
Barbara L: Gastric emptying of solids in morbid obesity. Int J Obes Relat Metab Disord 1996; 20: 
200­5
 49. Wright RA, Krinsky S, Fleeman C, Trujillo J, Teague E: Gastric emptying and obesity. Gastroenterol­
ogy 1983; 84: 747­51
 50. Xing J, Chen JD: Alterations of gastrointestinal motility in obesity. Obes Res 2004; 12: 1723­32
 51. Teixeira TF, Souza NC, Chiarello PG, Franceschini SC, Bressan J, Ferreira CL, Peluzio Mdo C: In­
testinal permeability parameters in obese patients are correlated with metabolic syndrome risk 
factors. Clin Nutr 2012; 31: 735­40
 52. Horton F, Wright J, Smith L, Hinton PJ, Robertson MD: Increased intestinal permeability to oral 
chromium (51 Cr) ­EDTA in human Type 2 diabetes. Diabet Med 2013
 53. French SJ, Murray B, Rumsey RD, Sepple CP, Read NW: Preliminary studies on the gastrointestinal 
responses to fatty meals in obese people. Int J Obes Relat Metab Disord 1993; 17: 295­300
 54. Wisen O, Johansson C: Gastrointestinal function in obesity: motility, secretion, and absorption 
following a liquid test meal. Metabolism 1992; 41: 390­5
 55. WHO: Global database on BMI classification World Health Organization 2006
 56. Green B, Duffull SB: What is the best size descriptor to use for pharmacokinetic studies in the 
obese? Br J Clin Pharmacol 2004; 58: 119­33
 57. Eleveld DJ, Proost JH, Absalom AR, Struys MM: Obesity and allometric scaling of pharmacokinet­
ics. Clin Pharmacokinet 2011; 50: 751­3; discussion 755­6
 58. Kuczmarski RJ, Ogden CL, Guo SS, Grummer­Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche 
AF, Johnson CL: 2000 CDC Growth Charts for the United States: methods and development. Vital 
Health Stat 11 2002; 246: 1­190
 59. http://www.cdc.gov/growthcharts/percentile_data_files.htm. Accessed 05­03­2014 Centers for 
Disease Control and Prevention
 60. Barlow SE: Expert committee recommendations regarding the prevention, assessment, and 
treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120 
Suppl 4: S164­92
 61. Devine J: Gentamycin Therapy. Ann Pharmacother 1974; 8: 650­655
3 | 94
 62. van Kralingen S, van de Garde EM, Knibbe CA, Diepstraten J, Wiezer MJ, van Ramshorst B, van 
Dongen EP: Comparative evaluation of atracurium dosed on ideal body weight vs. total body 
weight in morbidly obese patients. Br J Clin Pharmacol 2011; 71: 34­40
 63. Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A: The pharmacodynamic effects of 
rocuronium when dosed according to real body weight or ideal body weight in morbidly obese 
patients. Anesth Analg 2004; 99: 1086­9, table of contents
 64. Meyhoff CS, Lund J, Jenstrup MT, Claudius C, Sorensen AM, Viby­Mogensen J, Rasmussen LS: 
Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? 
Anesth Analg 2009; 109: 787­92
 65. Egan TD, Huizinga B, Gupta SK, Jaarsma RL, Sperry RJ, Yee JB, Muir KT: Remifentanil pharmacoki­
netics in obese versus lean patients. Anesthesiology 1998; 89: 562­73
 66. Pai MP: Drug dosing based on weight and body surface area: mathematical assumptions and 
limitations in obese adults. Pharmacotherapy 2012; 32: 856­68
 67. van Rongen A, Brill MJ, Diepstraten J, Knibbe CA: Applied pharmacometrics in the obese popula­
tion, Applied Pharmacometrics. USA Springer. In press
 68. Du Bois D, Du Bois EF: A formula to estimate th approximate surface area if height and weight be 
known. Arch Int Med 1916; 17: 863­71
 69. Mosteller RD: Simplified calculation of body­surface area. N Engl J Med 1987; 317
 70. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, 
Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH: Appropriate che­
motherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology 
clinical practice guideline. J Clin Oncol 2012; 30: 1553­61
 71. Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD: Evaluation 
of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 
2007; 25: 4707­13
 72. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B: Quantification of lean body­
weight. Clin Pharmacokinet 2005; 44: 1051­65
 73. Han PY, Duffull SB, Kirkpatrick CM, Green B: Dosing in obesity: a simple solution to a big problem. 
Clin Pharmacol Ther 2007; 82: 505­8
 74. Brill MJ, Houwink AP, Schmidt S, Van Dongen EP, Hazebroek EJ, van Ramshorst B, Deneer VH, 
Mouton JW, Knibbe CA: Reduced subcutaneous tissue distribution of cefazolin in morbidly obese 
versus non­obese patients determined using clinical microdialysis. J Antimicrob Chemother 
2014; 69: 715­23
 75. van Kralingen S, Diepstraten J, Peeters MY, Deneer VH, van Ramshorst B, Wiezer RJ, van Dongen 
EP, Danhof M, Knibbe CA: Population pharmacokinetics and pharmacodynamics of propofol in 
morbidly obese patients. Clin Pharmacokinet 2011; 50: 739­50
 76. Peters AM, Snelling HL, Glass DM, Bird NJ: Estimation of lean body mass in children. Br J Anaesth 
2011; 106: 719­23
 77. Diepstraten J, Chidambaran V, Sadhasivam S, Blusse van Oud­Alblas HJ, Inge T, van Ramshorst B, 
van Dongen EP, Vinks AA, Knibbe CA: An integrated population pharmacokinetic meta­analysis of 
propofol in morbidly obese and nonobese adults, adolescents, and children. CPT Pharmacomet­
rics Syst Pharmacol 2013; 2: e73
 78. Diepstraten J, Chidambaran V, Sadhasivam S, Esslinger HR, Cox SL, Inge TH, Knibbe CA, Vinks AA: 
Propofol clearance in morbidly obese children and adolescents: influence of age and body size. 
Clin Pharmacokinet 2012; 51: 543­51
3 | 95
 79. Mahmood I: Prediction of clearance and volume of distribution in the obese from normal weight 
subjects: an allometric approach. Clin Pharmacokinet 2012; 51: 527­42
 80. Bowman SL, Hudson SA, Simpson G, Munro JF, Clements JA: A comparison of the pharmacokinet­
ics of propranolol in obese and normal volunteers. Br J Clin Pharmacol 1986; 21: 529­32
 81. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI: Effect of age, gen­
der, and obesity on midazolam kinetics. Anesthesiology 1984; 61: 27­35
 82. Greenblatt DJ, Friedman H, Burstein ES, Scavone JM, Blyden GT, Ochs HR, Miller LG, Harmatz JS, 
Shader RI: Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther 1987; 42: 
193­200
 83. Flechner SM, Kolbeinsson ME, Tam J, Lum B: The impact of body weight on cyclosporine pharma­
cokinetics in renal transplant recipients. Transplantation 1989; 47: 806­10
 84. Cheymol G, Weissenburger J, Poirier JM, Gellee C: The pharmacokinetics of dexfenfluramine in 
obese and non­obese subjects. Br J Clin Pharmacol 1995; 39: 684­7
 85. Kees MG, Weber S, Kees F, Horbach T: Pharmacokinetics of moxifloxacin in plasma and tissue of 
morbidly obese patients. J Antimicrob Chemother 2011; 66: 2330­5
 86. Abernethy DR, Greenblatt DJ, Divoll M, Smith RB, Shader RI: The influence of obesity on the 
pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet 1984; 9: 177­83
 87. Brill M, van Rongen A, Houwink A, Burggraaf J, van Ramshorst B, Wiezer R, Van Dongen E, Knibbe 
C: Midazolam pharmacokinetics in morbidly obese patients following semi­simultaneous oral 
and intravenous administration: a comparison with healthy volunteers. Clin Pharmacokinet 2014; 
In press
 88. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami­Hodjegan A: Prediction of intestinal first­pass drug 
metabolism. Curr Drug Metab 2007; 8: 676­84
 89. Rostami­Hodjegan A, Tucker GT: The effects of portal shunts on intestinal cytochrome P450 3A 
activity. Hepatology 2002; 35: 1549­50; author reply 1550­1
 90. Jain R, Chung SM, Jain L, Khurana M, Lau SW, Lee JE, Vaidyanathan J, Zadezensky I, Choe S, Sa­
hajwalla CG: Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol 
Ther 2011; 90: 77­89
 91. Hanley MJ, Abernethy DR, Greenblatt DJ: Effect of obesity on the pharmacokinetics of drugs in 
humans. Clin Pharmacokinet 2010; 49: 71­87
 92. Blouin RA, Warren GW: Pharmacokinetic considerations in obesity. J Pharm Sci 1999; 88: 1­7
 93. Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI: Alterations in drug distribution and 
clearance due to obesity. J Pharmacol Exp Ther 1981; 217: 681­5
 94. van Kralingen S, Taks M, Diepstraten J, van de Garde EM, van Dongen EP, Wiezer MJ, van Rams­
horst B, Vlaminckx B, Deneer VH, Knibbe CA: Pharmacokinetics and protein binding of cefazolin 
in morbidly obese patients. Eur J Clin Pharmacol 2011; 67: 985­92
 95. Falagas ME, Kompoti M: Obesity and infection. Lancet Infect Dis 2006; 6: 438­46
 96. Diepstraten J, Hackeng CM, van Kralingen S, Zapletal J, van Dongen EP, Wiezer RJ, van Ramshorst 
B, Knibbe CA: Anti­Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin 
Strongly Correlate with Lean Body Weight in Morbidly Obese Patients. Obes Surg 2012
 97. Hirsh J, Raschke R: Heparin and low­molecular­weight heparin: the Seventh ACCP Conference on 
Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S­203S
 98. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE: Low­molecular­weight heparins in renal impair­
ment and obesity: available evidence and clinical practice recommendations across medical and 
surgical settings. Ann Pharmacother 2009; 43: 1064­83
3 | 96
 99. Barras MA, Duffull SB, Atherton JJ, Green B: Individualized compared with conventional dosing of 
enoxaparin. Clin Pharmacol Ther 2008; 83: 882­8
 100. Stein PD, Beemath A, Olson RE: Obesity as a risk factor in venous thromboembolism. Am J Med 
2005; 118: 978­80
 101. Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA: Impact of 
obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 2012; 51: 
277­304
 102. McLeay SC, Morrish GA, Kirkpatrick CM, Green B: The relationship between drug clearance and 
body size: systematic review and meta­analysis of the literature published from 2000 to 2007. Clin 
Pharmacokinet 2012; 51: 319­30
 103. Ghobadi C, Johnson TN, Aarabi M, Almond LM, Allabi AC, Rowland­Yeo K, Jamei M, Rostami­Hod­
jegan A: Application of a systems approach to the bottom­up assessment of pharmacokinetics in 
obese patients: expected variations in clearance. Clin Pharmacokinet 2011; 50: 809­22
 104. Hall RG, 2nd, Jean GW, Sigler M, Shah S: Dosing considerations for obese patients receiving cancer 
chemotherapeutic agents. Ann Pharmacother 2013; 47: 1666­74
 105. Mulla H, Johnson TN: Dosing dilemmas in obese children. Arch Dis Child Educ Pract Ed 2010; 95: 
112­7
 106. Kendrick JG, Carr RR, Ensom MH: Pharmacokinetics and drug dosing in obese children. J Pediatr 
Pharmacol Ther 2010; 15: 94­109
 107. Mahmood I: Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and 
Modelling Approaches in Paediatric Drug Development and Clinical Settings. Clin Pharmacokinet 
2014
 108. Knibbe CA, Danhof M: Individualized dosing regimens in children based on population PKPD 
modelling: are we ready for it? Int J Pharm 2011; 415: 9­14
 109. Knibbe CA, Krekels EH, Danhof M: Advances in paediatric pharmacokinetics. Expert Opin Drug 
Metab Toxicol 2011; 7: 1­8
 110. Admiraal R, van Kesteren C, Boelens JJ, Bredius RG, Tibboel D, Knibbe CA: Towards evidence­based 
dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic 
modelling. Arch Dis Child 2014; 99: 267­72
 111. Cella M, Knibbe C, Danhof M, Della Pasqua O: What is the right dose for children? Br J Clin Phar­
macol 2010; 70: 597­603
 112. De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA: The role of population PK­PD 
modelling in paediatric clinical research. Eur J Clin Pharmacol 2011; 67 Suppl 1: 5­16
 113. Koshida R, Nakashima E, Taniguchi N, Tsuji A, Benet LZ, Ichimura F: Prediction of the distribution 
volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic 
concepts. Pharm Res 1989; 6: 486­91
 114. Heble DE, Jr., McPherson C, Nelson MP, Hunstad DA: Vancomycin trough concentrations in over­
weight or obese pediatric patients. Pharmacotherapy 2013; 33: 1273­7
 115. Bartelink IH, van Kesteren C, Boelens JJ, Egberts TC, Bierings MB, Cuvelier GD, Wynn RF, Slatter MA, 
Chiesa R, Danhof M, Knibbe CA: Predictive performance of a busulfan pharmacokinetic model in 
children and young adults. Ther Drug Monit 2012; 34: 574­83
 116. Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB, Shaw PJ, Nath CE, Hempel 
G, Zwaveling J, Danhof M, Knibbe CA: Body weight­dependent pharmacokinetics of busulfan in 
paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin 
Pharmacokinet 2012; 51: 331­45
3 | 97
 117. Wang C, Peeters MY, Allegaert K, Blusse van Oud­Alblas HJ, Krekels EH, Tibboel D, Danhof M, 
Knibbe CA: A bodyweight­dependent allometric exponent for scaling clearance across the hu­
man life­span. Pharm Res 2012; 29: 1570­81
 118. Krekels EH, van Hasselt JG, Tibboel D, Danhof M, Knibbe CA: Systematic evaluation of the descrip­
tive and predictive performance of paediatric morphine population models. Pharm Res 2011; 28: 
797­811
 119. Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van Dijk M, Simons SH, van Lin­
gen RA, Jacqz­Aigrain EM, Danhof M, Tibboel D: Morphine glucuronidation in preterm neonates, 
infants and children younger than 3 years. Clin Pharmacokinet 2009; 48: 371­85
 120. Krekels EH, DeJongh J, van Lingen RA, van der Marel CD, Choonara I, Lynn AM, Danhof M, Tibboel 
D, Knibbe CA: Predictive performance of a recently developed population pharmacokinetic model 
for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin 
Pharmacokinet 2011; 50: 51­63
 121. Krekels EH, Neely M, Panoilia E, Tibboel D, Capparelli E, Danhof M, Mirochnick M, Knibbe CA: From 
pediatric covariate model to semiphysiological function for maturation: part I­extrapolation of a 
covariate model from morphine to Zidovudine. CPT Pharmacometrics Syst Pharmacol 2012; 1: e9
 122. Krekels EH, Johnson TN, den Hoedt SM, Rostami­Hodjegan A, Danhof M, Tibboel D, Knibbe CA: 
From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II­Sensitivity 
to Physiological and Physicochemical Properties. CPT Pharmacometrics Syst Pharmacol 2012; 1: 
e10
 123. De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, Danhof M, 
Knibbe CA: Maturation of the glomerular filtration rate in neonates, as reflected by amikacin 
clearance. Clin Pharmacokinet 2012; 51: 105­17
 124. De Cock RF, Allegaert K, Brussee JM, Sherwin CM, Mulla H, de Hoog M, van den Anker JN, Danhof 
M, Knibbe CA: Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vanco­
mycin clearance from neonates to adults: towards a semi­physiological function for maturation 
in glomerular filtration. Pharm Res. 2014; In press
 125. De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, Danhof M, Knibbe 
CA: A neonatal amikacin covariate model can be used to predict ontogeny of other drugs elimi­
nated through glomerular filtration in neonates. Pharm Res 2014; 31: 754­67
 126. Zhao W, Biran V, Jacqz­Aigrain E: Amikacin maturation model as a marker of renal maturation 
to predict glomerular filtration rate and vancomycin clearance in neonates. Clin Pharmacokinet 
2013; 52: 1127­34
 127. Huisinga W, Solms A, Fronton L, Pilari S: Modeling interindividual variability in physiologically 
based pharmacokinetics and its link to mechanistic covariate modeling. CPT Pharmacometrics 
Syst Pharmacol 2012; 1: e4

Influence of morbid 
obesity on cefazolin 
pharmacokinetics

Chap te r  4
Reduced subcutaneous tissue distribution of 
cefazolin in morbidly obese versus non­obese 














As morbidly obese patients are prone to surgical site infections, adequate blood and 
subcutaneous tissue concentrations of prophylactic antibiotic agents during surgery are 
imperative. In this study, we evaluated cefazolin subcutaneous adipose tissue distribu­
tion in morbidly obese and non­obese patients, thereby quantifying the influence of 
morbid obesity on cefazolin pharmacokinetics and enabling Monte Carlo simulations 
for subsequent dose adjustments.
Methods
Nine morbidly obese patients (body mass index (BMI) of 47 ± 6 kg/m2) of which eight 
were evaluable, and seven non­obese patients (BMI of 28 ± 3 kg/m2) received cefazolin 
2 gram intravenously before surgery (NCT01309152). Using microdialysis, interstitial 
space fluid (ISF) samples of subcutaneous adipose tissue were collected together with 
total and unbound plasma cefazolin samples until 240 min after dosing. Using NONMEM, 
population pharmacokinetic modelling, covariate analysis and Monte Carlo simulations 
were performed.
results
The unbound (free) cefazolin ISF penetration ratio (fAUCtissue/fAUCplasma) was 0.70 (0.68­
0.83) in morbidly obese patients versus 1.02 (0.85­1.41) in non­obese patients (p<0.05). 
A two­compartment model with saturable protein binding was identified in which the 
central volume of distribution and cefazolin distribution from the central compartment 
to the ISF compartment proved dependent on body weight (p<0.001 and p<0.01, re­
spectively). Monte Carlo simulations showed reduced probability of target attainment 
for morbidly obese versus non­obese patients for MIC values of 2 and 4 mg/L.
Conclusions
This study shows that cefazolin tissue distribution is lower in morbidly obese patients 




The prevalence of obesity (body mass index (BMI)  >30kg/m2) and morbid obesity 
(BMI >40kg/m2) is increasing worldwide. European obesity prevalence rates range be­
tween 4 and 37%, while in the USA 36% of the population is obese and 5% is morbidly 
obese 1­2. Obesity and morbid obesity are considered an independent risk factor for 
postoperative surgical site infection 3­5. To prevent surgical site infection, for surgery 
above or including the duodenum, cefazolin is the prophylactic agent of choice 6. As a 
target site for prophylactic antibiotics, distribution to the interstitial space fluid (ISF) of 
the subcutaneous adipose tissue should be considered. At least between opening and 
closure of the skin, the unbound cefazolin concentration in the ISF should be above the 
minimal inhibitory concentration (MIC) for the target micro­organisms 7.
Despite extensive use of cefazolin as antibiotic prophylaxis, there is limited data 
available from controlled clinical trials in morbidly obese patients. Previous studies in 
morbidly obese patients have so far only reported cefazolin concentrations in biopsy 
samples taken from fat tissue, but these samples inadequately reflect unbound cefazolin 
concentrations in the ISF as biopsy samples provide average concentrations for com­
bined intra­ and extracellular compartments 8­10. Furthermore, cefazolin is highly protein 
bound and thus only a relatively small part of the concentration is available for antibiotic 
effect. To date, clinical microdialysis is the only sampling technique that allows measure­
ment of extracellular, unbound (i.e. active) drug concentrations in virtually any tissue 
and is hence suitable for measuring unbound cefazolin concentrations in the ISF of the 
subcutaneous adipose tissue 11­12.
Therefore, the objective of this study is to measure and compare unbound cefazolin 
concentrations in the ISF of the subcutaneous adipose tissue of morbidly obese and 
non­obese patients, using a microdialysis technique. The results were used to quantify 
the influence of overweight on cefazolin pharmacokinetics by developing a model for 
total and unbound plasma cefazolin and unbound cefazolin in the ISF, which can be 
used for Monte Carlo simulations and subsequent dose adjustments.
MAterIAls And Methods
Patients
Morbidly obese patients (BMI>40 kg/m2) undergoing laparoscopic gastric bypass sur­
gery and non­obese patients (BMI 20­30 kg/m2 at the inclusion of the study) undergoing 
laparoscopic Toupet fundoplication surgery were considered for inclusion in the study. 
Patients were excluded from the study if they were pregnant, breastfeeding, suffered 
from renal insufficiency, had a known allergy to cefazolin or had an ejection fraction 
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below 35%. Before participation, all patients gave written informed consent. Laboratory 
values for evaluation of renal function were available after inclusion of the patient in the 
study. The study was approved by the local human research and ethics committee of 
Nieuwegein (VCMO), The Netherlands (NL33065.100.10) and was conducted according 
to the principles of the Declaration of Helsinki (version 22­10­2008) and in accordance 
with the Medical Research Involving Human Subjects Act (WMO) of The Netherlands.
study design and procedure
This was a prospective observational study (NCT01309152). For anesthesia, all patients 
received propofol/remifentanil and received a 2 gram intravenous (iv) bolus injection of 
cefazolin at 15.6 ± 4.3 (range of 8­24) minutes before start of surgery. Up to 4 hours after 
the cefazolin dose, blood and subcutaneous ISF samples were collected. Arterial blood 
samples were drawn for the measurement of total and unbound plasma cefazolin, while 
subcutaneous adipose ISF samples were collected using clinical microdialysis. Three 
hours before surgery a microdialysis probe (CMA60, Microdialysis, Solna, Sweden) was 
inserted in the subcutaneous tissue of the right or left side of the abdomen. After a 20 
minute baseline perfusion period with blank lactated Ringer’s, the catheter was per­
fused with 5 mg/L cefazolin in lactated Ringer’s solution for 40 minutes for calibration 
of the microdialysis catheter using the retrodialysis technique 13. A sample was collected 
during the last 20 minutes of the retrodialysis procedure to calculate the recovery:
Recovery (%) = 100 − (Cdialysate / Cperfusate × 100) (Eq. 1)
where Cdialysate is the cefazolin concentration in the dialysate leaving the probe and 
Cperfusate is the cefazolin concentration in the perfusion fluid entering the probe 14. The 
microdialysis recovery ratio was 27.1% ± 8.0 for morbidly obese patients (n=9) and 
27.4% ± 13.4 for non­obese patients (n=7). To prevent cefazolin carry over from the ret­
rodialysis procedure to the actual samples after the cefazolin iv dose, the microdialysis 
catheter was washed out with blank lactated Ringer’s solution for at least 2 hours after 
calibration. At the time of cefazolin iv administration, microdialysis sample collection 
was started and samples were collected every 20 minutes until 4 hours after the dose. 
As a result, each collected microdialysis sample represented the average concentrations 
over a time span of 20 minutes. Throughout the whole procedure the microdialysis flow 
rate was kept at 2 μL/minute.
In non­obese patients, to determine total and unbound cefazolin concentrations 
in plasma, arterial blood samples were taken before and at 5, 10, 30, 60, 120 and 240 
minutes after the cefazolin iv dose. In morbidly obese patients, arterial blood samples 
for total cefazolin concentrations in plasma, were taken before and at 10, 120 and 240 
minutes after dose and samples for unbound plasma cefazolin were collected at 5, 10, 
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30, 60, 120 and 240 minutes after the cefazolin iv dose. Blood samples were centrifuged 
at 3000 RPM (1500 g) for 15 minutes at 4ºC and plasma was collected. Both plasma and 
microdialysis samples were stored at ­80ºC until analysis.
drug assay
Total and unbound cefazolin concentrations in plasma were determined using a vali­
dated reversed­phase HPLC method with UV detection at 254 nm (total plasma cefazolin 
concentrations) and 272 nm (unbound cefazolin plasma and microdialysis concentra­
tions), based on a modification of the method of Kamani et al., described previously 15­16. 
In brief, a LiChrospher 100 RP­18 5 μm column was used for separation and the mobile 
phase, a mixture of 0.01 M acetic acid, acetonitrile and methanol (87.4/12/0.6, v/v/v), 
was eluted at 0.71 mL/min. Microdialysis samples were injected directly onto the HPLC 
column. The limit of detection and limit of quantification for unbound cefazolin concen­
trations in plasma and cefazolin in lactated Ringer’s (microdialysis samples) were 0.3 and 
1 mg/L, respectively. For total cefazolin concentrations in plasma, the limit of detection 
and lower limit of quantification were 1 mg/L and 5 mg/L, respectively.
statistical analysis
The student’s t-test was applied to test differences in demographic variables between 
the study groups. For cefazolin concentrations the nonparametric Mann­Whitney test 
was applied to test statistical differences between the groups. The observed area under 
the time­concentration curve from 0 to 4 hours after the dose (AUC0­4 h) was calculated for 
each patient separately, using the linear trapezoidal rule 17. Outlying data was evaluated 
using Grubb’s test for detecting outliers 18. These statistical analyses were performed 
using IBM SPSS software, version 19.0.0.
Population pharmacokinetic analysis and internal validation
The population pharmacokinetic analysis was performed by means of nonlinear mixed 
effects modelling using NONMEM (version 6.2, release 1.1; GloboMax LLC, Hanover, MD, 
USA) 19. S­Plus (version 6.2; Insightful Software, Seattle, WA, USA) with NM.SP.interface© 
version 05.03.02 (LAP&P, Leiden, The Netherlands) was used to visualize the data. Dis­
crimination between different models was made by comparison of the objective func­
tion value (OFV, i.e. ­2 log likelihood (­2LL)). A p value <0.05, representing a decrease of 
3.84 in the OFV, was considered statistically significant. In addition, goodness­of­fit plots 
(observed versus individual­predicted concentrations, observed versus population­
predicted concentrations, conditional weighted residuals versus time and conditional 
weighted residuals versus population­predicted concentrations plots) were used for di­
agnostic purposes. Furthermore, the confidence interval of the parameter estimates, the 
correlation matrix and visual improvement of the individual plots were used to evaluate 
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the model. The internal validity of the population pharmacokinetic model was assessed 
by the bootstrap re­sampling method using 250 replicates and normalized prediction 
distribution errors (NPDEs) 20. Parameters obtained with the bootstrap replicates were 
compared with the estimates obtained from the original dataset. NPDE plots were 
checked for normal distribution characteristics and trends in the data errors.
structural model
To describe all cefazolin concentrations (total plasma, unbound plasma and unbound 
subcutaneous ISF concentrations) a two­compartment model (ADVAN 6) was used. 
The model was parameterized in terms of the volume of distribution of the central 
compartment (V1), volume of distribution of the subcutaneous ISF compartment (V2), 
inter­compartmental clearance from the central compartment to the subcutaneous 
compartment (Q), clearance from the central compartment (CL) and the fraction un­
bound (FU), as depicted in Figure 1. The fraction unbound (FU) was modelled according 
to equation 2,
FU = (Ctotal −Bmax −Kd) +√ (Ctotal −Bmax −Kd)2 + 4 ×Kd) ×Ctotal (Eq. 2)
2×Ctotal
where Bmax is the maximal binding capacity, Ctotal is the total cefazolin plasma concentra­
tions and Kd is the dissociation constant for cefazolin binding to albumin.
Intercompartmental clearance between the central and subcutaneous ISF compart­
ment (Q) was equated to CL as both values were very similar and this improved good­











figure 1 Schematic illustration of the population pharmacokinetic cefazolin model. The lines pointing to­
wards a compartment indicate the type of observed data used for this compartment. CL= Clearance, FU= 
Fraction unbound, Q= Intercompartmental clearance, V1= Volume of distribution of central compartment, 
V2= Volume of distribution of subcutaneous compartment.
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statistical model
The individual parameter estimate (Empirical Bayes Estimate or post hoc value) of the ith 
individual was modelled according to (equation 3):
θi = θmean × expηi (Eq. 3)
Where θmean is the population mean, and ηi is a random variable for the ith individual with 
a mean of zero and variance of ω2, assuming log­normal distribution in the population.
The residual variability, resulting from assay errors, model misspecifications and other 
unexplained sources, was best described with a proportional error model for total and 
unbound cefazolin plasma concentrations and a separate proportional error for unbound 
subcutaneous ISF cefazolin concentrations. The jth observed cefazolin concentration of 
the ith individual (Yij) is described by equation 4:
Yij = Cpred,ij × (1 + εij) (Eq. 4)
Where Cpred,ij is the population predicted cefazolin concentration of the ith individual at 
the jth time, and εij is a random variable with a mean of zero and variance of σ2.
Covariate analysis
Covariates were plotted independently against the individual eta (η) estimates of phar­
macokinetic parameters to visualize potential relations. The following covariates were 
tested: total body weight (TBW), BMI, lean body weight (LBW) 21, sex, obesity and age. 
Covariates (except for sex and obesity) were tested using linear and allometric equations 
(equation 5 and 6):
Pi = Pp ×( COV )x (Eq. 5)COVmedian
Pi = Pp × (1 + Y × (COV − COVmedian) (Eq. 6)
where Pi and Pp represent individual and population parameter estimates, respectively; 
COV represents the covariate; COVmedian represents the median value of the covariate for 
the population; X represents the exponential scaling factor, which was fixed at 1 for a 
linear function or an estimated value for a power function; and Y represents a correlation 
factor between the population pharmacokinetic parameters and the change in covariate 
value. The binary covariates sex and obesity were tested using the following equation:
Pi = Pp × ZCOV (Eq. 7)
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where Pi and Pp represent individual and population parameter estimate, Z the esti­
mated factor of increase or decrease for the patients subgroup with COV equaling 1. 
Potential covariates were separately entered into the model and statistically tested 
by use of the OFV and, if applicable, the 95% confidence interval of the additional pa­
rameter. In addition, if applicable, we evaluated whether the interindividual variability 
in the parameter concerned reduced in value upon inclusion of the covariate on the 
parameter. When more than one significant covariate for the simple model was found, 
the covariate­adjusted model with the largest decrease in the OFV was chosen as a basis 
to sequentially explore the influence of additional covariates with the use of the same 
criteria. Finally, after forward inclusion (p<0.05), a backward exclusion procedure was 
applied to justify the inclusion of a covariate (p<0.01). The choice of the covariate model 
was further evaluated as discussed above (in Population pharmacokinetic analysis and 
internal validation).
Monte Carlo simulations
Monte Carlo simulations based on body weight and age distributions of the original 
populations, were performed to simulate cefazolin concentration­time profiles of 
5000 morbidly obese patients and 5000 non­obese patients. In these simulations, the 
unbound (free) area under the curve ratios (fAUCtissue/fAUCplasma) were calculated by al­




Nine morbidly obese patients with a mean body weight of 141.4 ± 22 kg (range 
107 – 175) and 7 non­obese patients with a mean body weight of 86.2 ± 13 kg (range 72 
­ 109) participated in the study. Immediately after inclusion, one morbidly obese patient 
was excluded from the study because of an estimated glomerular filtration rate (GFR) 
of 60 mL/min instead of an estimated GFR >60 mL/min (ID 3), which was noticed after 
inclusion. Furthermore, ISF measurements from another morbidly obese patient were 
excluded from the analysis because the unbound area under the ISF curve (fAUCISF 0­4 h) 
and fAUCtissue/fAUCplasma ratio of this patient were strongly deviating and outlying based 
on the Grubb’s test for detecting outliers 18 (p<0.05 and p<0.01, respectively (ID 2)).
Patient characteristics of 8 morbidly obese and 7 non­obese patients are summarized 
in Table 1.
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table 1 Patient characteristics
Morbidly obese range non-obese range p value
Male : Female 1/7 4/3
Age (years) 40.1 ± 5.5 (32­48) 53.7 ± 6.3 (42 ­ 61) 0.001
Body weight (kg) 140.4 ± 23 (107 ­175) 86.2 ± 13 (72 ­ 109) <0.001
Lean body weight (kg) 75.2 ± 8.5 (64 ­ 89) 55.5 ± 5.7 (48 ­ 62) <0.001
BMI (kg/m2) 47.0 ± 5.8 (41 ­ 57) 28.2 ± 2.8 (24 ­ 31) <0.001
Surgery duration (min) 63.6 ± 12 (51 ­ 86) 59.6 ± 19 (39 ­ 92) 0.640
Wound closure post dose (min) 79.4 ± 14 (65 ­ 105) 74.1 ± 19 (55 ­108) 0.557
Data are mean ± standard deviation and range (minimum­maximum).
figure 2 Observed cefazolin concentrations (me­
dian ± IQR in mg/L) in morbidly obese (black sym­
bols and line, n=7 for plot (a), n=8 for plot (b) and 
(c)) and non­obese (grey symbols and line, n=7) pa­
tients. (a) Subcutaneous ISF cefazolin. (b) Unbound 












































































































































































observed cefazolin concentrations in plasma and Isf
Figure 2 shows median and interquartile ranges of observed cefazolin concentrations 
for morbidly obese and non­obese patients; panel (a) shows unbound cefazolin in the 
ISF of the subcutaneous adipose tissue, panel (b) shows unbound plasma concentration 
and panel (c)shows total plasma concentrations.
The area under the time­ unbound concentration curve (fAUC0­4 h) for subcutaneous 
ISF was significantly lower in morbidly obese patients (n=7) in comparison with non­
obese patients (n=7), p<0.05. In contrast, the fAUC0­4 h for unbound plasma cefazolin 
concentrations did not differ significantly between the patient populations (p>0.05). 
The observed unbound cefazolin ISF penetration ratio, expressed as fAUCtissue/fAUCplasma, 
was 0.70 (range 0.68­0.83) in morbidly obese patients as opposed to 1.02 (range 0.85­
1.41) in non­obese patients (p<0.05).
Population pharmacokinetic model and validation
A two­compartment pharmacokinetic model with saturable plasma protein binding best 
described the data (Figure 1, equation 2). Using this structural model without covariates, 
total and unbound plasma cefazolin concentrations in both patient groups were well 
described, while individual and population­predicted subcutaneous ISF concentrations 
were overpredicted in morbidly obese patients and underpredicted in the non­obese 
patients. Exploration and testing of covariates for V1, V2, Q, CL and Bmax showed im­
provements of fit for unbound cefazolin plasma concentrations; however, the observed 
trend for subcutaneous ISF cefazolin concentrations (overprediction for morbidly obese 
patients, underprediction for non­obese patients) could not be explained by any of the 
preliminary covariates on any of the parameters. Therefore, potential nonlinearity in 
cefazolin distribution from the central (V1) to subcutaneous ISF compartment (V2) was 
evaluated by adding a power function (γ) on the cefazolin amount (concentration) in the 
central compartment (A1):
ΔA1/Δt = −k12 × A1γ × FU − k10 × A1 × FU + k21 × A2 (Eq. 8)
where Ax stands for the amount of cefazolin in the xth compartment, FU is the fraction 
unbound (equation 2) and k12 is a rate constant between compartments 1 and 2.
Although no nonlinearity was identified because gamma was not found to differ signif 
icantly from 1, addition of interindividual variability on gamma strongly improved the 
goodness of fit of the subcutaneous ISF concentrations (p<0.001, ­124 ΔOFV). Parameter 
values of the simple model without covariates are summarized in Table 2.
With the extended model, a covariate analysis was performed and exploratory plots of 
covariates against individual post hoc parameter estimates of the simple model showed 
potential relationships for different body size descriptors (TBW, BMI and LBW) with 
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volume of distribution (V1) and the γ factor, for age and TBW with clearance and for 
LBW with Bmax. After forward inclusion and backward deletion of covariates in the model, 
TBW proved to be the strongest predictor of interindividual variability of both central 
volume of distribution (p<0.001, ­77 ΔOFV) and γ representing cefazolin distribution 
to subcutaneous tissue (p<0.01, ­10 ΔOFV). For clearance, age significantly improved 
the model (p<0.01, ­10 ΔOFV). Finally, LBW seemed to be a covariate for Bmax; however, 
this covariate relationship was not included in the final model due to limited statistical 
significance (p>0.01, ­6 ΔOFV) in the backward deletion step.
table 2 Population pharmacokinetic parameters of the simple and final pharmacokinetic model for ce­
fazolin in morbidly obese and non­obese patients and results of bootstrap analysis (250/250 resamples 
successful).
Parameters simple model (Cv) final model (Cv) bootstrap (Cv)
Fixed effects
CL (L/min) 0.384 (7.5) ­ ­
CL= CL47 years*(AGE/47)­1
CL47 years (L/min) ­ 0.371 (5.7) 0.371 (5.5)
V1 (L) 8.79 (5.1) ­ ­
V1= V109 kg*(1+Y*(TBW­109))
V109 kg (L) ­ 8.94 (3.0) 8.97 (3.1)
Y ­ 0.0052 (18.0) 0.0051 (21.5)
V2 (L) 8.1 (8.9) 8.31 (7.8) 8.36 (7.6)
Bmax (μM) 530 (7.8) 469 (7.3) 471 (7.6)
Kd (μM) 81.2 (11.4)  71.3 (10.9) 71.7 (11.2)
Gamma 1 fixed ­ ­
Gamma= Gampop* (TBW/109)Z
Gampop ­ 1 fixed 1 fixed
Z ­ ­0.0946 (­27.6) ­0.0895 (­34.2)
Interindividual variability (%)
CL 31.2 (28.1) 22.6 (31.6) 21.5 (32.9)
Bmax 20.6 (41.6) 11.6 (33.4) 10.8 (41.4)
Gamma 3.9 (28.9) 2.8 (50.4) 2.7 (53.2)
Residual variability (%)
Total and unbound plasma 13.1 (18.2) 10.0 (22.2) 9.7 (22.1)
Subcutaneous ISF 16.5 (19.9) 17.0 (19.7) 16.7 (19.5)
OFV 1260.5 1166.5 1142.0 (9.7)
AGE= age in years, Bmax= maximal plasma protein binding capacity, CL= Clearance (L/min), CV= coefficient 
of variation (%), Gamma= gamma factor or γ, power function on the cefazolin amount in the central com­
partment, Kd= dissociation constant for cefazolin protein binding to albumin, OFV= Objective function 
value (­2LL), TBW= total body weight (kg), V1= central volume of distribution (L), V2= subcutaneous inter­
stitial space fluid (ISF) volume of distribution (L)
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figure 3 Observed versus individual predicted (a, c, e) and population predicted (b, d, f ) cefazolin con­
centrations of subcutaneous ISF cefazolin (a and b), unbound plasma cefazolin (c and d) and total plasma 
cefazolin (e and f ) in morbidly obese and non­obese patients. The dashed line represents the line of identity 
(x=y).
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Parameters estimates of the final covariate model are summarized in Table  2. The 
table  shows that implementation of the covariates age and total bodyweight on the 
parameters γ and clearance in the final model indeed explained variability in these 
parameters (decrease in interindividual variability in γ and clearance of 1.1 % and 8.6 
%). Figure  3 shows observed versus population predicted cefazolin concentrations in 
the ISF of subcutaneous tissue (b), unbound plasma (d) and total plasma (f ) for morbidly 
obese and non­obese patients of the final model. The figure shows that there was no 
remaining bias in any of the plots between data from morbidly obese or non obese 
patients, except for a slight overestimation of the lower subcutaneous concentrations in 
some of the morbidly obese patients (figure 3b).
table 3 Probability of 5000 Monte Carlo­simulated morbidly obese and 5000 non­obese patients attaining 
cefazolin MIC targets of 1, 2 and 4 mg/L at 120, 180 and 240 minutes after a 2 gram iv cefazolin dose
120 min post dose 180 min post dose 240 min post dose
Morbidly obese Non­obese Morbidly obese Non­obese Morbidly obese Non­obese
ISF
> 1 mg/L 1.00 1.00 1.00 1.00 0.998 1.00
> 2 mg/L 1.00 1.00 0.996 1.00 0.956 0.997
> 4 mg/L 0.996 1.00 0.909 0.995 0.663 0.949
Plasma
> 1 mg/L 1.00 1.00 1.00 1.00 0.999 1.00
> 2 mg/L 1.00 1.00 0.999 1.00 0.965 0.994









































































(a) Unbound ISF (b) Unbound plasma
figure 4 Probability of target attainment (PTA) at four different MIC values 120, 180 and 240 minutes after 
a 2 gram cefazolin iv dose in 5000 morbidly obese and 5000 non­obese Monte Carlo­simulated patients. 
(a) PTA of unbound cefazolin concentrations in the subcutaneous ISF. (b) PTA of unbound plasma cefazolin 
concentrations.
4 | 114
The final covariate model was validated using bootstrap analysis confirming the re­
sults (Table 2) and normalized predictions distributions errors analysis which indicated 
normal distributions of errors (Figure S1, available as Supplementary data at JAC Online 
and at the end of this Chapter).
Monte Carlo simulations
The final covariate model was used to simulate concentration­time profiles of subcuta­
neous ISF and unbound plasma cefazolin in 5000 morbidly obese and 5000 non­obese 
patients. The probability for the patient groups remaining above a certain minimal inhibi­
tory concentration (MIC) 120, 180 and 240 minutes after a 2 gram iv dose are summarized 
in Table 3. Figure 4 illustrates the probability of target attainment that can be expected 
for unbound cefazolin concentrations in the ISF of morbidly obese versus non­obese pa­
tients. It shows that the probabilities of target attainment of unbound cefazolin plasma 
concentrations are more similar in both patient groups. The mean simulated unbound 
cefazolin ISF penetration ratio, expressed as fAUCtissue/fAUCplasma, for morbidly obese pa­
tients was 0.85 ± 0.19 in morbidly obese patients and 1.14 ± 0.27 in non­obese patients.
dIsCussIon
This study aimed to measure and compare unbound cefazolin concentrations in the ISF 
of the subcutaneous adipose tissue of morbidly obese and non­obese patients and to 
quantify the influence of overweight and other covariates on cefazolin pharmacokinet­
ics. Using clinical microdialysis, it was found that unbound cefazolin subcutaneous tis­
sue penetration was lower in morbidly obese compared with non­obese patients. When 
analyzing these results in a population analysis, a two compartment population phar­
macokinetic model with saturable protein binding was found to adequately describe all 
measured cefazolin concentrations. The covariate analysis showed that central volume 
of distribution increased linearly with body weight and that cefazolin distribution from 
the central to subcutaneous compartment decreased with body weight in a nonlinear 
manner.
Unbound cefazolin concentrations in the ISF of the subcutaneous adipose tissue have 
not been reported previously for morbidly obese patients, despite the fact that reduced 
tissue penetration of antibiotic agents in morbidly obese versus non­obese patients has 
been reported before. Cefoxitin, which is a cephalosporin class antibiotic agent like ce­
fazolin, also showed a reduced tissue penetration in morbidly obese versus non­obese 
patients (0.08 ± 0.07 versus 0.37 ± 0.26, p<0.05), although this AUC ratio was calculated 
using total cefoxitin plasma concentrations instead of unbound plasma concentrations, 
while cefoxitin is ~34% protein bound 22. Also, in that study morbidly obese patients 
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were compared with mostly healthy volunteers who did not undergo surgery 22. Further­
more, reduced tissue penetration in morbidly obese patients was found for ciprofloxacin 
(0.45 ± 0.27 versus 0.82 ± 0.36, p<0.01), though in the study by Hollenstein et al. protein 
binding was not considered either 23. The lower drug penetration into the subcutaneous 
adipose tissue of morbidly obese patients found in these studies and in the present 
study may potentially be explained by lower subcutaneous adipose blood flow. It has 
been shown before that subcutaneous adipose tissue blood flow in obese and morbidly 
obese patients is lower than in healthy control subjects 24­25. Additionally, Joukhadar 
et al. found in healthy volunteers that enhanced subcutaneous blood flow resulted in 
higher subcutaneous ciprofloxacin concentrations 26. Therefore, we think that the lower 
subcutaneous adipose tissue penetration of cefazolin in morbidly obese patients after a 
single dose may be explained by lower subcutaneous adipose tissue blood flow.
In the population pharmacokinetic model the difference in subcutaneous ISF ce­
fazolin concentrations in morbidly obese and non­obese patients was not adequately 
described by TBW on central volume of distribution (V1) alone or by additional covari­
ates for intercompartmental clearance (Q) or the subcutaneous ISF compartment (V2). 
However, the introduction of interindividual variability on a γ factor (equation 8) on the 
distribution of cefazolin amount from the central (V1) to the subcutaneous compart­
ment (V2) was able to improve the goodness of fit of the subcutaneous cefazolin data 
for both patient groups. Despite the small absolute difference in γ between a morbidly 
obese and non­obese patient, it strongly impacts on cefazolin distribution from the 
central to the subcutaneous compartment: where a non­obese individual of 75 kg with 
a corresponding γ value of 1.02 transports 300 mg unbound cefazolin/minute from the 
central to subcutaneous compartment, a morbidly obese patient of 145 kg with a cor­
responding γ value of 0.96 transports only 210 mg per minute (30% difference). For the 
final pharmacokinetic model, TBW on V1 and TBW on the γ factor were found to be the 
most predictive covariates for the reduced cefazolin distribution observed in morbidly 
obese patients. The slight overestimation of lower subcutaneous cefazolin concentra­
tions in morbidly obese patient can be explained by the relatively high interindividual 
variability observed for cefazolin subcutaneous concentrations. While the model under­
predicts concentrations at 230 minutes after dosing for some morbidly obese patients, 
for others it overestimates other concentrations at the same time after dose for others.
In contrast to the differences observed in cefazolin distribution between morbidly 
obese and non obese patients, we found that cefazolin saturable protein binding was 
similar for both patient groups. Plasma albumin concentrations were not measured in 
this study and may have been a covariate for maximal binding capacity (Bmax). However, 
for this parameter interindividual variability was relatively small (11.6%) and thus the 
influence of difference in albumin concentration on cefazolin pharmacokinetics is as­
sumed to be limited. Furthermore, the extent of saturable protein binding corresponded 
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to earlier reports in non­obese and morbidly obese patients 16, 27­28, and estimated Bmax 
and Kd values correspond to values found in earlier studies in human plasma, in which 
Bmax was reported to be 438 μM and Kd was 50 and 60.2 μM 29­30.
To determine the efficacy of prophylactic cefazolin, currently the time of unbound 
plasma cefazolin above the MIC (fT>MIC) between opening and closure of the wound is 
used as the pharmacokinetic/pharmacodynamic (PK/PD) index. However, this is based 
on the assumption that cefazolin penetration from plasma to the ISF of the subcutane­
ous tissue is equal to 1 7, whereas in this study it was found that cefazolin tissue distribu­
tion is lower than 1 for morbidly obese patients. This suggests that for morbidly obese 
patients ISF tissue concentrations rather than unbound plasma concentrations should 
be considered as the PK/PD index to target for cefazolin efficacy. Monte Carlo simula­
tions allowed evaluation of cefazolin ISF tissue concentrations in large simulated patient 
populations and indicated that a dose of 2 gram iv cefazolin given prior to incision will 
be sufficient to prevent wound infections with pathogens for which the MIC is 1 mg/L 
in a 120 minute surgical procedure. However, when higher MIC values apply (e.g. 2 or 4 
mg/L) redosing may be required after 2 hours as the probability of attaining a target of 4 
mg/L at 180 minutes post dose has dropped to 0.909 for morbidly obese as opposed to 
0.995 for non­obese patients, while for a target of 2 mg/L the probability of target attain­
ment is 0.956 in morbidly obese versus 0.997 in non­obese patients at 240 minutes post 
dose (Table 3). Alternatively, it is obvious that if surgery is prolonged beyond 4 hours, 
an extra dose is necessary even when an MIC of 1 mg/L is taken as the reference value.
The design of the current study allowed for a straight forward and extensive compari­
son of unbound cefazolin concentrations in both plasma and ISF of the subcutaneous 
adipose tissue in morbidly obese and non­obese patients undergoing laparoscopic gas­
tric surgery. In addition, it allowed for a quantitative analysis of the influence of morbid 
obesity on cefazolin distribution. Nevertheless, the current study has some limitations. 
Firstly, this study only included 15 patients, which may limit an accurate estimation of 
interindividual and residual variability of pharmacokinetic parameters, which in turn 
may prevent broad conclusions being drawn regarding cefazolin efficacy in morbidly 
obese patients. Also, extrapolation of this model to patients beyond the body weight 
ranges of these data should be exercised with caution. However, the data gathered 
in this study is rather unique both in terms of methods (rich data, semi simultaneous 
observations in ISF and plasma) and patients, and currently no other evidence about 
cefazolin efficacy in morbidly obese patients is available. Secondly, the ISF data from 
one morbidly obese patient was excluded from the pharmacokinetic analysis, because 
the ISF time­concentration profile of this patient was highly deviating and outlying in 
comparison with the other morbidly obese patients in this study. This deviation may be 
explained by the relatively low microdialysis recovery ratio measured for this patient 
(13.6%, compared to a mean of 28.1% ± 7.9). Thirdly, it should be stated that the model 
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developed here, slightly overestimates lower subcutaneous cefazolin concentrations in 
some of the morbidly obese patients. If the model had predicted these lower cefazolin 
ISF concentrations more accurately, the probability of target attainment results from the 
Monte Carlo simulation may have been even more disadvantageous for morbidly obese 
patients. Finally, it is assumed that these potential weaknesses do not explain the lower 
cefazolin tissue penetration found for morbidly obese patients in this study.
In conclusion, this study showed that cefazolin distribution to the ISF of the subcutane­
ous adipose tissue is reduced in morbidly obese versus non­obese patient, that cefazolin 
tissue distribution reduces with increasing body weight and that dose adjustments are 
required in this patient group.
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Influence of morbid obesity 
and weight loss surgery on 
the pharmacokinetics of 
CYP3A substrate midazolam

Chap te r  5
Midazolam pharmacokinetics in morbidly 
obese patients following semi­simultaneous 
oral and intravenous administration: 







Eric P.A. van Dongen
Catherijne A.J. Knibbe




While in vitro and animal studies have shown reduced CYP3A activity due to obesity, 
clinical studies in (morbidly) obese patients are scarce. As CYP3A activity may influence 
both clearance and oral bioavailability in a distinct manner, in this study the pharmaco­
kinetics of the CYP3A substrate midazolam were evaluated after semi­simultaneous oral 
and intravenous administration in morbidly obese patients, and compared with healthy 
volunteers.
Methods
Twenty morbidly obese patients (mean body weight 144 kg (112­186 kg) and mean BMI 
47 kg/m2 (40­68 kg/m2) participated in the study. All patients received a midazolam 7.5 
mg oral and 5 mg intravenous dose (separated by 159 ± 67 minutes) and per patient 22 
samples over 11 hours were collected. Data from 12 healthy volunteers were available 
for a population pharmacokinetic analysis using NONMEM®.
results
In the three­compartment model in which oral absorption was characterized by a transit 
absorption model, population mean clearance (relative standard error %) was similar 
(0.36 (4.4%) L/min), while oral bioavailability was 60% (13.2%) in morbidly obese pa­
tients versus 28% (7%) in healthy volunteers (p<0.001). Central and peripheral volumes 
of distribution increased substantially with body weight (both p<0.001) and absorption 
rate (transit rate constant) was lower in morbidly obese patients (0.057 (5%) versus 0.130 
(14%) min­1, p<0.001).
Conclusions
In morbidly obese patients, systemic clearance of midazolam is unchanged, while oral 
bioavailability is increased. Given the large increase in volumes of distribution, dose 
adaptations for intravenous midazolam should be considered. Further research should 




The prevalence of obesity (body mass index, BMI,  >30 kg/m2) and morbid obesity 
(BMI >40 kg/m2) is increasing rapidly. In 2010, 6.6% (15.5 million) of the U.S adult popula­
tion was morbidly obese, a 70% increase since 2000 1, while 36% of the U.S. population 
was obese 2. In Europe, approximately 20% of the adult population is currently obese 3.
In obese mice, studies have shown reduced hepatic Cytochrome P450 3A (CYP3A) pro­
tein expression 4­5 . Similarly, in in vitro studies with hepatocytes from human fatty livers, 
reduced CYP3A expression and activity has been reported 6­7 with increasing severity 
of fatty liver and non­alcoholic steatohepatitis (NASH), which are both highly associ­
ated with (morbid) obesity 8­9. However, these measurements concern absolute values 
and were not normalized for the weight of the whole liver and/or the body weight of 
the mouse. CYP3A is an important enzyme system that is responsible for the primary 
metabolism of 25% of all clinically used drugs 10, including many drugs that are relevant 
for obese patients, such as statins, cardiovascular drugs, antipsychotics and oncolytic 
drugs 11. In obese as compared to non­obese subjects, it was shown that hepatic and 
intestinal CYP3A protein expression decreased with increasing BMI 12 and that oral clear­
ance (CL/F) of CYP3A substrates such as triazolam, carbamazepine and taranabant was 
lower 13­14, even though a similar systemic clearance (CL) was found in obese individuals 
for midazolam 15. An explanation for the reduction in CYP3A activity upon obesity could 
be an increased state of inflammation, caused by infiltration of macrophages and adi­
pocytes into the adipose tissue excreting inflammation markers and adipokines, such as 
interleukin (Il)­6 and tumor necrosis factor (TNF)­α 16­18. Both in vitro and animal studies 
have shown that inflammation factors such as Il­6 may decrease CYP3A expression, re­
sulting in down regulation of CYP3A mediated metabolism 19­23. Finally, reduced CYP3A 
activity due to inflammation has also been shown in critically ill patients 24­25.
Midazolam which is considered a specific marker of CYP3A activity because it is pri­
marily metabolized by CYP3A 26, is a widely applied oral or intravenous drug for sleeping 
disorders, (pre)anesthesia, sedation for scopic interventions and in the intensive care 
unit. As CYP3A is located in both the liver and the intestines, the activity of the CYP3A 
enzyme is an important determinant of midazolam systemic clearance (CL) and oral 
bioavailability (F) 27­28. In view of the ever­increasing body weights of morbidly obese 
patients, in this pharmacokinetic study we evaluate the influence of morbid obesity on 
CYP3A­mediated systemic clearance and oral bioavailability of midazolam when studied 
after semi­simultaneous oral and intravenous administration, allowing these parameters 
to be characterized in a distinct manner. For the analysis, midazolam data from a healthy 
volunteer study with the same study design were also available. The results of this study 




study design and patients
This prospective observational study in morbidly obese patients (NTC01519726 and Eu­
draCT 2011­003293­93) was approved by the local human research and ethics committee 
of the Sint Antonius Ziekenhuis (VCMO, NL35861.100.11) and conducted in accordance 
with the principles of the Declaration of Helsinki and the Medical Research Involving 
Human Subjects Act (WMO) of the Netherlands. Before participation, all patients gave 
written informed consent.
Adult morbidly obese patients (BMI>40 kg/m2) undergoing laparoscopic gastric by­
pass or sleeve surgery were eligible for inclusion in the study. Patients were excluded 
if they used CYP3A inducing or inhibiting medication according to Cytochrome P450 
Drug Interaction Table  11, used products containing grapefruit, wild grape, banpeiyu, 
pomegranate, star fruit or black berry within 2 weeks before the study, were pregnant or 
breastfeeding, or suffered from renal insufficiency (estimated glomerular filtration rate 
(Modification of Diet in renal Disease, MDRD4, <60 mL/min)).
study procedure
Twenty morbidly obese patients were studied on the day of laparoscopic bariatric 
surgery after an overnight fast. Midazolam was administered in a semi­simultaneous 
manner. Approximately 2.5 hours before induction of anesthesia, patients received mid­
azolam 7.5 mg orally as a tablet (Dormicum®, Roche). At the induction of anesthesia (159 
± 67 minutes after the oral dose), 5 mg of intravenous midazolam (Midazolam, Actavis 
5mg/ml) was administered. Blood samples were collected at T = 0, 5, 15, 30, 45, 55, 65, 
75, 90, 120, 150 minutes after the oral dose and T = 5, 15, 30, 30, 90, 120, 150, 180, 210, 
270, 330, 390, 510 minutes after the intravenous dose. Blood samples were collected in 
lithium heparin tubes and centrifuged at 3,000 rpm for 10 minutes at 4º C. Plasma was 
separated and immediately stored at ­80 º C until analysis.
Blood samples to measure markers of liver function (aspartate aminotransferase 
(ASAT), alanine aminiotransferasem (ALAT), bilirubin, gamma­glutamyltransferase 
(gamma GT), and albumin) in morbidly obese patients were collected before the oral 
midazolam dose was administered.
Control group
Data from 12 healthy volunteers receiving midazolam in an identical semi­simultaneous 
dosing design were available for analysis (EudraCT 2009­010331­40). Subjects had to fast 
from 2 hours before drug administration and received a 2 mg oral midazolam solution 
(Midazolam, Synthon) at 10:00 am. After 150 minutes they received a 1 mg intravenous 
midazolam dose (Midazolam, Synthon) and blood samples were collected at T = 15, 30, 
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45, 60, 65, 70, 75, 80, 90, 120, 148, 155, 165, 180, 210, 240, 270, 330, 390 minutes after 
oral dose.
drug assay
In the plasma samples from morbidly obese patients, midazolam was analyzed using a 
MassTox® TDM series A BASIC­Kit for ultra performance liquid chromatography (UPLC)­
tandem mass spectrometry (MS/MS) from Chromsystems Instruments & Chemicals 
GmbH (Gräfelfing/München, Germany), a commercially available kit including mobile 
phases, dilution buffers and extraction buffer. For sample preparation, 25 μl of MassTox® 
BASIC­Kit A extraction buffer was added to 50 μl of the sample. After short vortex mixing, 
this mixture was let to incubate for 2 minutes. Then 250 μl MassTox® BASIC­Kit A internal 
standard mix was added and the mixture was vortexed for 30 seconds and centrifuged 
at 15,000 g for 5 minutes. Ten µl of the supernatant was injected onto the ULPC column 
(Chromsystems MasterColumn) without a precolumn using a Waters Acquity UPLC 
system connected to a Waters TQD mass spectrometer with electrospray ionization. 
The column was kept at 25º C. Eluent was used at a flow rate of 0.6 ml/min. Intra­assay 
and inter­assay coefficients of variation were 4.7% and 3.3%, respectively. Midazolam 
recovery was 90%. The lower limit of quantification (LLOQ) was 0.8 ng/ml.
In the plasma samples from healthy volunteers, midazolam was measured using a 
validated liquid chromatographic­tandem mass spectrometric (LC­MS/MS) assay. Briefly, 
500 µl acetonitrile containing midazolam­D4 (4µg/L) was added to 200 µl serum. After 
3 min vortex mixing and 5 min centrifugation at ambient temperature the supernatant 
was collected and transferred into an autosampler vial. Next, 10 µl was injected on an 
Atlantis T3 C18 3µm column (2.1 x 50 mm; Waters), protected with a guard column (ODS; 
4 x 3 mm), which was kept at 30 °C. Gradient elution was performed with a mobile phase 
consisting of 0.1% v/v aqueous formic acid and 0.1% v/v formic acid in acetonitrile at 
a flow rate of 0.3 ml/min. The effluent was monitored with a Micromass Quattro Micro 
triple­quadrupole mass spectrometric detector (Waters). The detector was operated in 
the positive electrospray ionization mode and configured in the multiple reaction moni­
toring (MRM) mode. Within­day and between­day inaccuracy and imprecision were less 
than 5%. The LLOQ was 0.3 ng/mL.
Population pharmacokinetic analysis and internal validation
Population pharmacokinetic modeling was performed on all data by means of nonlinear 
mixed effects modelling using NONMEM® (version 7.2; GloboMax LLC, Hanover, MD, 
USA) 29. Pirana (2.7.1; Pirana Software & Consulting BV) and R (2.15) were used to visual­
ize the data. All midazolam plasma concentration values that were received from the 
laboratory were inserted in the datafile, even if these were below the limit of quantifica­
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tion (LOQ). Of the 434 samples from morbidly obese patients, 42 were below the LOQ. 
For healthy volunteers, no data was below the LOQ.
Discrimination between different models was made by comparison of the objective 
function value (OFV, i.e. ­2 log likelihood (­2LL)). A p value below 0.05, representing 
a decrease of 3.84 in the OFV for one degree of freedom, was considered statisti­
cally significant. In addition, goodness­of­fit plots (observed versus individual­predicted 
concentrations, observed versus population­predicted concentrations, conditional 
weighted residuals versus time and conditional weighted residuals versus population­
predicted concentrations plots) were used for diagnostic purposes. Furthermore, the 
confidence interval of the parameter estimates, the correlation matrix and visual im­
provement of the individual plots were used to evaluate the model. The internal validity 
of the population pharmacokinetic model was assessed by the bootstrap re­sampling 
method using 500 replicates and normalized prediction distribution errors (NPDE) using 
1,000 simulation of each dataset 30. Parameters obtained with the bootstrap replicates 
were compared with the estimates obtained from the original dataset. NPDE plots were 
checked for normal distribution characteristics and trends in the data errors 30.
For the structural model, one­ , two, and three­compartment models with an oral dos­
ing compartment were tested. To describe the midazolam oral absorption phase, zero 
order and first order absorption models were tested, in addition to a lag time model 
and a transit absorption model 31. For the transit absorption model, a varying number of 
transit compartments was tested. As the transit rate (Ktr) was set equal to the absorption 
rate (Ka), the mean transit time (MTT) can be calculated from Ktr with (n+1)/Ktr in which n 
is the number of transit compartments 32.
For the statistical model, the individual parameter estimate (empirical Bayes estimate 
or post hoc value) of the ith individual was modelled according to (equation 1):
θi = θmean × eηi (Eq. 1)
where θmean is the population mean, and ηi is a random variable for the ith individual with 
a mean of zero and variance of ω2, assuming log­normal distribution in the population.
For residual variability, resulting from assay errors, model misspecifications and other 
unexplained sources, a proportional error model and a combined proportional and 
additive model was tested for each of the data sets. The jth observed midazolam con­
centration of the ith healthy volunteer (Yij) is described by Eq. 2, while the jth observed 
midazolam concentration of the ith morbidly obese patient (Yij) is described by Eq. 3
Yij = Cpred,ij × (1 + εij) (Eq. 2)
Yij = Cpred,ij × (1 + εij) + εij (Eq. 3)
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where Cpred,ij is the population predicted midazolam concentration of the ith individual 
at the jth time, and εij is a random variable with a mean of zero and variance of σ2.
Covariate analysis
Covariates were plotted independently against the individual post hoc values and eta 
estimates of pharmacokinetic parameters to visualize potential relations. The following 
covariates were tested: total body weight (TBW), BMI, lean body weight (LBW) 33, sex, 
morbid obesity and age. All covariates except for sex and morbid obesity were tested 
using linear and allometric equations (Eqs. 4 and 5):
Pi = Pp × (1 + W × (COVi − COVmedian) (Eq. 4)
Pi = Pp ×( COV )x (Eq. 5)COVmedian
where Pi and Pp represent individual and population parameter estimates, respectively; 
COV represents the covariate; COVmedian represents the median value of the covariate for 
the population; W represents a correlation factor between the population pharmacoki­
netic parameters and the change in covariate value; and X represents the exponential 
scaling factor for a power function. The binary covariates ‘sex’ and ‘morbid obesity’ were 
tested using Eq. 6:
Pi = Pp × Z COV (Eq. 6)
where Pi and Pp represent individual and population parameter estimate, Z the estimated 
factor of increase or decrease for the patients subgroup with COV equalling one.
Potential covariates were separately entered into the model and statistically tested by 
use of the OFV and, if applicable, the 95% confidence interval of the additional parameter. 
In addition, if applicable, it was evaluated whether the inter­individual variability (eta) in 
the parameter concerned decreased upon inclusion of the covariate on the parameter 
and whether the trend in the eta versus covariate plot had resolved. When more than 
one significant covariate for the simple model was found, the covariate­adjusted model 
with the largest decrease in the OFV was chosen as a basis to sequentially explore the 
influence of additional covariates with the use of the same criteria. Finally, after forward 
inclusion (p<0.05), a backward exclusion procedure was applied to justify the inclusion 
of a covariate (p<0.01). The choice of the covariate model was further evaluated as 
discussed in the Population pharmacokinetic analysis and internal validation section.
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Model simulations
Using NONMEM® 7.2, the final population pharmacokinetic model was used to simulate 
the concentration­time profiles of four typical patients from the dataset, including one 
healthy volunteer of 76 kg and three morbidly obese patients of 112, 145 and 186 kg. 
The 76 kg and 145 kg dose simulations represent the median body weight of the healthy 
volunteer and morbidly obese patient group, respectively. In addition, the 112 kg and 
186 kg dose simulations represent the extremes of the body weight range of the mor­
bidly obese patient group (see Table 1).
results
Patients and data
Twenty morbidly obese patients participated in this study and a mean of 22 ± 3 samples 
per patient were available for analysis. In addition, data from 12 healthy volunteers with 
19 midazolam concentrations per subject were used as a control group in this analysis.
Liver function markers in morbidly obese subjects were all within three times the upper 
limit of normal, with the vast majority being within two times the upper limit of normal 
of the different markers. The demographics of all subjects are summarized in Table 1.
Population pharmacokinetic model and validation
A three­compartment model with two equalized peripheral volumes of distribution 
best fitted the data. This model showed an improved fit over a two­compartment model, 
while a full three compartment model could not be estimated with adequate precision. 
The pharmacokinetic model was parameterized in terms of the oral Ka, oral bioavailabil­
ity (F), volume of distribution of the central compartment (V1), two equalized volumes 
of distribution of the peripheral compartments (V2 and V3), inter­compartmental clear­







Age (years) 43.6 ± 7.6 26 ­ 57 22.0 ± 3.1 18 ­ 27 P< 0.001
Body weight (kg) 144.4 ± 21.7 112 ­ 186 76.0 ± 8.7 63 ­ 93 P< 0.001
Lean body weight (kg) 33 71.5 ± 11.9 53 ­ 95 61.2 ± 5.0 53 ­ 70 P< 0.005
BMI (kg/m2) 47.1 ± 6.5 40 ­ 68 22.3 ± 2.4 19 ­ 26 P< 0.001
Number of samples per patient 21.7 ± 2.7 13­24 19 ± 0.0 19 ­ 19 P< 0.001
Samples below the limit of quantification (%) 9.7 ­ 0 ­ ­
Values are expressed as mean ± standard deviation (range) unless specified otherwise
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ances from the central compartment to each peripheral compartment (Q and Q2), and 
clearance from the central compartment (CL). Midazolam oral absorption described by 
three transit absorption compartments proved superior over the other oral absorption 
models (zero and/or first order absorption models or a lag time model) (Figure 1). An 
omega block was implemented to account for the correlation between the central and 
peripheral volume of distribution. Table 2 shows the parameter estimates of the simple 
model without covariates.
In the covariate analysis, a significant influence of TBW or ‘morbid obesity’ was found 
on four different parameters, which is visualized in Figure 2 where the post hoc param­
eters of the simple model without covariates are given. It was found that the peripheral 
volumes of distribution increased in a non­linear manner with TBW (p<0.001, ­24 ΔOFV), 
and that the central volume of distribution showed a linear increase with body weight 
(p<0.001, ­17 ΔOFV). For oral bioavailability and absorption rate (or Ktr), ‘morbid obesity’ 
was a significant covariate and significantly improved the model (p<0.001, ­22 ΔOFV 
and p<0.001, ­20 ΔOFV, respectively). For clearance, there was a trend towards a positive 
influence of LBW but not for TBW; however, the statistical significance was insufficient 
for inclusion of LBW in the final covariate model (p<0.05, ­4 ΔOFV), the estimated corre­
lation factor was not estimated with adequate precision and the eta for clearance value 
figure 1 Schematic illustration of the population pharmacokinetic model of oral and intravenous adminis­
tered midazolam. CL= clearance, F= oral bioavailability, Ka= oral absorption rate, Ktr= transit rate constant, 
MDZ= midazolam, Q= intercompartmental clearance to first peripheral volume, Q2= intercompartmental 
clearance to second peripheral volume, V= volume of distribution.
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was not reduced. Eta distributions for clearance versus body weight and LBW of the 
simple and final covariate model are included in the Electronic Supplementary Material 
(ESM 1, see end of this Chapter). After inclusion of the covariates in the model, the trends 
in eta value of the parameter and the covariate had disappeared and no residual trends 
were observed (Electronic Supplementary Material, ESM 2). All parameter estimates of 
the final model are shown in Table 2. Figure 3 demonstrates the goodness­of­fit plots of 
the final covariate model. The plots show no remaining bias for predicted midazolam 
concentrations in morbidly obese patients or healthy volunteers. The final model was 
internally validated by means of 500 bootstrap runs (Table  2), which were successful 
















































































figure 2 Post hoc parameter estimates of morbidly obese individuals (n=20, black dots) and healthy in­
dividuals (n=12, grey dots) from the simple pharmacokinetic model versus total body weight, including 
central volume of distribution versus total body weight (a), peripheral volume of distribution versus total 
body weight (b), oral bioavailability versus total body weight (c), and oral absorption rate versus total body 
weight (d).
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table 2 Population pharmacokinetic parameters of the simple and final pharmacokinetic model for mid­
azolam in 20 morbidly obese patients and 12 healthy volunteers and results from a bootstrap analysis of the 
final model (479/500 resamples successful).
Parameter simple model (rse%) final model (rse%) bootstrap (se)
Fixed effects
CL (L/min) 0.36 (4.9) 0.359 (4.4) 0.358 (0.016)
F 0.414 (12.8) ­
 F morbidly obese ­ 0.603 (13.2) 0.603 (0.081)
 F healthy volunteers ­ 0.284 (7.0) 0.286 (0.020)
Ka (min­1) = Ktr 0.086 (3.4)a ­
 Ka = Ktr morbidly obese ­ 0.057 (13.6)b 0.058 (0.059)
 Ka = Ktr healthy volunteers ­ 0.13 (5.1)b 0.130 (0.006)
Vcentral (L) 36.4 (7.8) ­
Vcentral = V127 kg *(1+Z*(TBW­127))
 Vcentral, 127 kg ­ 44.1 (16.1) 43.6 (6.9)
 Z ­ 0.0105 (15.8) 0.0102 (0.002)
Vmidazolam peripheral (L) 76.6 (8.4) ­
Vperipheral = V127 kg *(TBW/127)W
 Vperipheral, 127 kg ­ 139 (15.2) 138.7 (22.9)
 W ­ 3.06 (8.2) 3.07 (0.28)
Q (L/min) 1.31 (12.8) 1.33 (11.8) 1.33 (0.143)
Q2 (L/min) 0.153 (12.1) 0.15 (14.6) 0.15 (0.023)
Interindividual variability (%)
 CL 19.7% (32.6) 18.1% (30.7) 17.2% (14.6)
F 61.2% (20.8) 26.4% (17.4) 25.4% (14.6)
Ka = Ktr 50.7 %(10.9) 41.4% (12.8) 39.9% (18.4)
Vcentral 102.8% (13.2) 55.2% (17.5) 53.5% (30.8)
Vperipheral 152.3% (13.9) 34.4% (26.5) 33.6% (23.7)
Correlation between eta Vcentral and Vperipheral 0.783 (50.0) 0.12 (24.5) 0.10 (0.058)
Residual variability (%)
Proportional error Healthy volunteers 10.0% (21.5) 10.0% (21.3) 9.9% (4.4)
Proportional error Morbidly obese patients 31.0% (17.1) 46.7% (11.6) 46.6% (15.6)
Additive error morbidly obese patients 3.1 (37.3) ­ ­
OFV 4077 4003 3982 (145)
CL= systemic clearance of midazolam, F= oral bio­availability, Ka= oral absorption rate, Ktr= transit compart­
ment rate, V= volume of distribution, Q= inter­compartmental clearance of midazolam between central 
and first peripheral compartment, Q2= inter­compartmental clearance of midazolam between central and 
second peripheral compartment, OFV= Objective Function Value, RSE= relative standard error, SE= stan­
dard error, TBW= total body weight, V= volume of distribution
a Mean transit time is 46.5 minutes.
b Mean transit times are 70.2 and 30.8 minutes, respectively.
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in 96% of the runs and confirmed the parameter values. Finally, an NPDE analysis was 
performed showing a normal distribution of errors without trends, except for the initial 
midazolam concentrations in morbidly obese patients, which were below the LOQ (see 
Electronic Supplementary Material , ESM 3). The NONMEM® control file of the final model 
is provided as online resource (ESM 4).
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figure 3 Observed versus individual predicted midazolam concentrations (a), observed versus population 
predicted midazolam concentrations (b), conditional weighted residuals (CWRES) versus population pre­
dicted midazolam concentrations (c) and conditional weighted residuals (CWRES) versus time of the final 
model for 20 morbidly obese patients (black dots) and 12 healthy volunteers (grey dots). The dashed line 
represents the line of identity (x=y).
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figure 4 Population predicted midazol­
am concentrations over time in three 
typical morbidly obese patients (112, 145 
and 186 kg) and one healthy volunteer 
(76 kg) after a 5 mg intravenous bolus 
dose (logarithmic scale) (a), a 2.5 mg/h 
continuous infusion (linear scale) (b) and 
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Figure 4 shows population predicted midazolam concentrations after a 5 mg intravenous 
bolus dose, a 2.5 mg/h continuous infusion for a duration of 10 days (14,400 minutes) 
and a 7.5 mg oral dose in 4 typical subjects from the dataset (i.e. 76 kg, 112, 145 and 186 
kg). The plot shows that for the intravenous bolus dose, midazolam (peak) concentra­
tions (Cmax) are lower in morbidly obese patients (Figure 4a), which may be the result of 
the higher central volume of distribution in morbidly obese patients. In addition, the 
plot illustrates the longer midazolam half­life (t½) in morbidly obese patients, which 
can be attributed to the increase in volumes of distribution with body weight, while 
clearance is the same in all patients. The continuous intravenous infusion simulation 
(Figure  4b) shows that with increasing body weight the midazolam steady­state con­
centrations are reached at a later time point. In a 76 kg healthy volunteer, steady­state is 
expected to be reached after 24 hours, while this is 170 hours in a 145 kg morbidly obese 
patient and >240 hours in a 186 kg morbidly obese patient (Figure 4b). Finally, the oral 
midazolam dose simulations (Figure 4c) show that the time to reach the Cmax is later (31 
minutes) in morbidly obese patients than in healthy volunteers, while the Cmax is slightly 
lower in morbidly obese patients.
dIsCussIon
As there is only limited information on the influence of morbid obesity on CYP3A­
mediated clearance of drugs in patients, this study aimed to evaluate the pharmaco­
kinetics of CYP3A substrate midazolam in morbidly obese patients following oral and 
intravenous midazolam administration. As clearance after oral dosing is dependent on 
oral bioavailability, which may be influenced by CYP3A enzyme activity in the intestines, 
this semi­simultaneous design allows for an estimation of both systemic clearance and 
oral bioavailability in a distinct manner. An available dataset of midazolam concentra­
tions collected on the basis of an equivalent study design in healthy volunteers allowed 
for a head­to­head comparison between morbidly obese patients and non­obese 
healthy subjects. The results from this study show that midazolam clearance was similar 
in morbidly obese patients and healthy volunteers, oral bioavailability was substantially 
higher (60% instead of 28%), oral absorption rate was reduced and that the central and 
peripheral volumes of distribution increased substantially with body weight. Particularly 
for intravenous dosing, the net results of all these changes should be considered when 
administering midazolam to morbidly obese patients.
In this study, we could not identify an influence of morbid obesity on the systemic 
clearance (CL) of midazolam, even though a wide range in body weights was included 
in this study. We did find a trend of increasing midazolam clearance with lean body 
5 | 139
weight; however, this trend was not strong enough for inclusion in the final covariate 
model. Possibly, the patient numbers in this analysis (n=12 + n=20) are insufficient to ad­
equately detect a small increase in clearance with LBW. While these results indicate a lack 
of change in absolute hepatic CYP3A mediated metabolism of midazolam in morbidly 
obese individuals, the results are in contrast with our expectations of a lower midazolam 
clearance in morbidly obese patients which was based on reports in in vitro and animal 
studies 4­7 and on oral clearance of CYP3A substrates in studies in obese subjects 13­14. 
Assuming that indeed the relative CYP3A activity per unit of liver is reduced in morbidly 
obese patients 12, we hypothesize that this effect may be counteracted by a higher liver 
volume 34, resulting in a similar absolute hepatic CYP3A metabolising capacity in both 
groups. In agreement with this hypothesis, also Greenblatt et al. found no significant 
difference in absolute systemic clearance of midazolam between normal weight (66 ± 
2 kg) and obese subjects (117 ± 8 kg) (0.53 ± 0.04 vs. 0.47 ± 0.04 L/min, respectively) 15. 
However for a study with triazolam, another benzodiazepine CYP3A substrate, a lower 
oral clearance (CL/F) was found for obese patients 35. Lower CL/F values were also found 
for obese patients for the CYP3A substrates taranabant and carbamazepine 36­37. Based 
on the results found in the current midazolam study upon both oral and intravenous 
administration, it may be hypothesized that these lower oral clearance (CL/F) values 35­37 
are due to an increase in oral bioavailability (F) instead of a decrease in systemic clear­
ance (CL).
Oral bioavailability was found to be higher in morbidly obese patients compared to 
healthy volunteers (0.60 (13.2%) versus 0.28 (7.0%)). In contrast, Greenblatt et al. found 
similar values of oral midazolam bioavailability in obese (0.42 ± 0.04) and normal weight 
patients (0.40 ± 0.03) (p>0.05). This disagreement in results may be explained by the 
higher body weights of the morbidly obese subjects in our study versus the study of 
Greenblatt et al. (mean of 144 ± 22 versus 117 ± 8 kg). In addition, the concentration­
time profiles after oral and intravenous midazolam of a non­obese and an obese subject 
shown in their publication, may also point at a higher bioavailability in the obese pa­
tient 15. We anticipate that the increase in oral bioavailability in morbidly obese patients 
found in our study may be due to reduced CYP3A metabolizing activity in the intestines. 
Ulvestad et al. found in a study with 19 obese individuals (median BMI 45 (34­59) kg/m2) 
that CYP3A4 protein expression in the small intestine and liver is lower with increasing 
BMI. Another possible cause of increased bioavailability is an increase in splanchnic 
blood flow, which has been reported before in morbidly obese patients 38. An increase in 
villous blood flow in the gut wall will cause an increase in substrate transport and thus 
carry the substrate away from the intestinal CYP3A metabolizing enzymes 39­40. More­
over, increased intestinal permeability may be responsible for increased midazolam 
bioavailability as obese patients showed increased paracellular absorption measured 
with lactulose and chromium (Cr)­EDTA, which may possibly be due to reduced tight 
5 | 140
junction function 41­42. A question would be whether the observed difference in absorp­
tion rate (Ka) between the morbidly obese patients and healthy volunteers, which 
can be attributed to a difference in formulation (tablet versus oral solution), may have 
contributed to the reported difference in oral bioavailability. In our opinion, this differ­
ence in formulation is unlikely to influence oral bioavailability, as midazolam is a highly 
soluble and permeable drug which is expected to be 100% absorbed in the intestines 43. 
Correspondingly, a study in which 6 healthy volunteers received a 10 mg midazolam 
oral solution, a 10 mg tablet and a 5 mg intrvaneous bolus dose, showed similar oral 
bioavailability after both oral dose formulations, 0.35 ± 0.07 versus 0.38 ± 0.12 (p>0.6), 
indicating no influence of oral formulation on midazolam bioavailability 44.
To understand the net result of the influence of different degrees of (morbid) obe­
sity on each of the midazolam pharmacokinetic parameters, simulations using the final 
model were performed to yield midazolam concentration­time profiles for subjects with 
different body weights. The dose simulations show that the same intravenous bolus 
dose to all subjects leads to lower initial concentrations in morbidly obese patients due 
to a substantially higher central and peripheral volume of distribution. This observed 
increase in volume of distribution is in agreement with the midazolam study of Greenb­
latt et al. in which a substantial increase in total volume of distribution for obese versus 
normal weight subjects of 311± 27 L versus 114 ± 7 L (p<0.001) was also reported 15. 
Potentially, these results can be explained by an increase in body volume in terms of 
both well­perfused compartments (organ and blood volume) and adipose tissue with 
obesity, which is of specific relevance because midazolam is a lipophilic drug 38, 45. As 
such, directly after an intravenous bolus dose, lower midazolam concentrations and 
associated effects may be expected in morbidly obese patients. In addition, morbidly 
obese patients show an increased elimination half­life (Figure 4), which can be attrib­
uted to the larger volumes of distribution as well, as they allow for significant midazolam 
disposition from the blood and may lead to prolonged midazolam effects in morbidly 
obese patients versus healthy volunteers. In contrast, a similar midazolam oral dose 
will result in only slightly lower initial concentrations in morbidly obese patients versus 
healthy volunteers because the increased oral bioavailability counteracts the influence 
of increased central volume of distribution on midazolam peak concentrations (Fig­
ure 4). Finally, the increase in the volumes of distribution with body weight also explains 
the increased duration for morbidly obese patients to reach steady­state concentrations 
after a continuous intravenous infusion. This phenomenon has been described before 
for diazepam in obese patients 46. Therefore a loading dose or a higher initial continuous 
infusion rate may be considered to reach midazolam steady­state concentrations more 
rapidly in morbidly obese patients.
There are some limitations to this study. Firstly, the sampling duration after oral 
administration may have been relatively short. Particularly in morbidly obese patients, 
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the midazolam peak concentrations after the oral dose occurred at approximately 90 
minutes post dose, leaving only a 60 minute time interval to collect data on the concen­
tration decline after oral dose before the intravenous dose was administered. However, 
in six of the 20 patients this interval was >180 minutes (due to a delay in the surgery 
schedule), thus providing significant information on the midazolam pharmacokinetics 
after oral absorption in the morbidly obese patients. Secondly, the healthy volunteer 
group lacks a late sample post intravenous dose, which have may have an effect on the 
clearance and peripheral volume of distribution estimates of the healthy volunteers and 
thus obscure the covariate analysis. However, estimated pharmacokinetic parameter 
values for this group closely match those found in previous midazolam pharmacokinetic 
studies in healthy volunteers, indicating adequate precision of the pharmacokinetic 
parameters in healthy volunteers and justifying the results from the covariate analysis. 
Thirdly, morbidly obese patients underwent surgery during the study, which may influ­
ence midazolam clearance and distribution. However, we think that surgery was only 
of minor influence as only the intravenous dose was administered during surgery and 
systemic clearance and volume of distribution found in this study were fairly similar 
to earlier reported values in non­surgery obese patients 15. Finally, the stable isotope 
method for determining oral bioavailability in a single person on a single occasion may 
have been preferable over the current semi­simultaneous dosing design. Though, the 
semi­simultaneous oral­intravenous administration method has proved a reliable and 
accurate method for estimating oral bioavailability and systemic clearance in a single 
person, on a single occasion as well 47­50. Moreover, the available control data (midazol­
am concentrations in healthy volunteers) was gathered in a semi­simultaneous design. 
Lastly, the preparation of the labeled drug and the determination of the labeled drug in 
the samples is very expensive and labor intensive. For these reasons, we have chosen to 
apply the semi­simultaneous design.
In conclusion, this study shows that midazolam hepatic clearance was not changed 
in morbidly obese patients versus healthy volunteers, while oral bioavailability was 
increased in morbidly obese patients. Midazolam central and peripheral volumes of 
distribution increased substantially with body weight resulting in lower midazolam con­
centrations after intravenous bolus administration and in increased duration to reach 
steady state concentrations after midazolam continuous infusion in morbidly obese 
patients in comparison to healthy volunteers. Finally, initial midazolam concentrations 
after an oral dose were similar in morbidly obese patients versus healthy volunteers. 
Further research should elucidate the exact physiological changes at intestinal and 
hepatic level contributing to these findings.
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1.0 Morbidly obese patients (n=20)
Healthy volunteers (n=12)















































Simple model Final model
esM 1 Eta distributions for clearance for the simple (a and c) and final (b and d) pharmacokinetic model 
versus lean body weight (a and b) and body weight (c and d) in 20 morbidly obese patients (black dots) and 














































































































































































Simple model Final model
esM 2 Eta distributions for central volume of distribution (a and b), peripheral volume of distribution (c 
and d), oral bioavailability (e and f ), oral absorption rate (Ktr) (g and h) in 20 morbidly obese patients (black 
dots) and 12 healthy volunteers (grey dots) for the simple (a, c, e, g) and final midazolam pharmacokinetic 
model (b, d, f, h).
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esM 3 Normalized prediction distribution errors (npde) for the midazolam data from 20 morbidly obese 
patients (a) and from 12 healthy volunteers (b). The X indicates the time after dose and Y indicates the 
midazolam concentration in nmol/L.
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esM 4 nonMeM control stream of the final pharmacokinetic model
$PROBLEM Final model #61
$INPUT ID TIME AMT RATE DROP DV CMT MDV TAD TADI OBES TBW LBW IBW BMI WHR 
















F1= TVF1*EXP(ETA(2)) ; oral bioavailability
TVV2= THETA(3)*(1+THETA(8)*(TBW­127))
V2= TVV2*EXP(ETA(5)) ; volume (L)
TVQ= THETA(4)
Q= TVQ*EXP(ETA(3)) ; intercompartmental clearance (L/min)
TVV3= THETA(5)*(TBW/127)**THETA(9)
V3= TVV3*EXP(ETA(6)) ; peripheral volume of distribution (L)
TVKA= THETA(6)*THETA(11)**OBES
KA= TVKA*EXP(ETA(4)) ; oral absoprtion rate or Ktr (min­1)
KTR= KA
V4= V3 ; 2nd volume periph. compartment (L)





























IPRED=F ; individual prediction
;
Y1=IPRED*(1+ERR(1)) ; healthy volunteers




IRES=DV­IPRED ; individual residual




 (0, 0.2) ;CL (L/min)
(0, 0.3) ;F1 healthy volunteers
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(0, 30) ;V2 (L)
(0, 0.9) ;Q (L/min)
(0, 100) ;V3 (L)
(0, 0.1) ;KA healthy volunteers
(0, 0.1) ;Q4
(0, 0.003) ;TBW V2
(0, 2) ;TBW V3
(0, 2) ;fraction F1 morbidly obese









0.05 0.1 ;V3 (peripheral)
;
$SIGMA
0.005 ; healthy volunteers
0.1 ; morbidly obese
$EST SIGDIG=3 MAXEVAL=9999 PRINT=5 NOABORT METHOD=1 INTERACTION POSTHOC
$COV COMP
$TABLE ID TIME TAD TADI IPRED IWRES CWRES CMT ROUN OBES IV NOPRINT ONEHEADER 
FILE=sdtab61
$TABLE  ID TAD CMT TADI ROUN OBES IV CL V2 Q V3 Q4 KA F1 V4 TBW LBW IBW AGE 
BMI WHR ETA(1) ETA(2) ETA(3) ETA(4) ETA(5) ETA(6) NOPRINT NOAPPEND ONEHEADER 
FILE=patab61
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midazolam in morbidly obese patients before 
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Bariatric surgery is nowadays commonly applied as treatment for morbid obesity 
(BMI >40 kg/m2). As information about the effects of this procedure on a drug’s phar­
macokinetics is limited, we aimed to evaluate the pharmacokinetics of CYP3A probe 
substrate midazolam after oral and intravenous administration in a cohort of morbidly 
obese patients that was studied before and 1 year post bariatric surgery.
Methods
Twenty morbidly obese patients (aged 26­58 years) undergoing bariatric surgery 
participated in the study of which 18 patients returned one year after surgery. At both 
occasions, patients received 7.5 mg oral and 5 mg intravenous midazolam separated by 
160 ± 48 minutes. Per patient and occasion, a mean of 22 blood samples were collected. 
Midazolam concentrations were analyzed using population pharmacokinetic modeling.
results
One year after bariatric surgery, systemic clearance of midazolam was higher [0.65 (7%) 
versus 0.39 (11%) L/min, mean ± RSE (P<0.01), respectively] and mean oral transit time 
(MTT) was faster [23 (20%) versus 51 (15%) minutes (P<0.01)], while oral bioavailability 
was unchanged (0.54 (9%)). Central and peripheral volumes of distribution were overall 
lower (P<0.05).
Conclusions
In this cohort study in morbidly obese patients, systemic clearance was 1.7 times higher 
one year after bariatric surgery, which may potentially result from an increase in hepatic 
CYP3A activity per unit of liver weight. Although MTT was found to be faster, oral bio­
availability remained unchanged, which considering the increased systemic clearance 
implies an increase in the fraction escaping intestinal first pass metabolism.
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IntroduCtIon
The prevalence of morbid obesity (body mass index, BMI  >40 kg/m2) is increasing 
worldwide. In the United States, 6% of the population is morbidly obese while in Europe 
prevalence of obesity (BMI >30 kg/m2) ranges between 10 and 30% depending on the 
country 1­2. Exact numbers on the prevalence of morbid obesity in Europe are lacking, 
but are estimated to range between 1­7% 3­5.
Bariatric surgery is considered the most effective treatment for morbid obesity 6­7. 
In 2011, more than 340,000 bariatric surgeries, including Roux and – Y gastric bypass 
(RYGB) and sleeve gastrectomy, were performed worldwide 8. During a bariatric proce­
dure, the stomach is reduced to a sleeve like structure or a small pouch and, in case of 
a Roux and –Y gastric bypass, the duodenum and initial part of the small intestine are 
bypassed 9­11. These alterations in the gastro­intestinal tract may cause an increase in 
stomach pH, an increase in gastric emptying time, and a decrease in the surface area of 
absorption 9, 12­13.
As such, a bariatric procedure may impact a drug’s pharmacokinetics and have con­
sequences for dosing. In particular for drugs undergoing CYP3A metabolism, it seems 
relevant to study the impact of bariatric surgery, as the CYP3A enzyme resides not 
only in the liver but also in the gut wall and is an important drug metabolising enzyme 
involved in the metabolism of approximately 25% of all clinically used drugs 14. Besides 
bariatric surgery induced anatomical changes to the gastro­intestinal tract, the resulting 
reduction in (over)weight may also influence CYP3A activity itself 15. It is well known 
that obese patients suffer from low­grade inflammation caused by macrophages and 
adipocytes in the adipose tissue which excrete inflammation markers and adipokines, 
including Il­6 and TNF­alpha16­18 which may lead to reduced CYP3A activity 15, 19­20. As 
studies in morbidly obese patients before and after bariatric surgery show a reduc­
tion in inflammation status in patients after bariatric surgery, it is hypothesized that 
CYP3A activity in patients after bariatric surgery recovers 21­22. However, it seems that 
the inflammation status does not completely change back to non­obese (never been 
obese) individuals, as 6 months post surgery values of leptin, adiponectin and C­reactive 
protein (CRP) did not return to values found for lean (never been obese) patients 21.
Midazolam is considered a model substrate drug for CYP3A activity as it is primarily 
metabolized by CYP3A 23. Therefore, in this study we aimed to evaluate the pharmaco­
kinetics of midazolam after oral and intravenous administration in a cohort of morbidly 
obese patients that was studied before and 1 year post bariatric surgery. The results 




study design and patients
This is a prospective observational and interventional study in morbidly obese adult 
patients (NTC01519726, EudraCT 2011­003293­93). Before participation, all patients 
gave written informed consent. The study was approved by the local human research 
and ethics committee (VCMO, NL35861.100.11) and was conducted according to the 
principles of the Declaration of Helsinki (version 22­10­2008) and in accordance with the 
Medical Research Involving Human Subjects Act (WMO) of the Netherlands.
Morbidly obese patients undergoing a laparoscopic gastric bypass or sleeve surgery 
between 18 and 65 years were eligible for inclusion in the study. Patients were excluded 
if they used CYP3A inducing or inhibiting medication 24, used products containing 
grapefruit, wild grape, banpeiyu, pomegranate, star fruit or black berry within two 
weeks before the study, were pregnant, were breastfeeding, were younger than 18 or 
older than 60 years or suffered from renal insufficiency (eGFR MDRD4 <60 mL/min).
study procedures
The study consisted of two occasions. The first occasion was on the day of laparoscopic 
bariatric surgery (occasion 1), of which the details and results have been described in a 
previous report 25. One year after bariatric surgery, the 20 patients who participated on 
occasion 1, were invited to participate in the second part of the study (occasion 2). The 
period of one year was chosen based on the Swedish Obese Subjects study showing a 
mean weight loss optimum of 32% of body weight 0.5­2 years after bariatric surgery 26.
For both occasions, patients fasted from midnight until the study started in the 
morning (typically at 09:00 o’clock) and were not allowed to eat or drink until 1 hour 
post intravenous midazolam dose. At first a 7.5 mg midazolam tablet was administered 
orally and after 160 ± 48 minutes an i.v. dose of 5 mg was administered. For the first 
occasion, the i.v. dose coincided with the induction of anesthesia for the bariatric surgi­
cal procedure while for the second occasion the i.v. dose was administered at 150 min 
after oral dose. Blood samples were collected at 5, 15, 30, 45, 55, 65, 75, 90, 120, 150 
after oral dose and at 5, 15, 30, 60, 90, 120, 150, 180, 240 and 300, 390 and 510 minutes 
after intravenous dose at occasion 1, and at 5, 15, 30, 60, 90, 120, 150, 180, 240 and 
300 minutes after intravenous dose at occasion 2. After collection, blood samples were 
centrifuged and plasma was stored at ­80 ºC until analysis. Samples were analyzed as 
described before25. The Richmond Agitation Sedation Scale (RASS) was used to score the 
level of sedation in each participant after midazolam oral dose until administration of 
the intravenous dose 27.
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Population pharmacokinetic analysis and internal validation
The population pharmacokinetic analyses was performed by means of nonlinear mixed 
effects modelling using NONMEM (version 7.2)28; Pirana (2.7.1) and R (2.15) were used 
to visualize the data. Discrimination between different structural and statistical models 
was made by comparison of the objective function value (OFV, i.e. ­2 log likelihood 
[­2LL]). A p­value below 0.05, representing a decrease of 3.84 in the OFV, was considered 
statistically significant. In addition, goodness­of­fit plots (observed versus individual­
predicted concentrations, observed versus population­predicted concentrations, condi­
tional weighted residuals versus time and versus population­predicted concentrations 
plots) were used for diagnostic purposes. Furthermore, the confidence interval of the 
parameter estimates, the correlation matrix and visual improvement of the individual 
plots were used to evaluate the model. The internal validity of the population pharma­
cokinetic model was assessed by the bootstrap re­sampling method using 500 repli­
cates and normalized prediction distribution errors (NPDE) 29. Parameters obtained with 
the bootstrap replicates were compared with the estimates obtained from the original 
dataset and NPDE plots were checked for normal distribution characteristics and trends 
in the errors.
Midazolam concentration­time profiles were analysed separately (occasion 1, occa­
sion 2) and simultaneously (occasion 1 and 2). The separate pharmacokinetic analyses 
allowed for initial exploration of the data and evaluation of covariate relationships within 
each population. For all analyses, two­ and three compartment pharmacokinetics mod­
els were tested. For the description of the oral absorption phase, different models were 
tested including first order absorption, zero order absorption and a transit compartment 
model in which transit compartment rates (Ktr) were equalized to the absorption rate 
constant (Ka) 30. The mean oral transit time (MTT), which represents the average time for 
the drug from oral dose administration to appearance at the sample site, can be calcu­
lated from Ktr using MTT= (N+1)/Ktr in which N is the number of transit compartments. 
For the statistical model, the individual parameter estimate (Empirical Bayes Estimate or 
post hoc value) of the ith individual was modelled according to (equation 1):
θi = θmean × exp(ηi) (Eq. 1)
where θmean is the population mean parameter value, and ηi is a random variable for the 
ith individual with a mean of zero and variance of ω2, assuming log­normal distribution 
in the population. The residual variability, resulting from assay errors, model misspecifi­
cations and other unexplained sources, was best described with a proportional error 
model. The jth observed midazolam concentration of the ith patient (Yij) in equation 2:
Yij = Cpred,ij × (1 + εij) (Eq. 2)
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where Cpred,ij is the population predicted midazolam concentration of the ith individual at 
the jth time, and εij is a random variable with a mean of zero and variance of σ2. Covariate 
analysis Covariates were plotted independently against the individual estimates of phar­
macokinetic parameters to visualize potential relations. The following covariates were 
tested: body weight, BMI, lean body weight 31, age, sex and bariatric surgery. The influence 
of the binary covariates bariatric surgery and sex was explored by means of estimating 
two separate thetas or by a factor (‘Z’) of increase/decrease according to equation 3:
Pi = Pp × ZCOVARIATE (Eq. 3)
where Pi and Pp represent the individual and population parameter estimate, Z rep­
resents the factor for increase or decrease for the patients subgroup with a Z of 1 in 
case the covariate equals 0 or a Z of Z in case the covariate equals 1. In case the binary 
covariate bariatric surgery for a specific parameter improved the model significantly, it 
was evaluated whether this factor of increase or decrease could be related to the differ­
ence in body weight, lean body weight 31 or BMI between occasion 1 and 2 using the 
following equations:
If Occasion = 1: Pi = Pp (Eq. 4)
If Occasion = 2: Pi = Pp × factor · (COVBeforeSurgery − COVAfterSurgery) (Eq. 5)
Furthermore, it was tested whether body weight, lean body weight, age or BMI was a 
linear (Eq. 7) or nonlinear (Eq. 8) covariate within occasion 1 or 2 using the following 
equations:
If Occasion = 1: Pi = Pp (Eq. 6)
If Occasion = 2: Pi = Pp × (1 + W × (COV − COVmedian) (Eq. 7)
And/or:




where Pi and Pp represent individual and population parameter estimates, respectively; 
COV represents the covariate; COVmedian represents the median covariate value; X repre­
sents the exponential scaling factor; and W represents the correlation factor between 
the population pharmacokinetic parameters and the covariate. The occasion conditions 
were switched vice versa to test covariate relationships within both groups.
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Continuous covariates for both occasion 1 and 2 simultaneously were tested using 
linear and non­linear equations (equation 9 and 10).
Pi = Pp ×( COV )x (Eq. 9)COVmedian
Pi = Pp × (1 + W × (COV − COVmedian) (Eq. 10)
Potential covariates were separately entered into the model and statistically tested by 
use of the OFV and, if applicable, the 95% CI of the additional parameter. In addition, if 
applicable, it was evaluated whether the interindividual variability in the parameter con­
cerned reduced in value upon inclusion of the covariate on the parameter. After forward 
inclusion (p<0.05), a backward exclusion procedure was applied to justify the inclusion 
of a covariate (p<0.001).The choice of the covariate model was further evaluated as dis­
cussed above (see Population pharmacokinetic analysis and internal validation section).
Model simulations
The final population pharmacokinetic model was used to simulate the midazolam con­
centration time curves after a 7.5 mg oral dose, a 5 mg intravenous dose and a 2.5 mg/h 
continuous infusion. Using Monte Carlo simulations, 1000 individuals were randomly 
generated based on body weight distribution of our study (144 ± 26 kg) and simulations 
based on theta and eta values of the final PK model were performed using NONMEM.
results
Patients and data
Of the 20 morbidly obese patients who participated in the first part of the trial (occasion 
1), 18 patients returned 52 ± 3 weeks after bariatric surgery (occasion 2) and lost a mean 
of 44.5 ± 10.2 kg of body weight. Two of the 20 patients were lost to follow up to partici­
pate at occasion 2. Patients and study characteristics are summarized in Table 1. Figure 1 
shows the midazolam concentration time values measured at both study occasions. At 
occasion 1, the occurrence of the peak concentrations after the i.v. dose were found to 
vary largely, which resulted from differences in time of administration of the intravenous 
midazolam. For post­bariatric surgery patients, the concentration time curves show a 
slightly earlier maximum concentration (Cmax) after oral dose in comparison to morbidly 
obese patients before bariatric surgery, while in a few individuals of the morbidly obese 
patient group peak concentrations after the intravenous dose seemed higher.
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Pharmacokinetic analysis
For the population pharmacokinetic analysis including the data of both occasions a 
three compartment model, in which the second peripheral volume was a fraction of 
the first peripheral compartment best described the data. Midazolam oral absorption 
was best described using 5 transit compartments, while the addition of more transit 
compartments did not further improve the fit of midazolam concentrations after both 
oral and intravenous administration. Table  2 shows the parameters estimates of the 
simple pharmacokinetic model without covariates.














Age (years) 43.6 ± 7.6 26 – 57 45.5 ± 7.4 27 – 58
Body weight (kg) 144.4 ± 21.7 112 – 186 98.3 ± 18.0 62 – 138
LBW (kg) 71.5 ± 11.9 53 – 95 59.5 ± 10.0 39 – 73
BMI (kg/m2) 47.1 ± 6.5 40 – 68 31.9 ± 5.9 24 – 50
Weight loss (kg) ­ ­ 44.5 ± 10.2 21 – 58
Number of midazolam samples per patient 22 ± 3 13 ­ 24 21 ± 1 19 ­ 22
Gastric bypass/ sleeve gastrectomy ­ ­ 16/2 ­
Time post surgery (weeks) ­ ­ 51.8 ± 2.5 49 – 57
BMI= body mass index; LBW= lean body weight

















Morbidly obese patients before bariatric
surgery (n=20)
Patients after bariatric surgery (n=18)
figure 1 Midazolam concentration versus time after oral dose profiles upon a 7.5 mg oral midazolam dose 
and a 5 mg intravenous dose separated by 160 ± 48 minutes in 20 morbidly obese patients before (black lines) 
and 1 year after surgery (grey dotted lines). Two patients were unable to participate one year after surgery.
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table 2 Parameter values of the simple (without covariates) and final (with covariates) population pharma­
cokinetic models and results of the bootstrap analysis.
Parameter
simple model of 
simultaneous analysis
final model of 
simultaneous analysis
bootstrap of final 
simultaneous model
Value (RSE) Value (RSE) Median (2.5 - 97.5 
percentile)
Fixed effects
Ka = Ktr 0.199 (11%) ­ ­
Ka = KtrMorbidly obese (min­1) ­ 0.117 (15%) 0.114 (0.08­0.15)
Ka = KtrBariatric patients (min­1) ­ 0.267 (19%) 0.263 (0.08­0.45)
F 0.560 (10%) 0.537 (9%) 0.543 (0.44 ­ 0.63)
CL (L/min) 0.381 (26%) ­ ­
CLMorbidly obese (L/min) ­ 0.385 (11%) 0.366 (0.29­0.48)
fCLBariatric patients(L/min) ­ 1.68 (7%)
(* CLmorbidly obese= 0.647)
1.70 (1.18­2.18)
(* CLmorbidly obese = 0.634)
Q (L/min) 0.888 (21%) ­ ­
QMorbidly obese (L/min) ­ 0.669 (24%) 0.764 (0.11­1.23)




Q2 0.644 (21%) 0.551(23%) 0.548 (0.25­0.86)
Vcentral (L) 54.7 (17%) ­ ­
Vcentral Morbidly obese = Vmedian BW *(1+X*(BW­median BW))
 Vmedian BW ­ 37.3 (18%) 37.2 (17.8­56.8)
 X ­ 0.0435 (92%) 0.052 (­0.42­0.51)
Vcentral Bariatric patients (L) ­ 37.3 (18%) 37.2 ()
V1st peripheral (L) 247 (30%) ­ ­
VPeripheral Morbidly obese = Vmedian BW*(BW/median BW)Y
 Vmedian BW ­ 106 (17%) 113 (20.9­190.3)
 Y ­ 3.93 (20%) 3.99 (1.9­5.9)
V1st peripheral Bariatric patients (L) ­ 106 (17%) 113 (1.9­5.9)
fV2nd peripheral 0.169 (25%)






Ktr=Ka 50 (17%) 42.4 (15%) 40.6 (27­54)
CL 41.5 (24%) 19.7 (38%) 17.7 (­14­32)
F 28.6 (23%) 33.4 (18%) 32.6 (16­45)
Vcentral 60.8 (20%) 53.7 (39%) 54.3 (­49­102)
V1st peripheral 0 FIX 0 FIX 0 FIX
Proportional residual error (%)
46.2 (6%) 42.1 (5%) 41.0 (12.2)
OFV 6218 5885 5997 (804)
BW= body weight (median=127 kg for all data), CL=Clearance (L/min), F= Oral bioavailability, fCLBariatric 
patients(L/min)= fraction of midazolam clearance of morbidly obese patients to estimate bariatric patient 
clearance, fQBariatric patients = fraction of intercompartmental clearance of morbidly obese patients to estimate 
intercompartmental clearance of bariatric patients, fVperipheral= fraction of first peripheral volume of distribu­
tion to estimate second peripheral volume, Ktr= transit compartment rate (min­1), Ka= oral absorption rate 
(min­1), OFV= Objective function value (­2LL), Q=intercompartmental clearance (L/min), RSE(%)=relative 
standard error, V=Volume of distribution (L), VPeripheral= first peripheral volume of distribution.
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In the covariate analysis, the binary covariate ‘bariatric surgery’ proved an important 
covariate for clearance (CL), oral absorption rate (Ka), inter compartmental clearance 
(Q) and volumes of distribution (V). For clearance, the covariate bariatric surgery gave 
the largest drop in OFV (­91 ΔOFV, p<0.001), while a linear covariate relation with body 
weight resulted in a drop in OFV (­80 ΔOFV). After bariatric surgery, clearance was 1.68 
times higher than in morbidly obese patients before surgery, while the extent of this 
increase could not be related to the loss in (lean) body weight (p>0.05, table 2). Bariatric 
surgery as covariate on Ka also resulted in an improved fit of the model (­167 ΔOFV, 


























































































































































































































































































figure 2 Observed versus individual predicted midazolam concentrations (A), observed versus population 
predicted midazolam concentrations (B), conditional weighted residuals (CWRES) versus time in minutes 
(C) and population predicted midazolam concentrations (D) of the final model for 20 morbidly obese pa­
tients (black dots, occasion 1) of which 18 returned 1 year post surgery for a second study visit (grey dots, 
occasion 2). The dashed line represents the line of identity (x=y).
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p<0.001). In the final model, Ka was separately estimated for both occasions and was 
found to have a larger value in patients after bariatric surgery (0.117 versus 0.267 min­1, 
Table 2). As a consequence, the mean oral transit time (MTT), which is calculated from 
the oral absorption rate, was 51.3 (15%) before versus 22.6 (19%) minutes after bariatric 
surgery. Furthermore, bariatric surgery resulted in a 3.22 times increase in inter com­
partmental clearance, Q (0.669 to 2.15 L/min, ­16 ΔOFV, p<0.001). Finally, the central 
and the peripheral volumes of distribution were overall lower in patients after bariatric 
surgery without a significant influence of (lean) bodyweight within this group. In the 
morbidly obese patients group, central and peripheral volume increased with body 
weight (­6 ΔOFV, p<0.02 and ­68 ΔOFV, p<0.001, respectively, Table 2). As the second pe­
ripheral volume of distribution was modeled as a fraction of the first peripheral volume 
of distribution, for morbidly obese patients before surgery it varied with body weight in 
a similar manner as the first peripheral volume of distribution (Table 2). Concerning oral 
bioavailability (F) and inter­compartmental clearance to the second peripheral com­
figure 3 Population mean (black line) and 90% in­
terval (grey areas) of midazolam concentrations 
versus time after a 5 mg intravenous dose (A), a 
2.5 mg/h continuous infusion (B) and a 7.5 mg oral 
dose (C) in morbidly obese patients before bariatric 
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partment (Q2) none of the covariates were of significant influence (p>0.05). Parameters 
estimates of the final pharmacokinetic model are shown in Table  2 and goodness of 
fit plots are shown in Figure 2. A 500 replicate bootstrap showed validity of the model 
(94% successful, Table 2) and NPDE plots are presented in the electronic supplementary 
material (ESM 1, see end of this Chapter) and showed a normal distribution of errors 









































































figure 4 Empirical bayes estimates (black dots) and population mean estimates (black lines) of midazolam 
clearance (A) and oral bioavailability (B) of the final pharmacokinetic model in 20 morbidly obese patients 
(black closed dots) and 18 bariatric patients (black open dots) versus body weight (kg). Parameter values 
found for healthy volunteers studies from the literature were added for comparison (grey dots)25, 34­40.
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In Figure 3 the population mean and 90% confidence interval of 1000 Monte Carlo 
midazolam dose simulations for morbidly obese patients before and after surgery are 
presented. After a 5 mg intravenous dose, midazolam concentrations in a bariatric 
surgery patient show a higher initial midazolam concentration and a faster decline 
over time compared to a morbidly obese patient before surgery (Figure  3A). Upon a 
midazolam 2.5 mg/h continuous infusion a bariatric patient is exposed to a lower steady 
state concentration in comparison to a morbidly obese patient (Figure 3B), while steady 
state concentrations are reached approximately 2.5 times faster in bariatric patients (~14 
h) than in morbidly obese patients (~37 h). Finally, oral midazolam in a bariatric patient 
will result in a shorter time to maximum concentration (Tmax, 32 versus 65 minutes) and 
1.5 times increase in midazolam maximum concentration (Cmax) in comparison to before 
surgery (Figure 3C).
dIsCussIon
In this cohort study in which morbidly obese patients are studied until one year after 
bariatric surgery, we aimed to determine how and to what extent midazolam pharma­
cokinetics after oral and intravenous administration are affected by bariatric surgery. 
One year post bariatric surgery, we found that midazolam systemic clearance and 
mean oral transit time were substantially increased while oral bioavailability remained 
unchanged. Central and peripheral volumes of distribution were generally lower in 
patients after bariatric surgery. The main finding of this study is the substantial increase 
in midazolam systemic clearance in all 18 patients one year after bariatric surgery com­
pared to their values before surgery. This increase in clearance after bariatric surgery 
could not be contributed to the decrease in body weight as the body weight model 
was inferior to the bariatric surgery model (p<0.05), (Figure 4). Hepatic CYP3A protein 
expression in liver biopsies has been reported to be unaltered after bariatric surgery 
indicating unchanged CYP3A mediated clearance 32. However, Tandra et al. also found 
increased systemic clearance of midazolam in 18 bariatric patients >1 year post RYGB 
surgery in comparison with 18 controls (1.57 ± 0.95 versus 0.92 ± 0.72 L/min, p=0.03) 33. 
In their study, control patients were matched for age, sex, race, and body mass index, 
while in our study we compared midazolam pharmacokinetics within the same cohort 
using a follow up design. Comparing our values to systemic clearance values in healthy 
volunteers (Figure 4A), it seems that systemic clearance values post bariatric surgery are 
higher than those of healthy volunteers found in the literature 25, 34­40. We anticipate that 
the increase in systemic midazolam clearance may be explained by a recovery of hepatic 
CYP3A activity due to decreased inflammation status, as many studies have shown a 
reduction in inflammatory adipokines in the plasma of patients after bariatric surgery 22. 
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Moreover, it has been shown in in vitro and animal studies that a fatty liver, which is 
highly associated with morbid obesity, represses CYP3A activity 41­42. While CYP3A activ­
ity may have recovered one year after bariatric surgery, Immonen et al. showed on the 
other hand that 6 months after bariatric surgery both the fat content and size of the liver 
is reduced to almost the level of lean subjects, which could imply a reduced clearance 21. 
The fact that we identify in our study an increase in systemic midazolam clearance post 
bariatric surgery implies that the increased CYP3A activity per unit of liver compensates 
and surpasses the reduction in liver size that is associated with bariatric surgery in these 
patients. Another explanation could be a recovery in total liver blood flow, due to recov­
ery of fatty liver and/or steatosis 43, but as midazolam is an intermediate extraction ratio 
drug this seems unlikely 44.
Midazolam mean oral transit time was twice as fast in patients one year post bariatric 
surgery in comparison to before surgery. Decreased Tmax in bariatric surgery patients 
has been reported before for oral caffeine, tolbutamide, midazolam, omeprazole and 
duloxetine administration 33, 45. The faster midazolam oral absorption may be explained 
by faster gastric emptying of the stomach due to the reduced stomach size 12­13, 46­47. In 
contrast to more rapid oral absorption, for oral bioavailability, we found no difference 
before and after bariatric surgery. From a comparison to healthy volunteers (Figure 4B), 
it can be concluded that oral bioavailability values in bariatric patients do not seem to 
return to values found for healthy volunteers, but remains at the level of those found 
for morbidly obese patients. The oral bioavailability value (F) may be deduced to its 
individual contributors, which are the fraction absorbed (fa), the fraction escaping gut 
wall metabolism (FG) and the fraction escaping first pass hepatic metabolism (FH).
As midazolam is a highly soluble and permeable drug, fa can be assumed to be equal 
to 1 in morbidly obese patients before and after surgery 48. In addition, assuming no 
change in hepatic blood flow and blood to plasma partition ratio before and after 
surgery, FH will decrease approximately 1.68 times post bariatric surgery as a result of 
1.68 times increased systemic clearance. So, given the unchanged total bioavailability, 
Ftotal, we identified in our study, this implies that the midazolam fraction escaping gut 
wall (FG) increases 1.68 times one year after bariatric surgery. An increase in FG was also 
predicted by Darwich et al., who showed that post RYGB surgery the FG of CYP3A sub­
strate simvastatin increased with 13% 49. Increased FG may be due to the bypass of the 
intestines resulting from this type of surgery, in which normally approximately 75% of 
the midazolam dose would have been absorbed 48, 50. Another explanation could be an 
increase in splanchnic blood flow resulting in an increase in FG, however this seems very 
unlikely in view of the decrease in bodyweight associated with bariatric surgery and 
therefore an anticipated decrease in splanchnic blood flow instead of increase.
For midazolam central and peripheral volume of distribution we observed overall 
lower values in post bariatric surgery patients without variation due to body weight 
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(p>0.05, Table 2). While we anticipate that this is due to the smaller range in bodyweight 
in the bariatric patient group, as within the morbidly obese patient group volume of 
distribution was highly depended on body weight as was reported before 25. To account 
for the influence of body weight on both the first and second peripheral volume of 
distribution, the second peripheral volume was modeled as a fraction of the first volume 
of distribution. The general reduction in volume of distribution after bariatric surgery 
may result from weight loss resulting in substantial reductions in blood volume and 
adipose tissue 51.
Although this study provides unique information on the pharmacokinetics of midazol­
am after both oral and intravenous dose administration in a new and emerging patient 
population, the study may have some limitations. First, 2 of the 18 patients underwent a 
sleeve gastrectomy procedure, which is an insufficient number to draw any conclusion 
on the effect of a sleeve gastrectomy on midazolam pharmacokinetics. However, these 
2 patients did show a major loss in body weight to an extent that was similar to that of 
the 16 gastric bypass patients, which was the reason why we included these patients 
in the analysis. Moreover, when excluding these two patients from the dataset, none of 
parameter estimates were significantly different (data not shown). Second, at occasion 
1, patients underwent surgery and anesthesia, which was not the case during occasion 
2. This may potentially have influenced the results on midazolam PK we report in this 
study. It is well known that during a surgery cardiac output is lowered which may have 
caused lower midazolam clearances for morbidly obese patients. However, the duration 
of surgery and anesthesia was quite limited (86.4 ± 31 minutes) in comparison to the 
study period of the first occasion (~660 minutes), minimizing the influence of surgery. 
Moreover, bariatric surgery was performed using minimally invasive techniques (laparo­
scopic techniques) reducing hemodynamically induced changes. Furthermore, surgery 
was performed 159 ± 67 minutes after oral midazolam dose administration, which 
excludes any influence of surgery/anesthesia on midazolam the oral absorption phase. 
For these reasons, we think that the short duration of surgery/anesthesia during the first 
occasion is not of significant influence on the conclusion drawn based on these data.
The midazolam dose simulations provide insight in how the altered pharmacokinetics 
in bariatric patients affect midazolam concentration time profiles after oral or intrave­
nous administration. A 5 mg intravenous midazolam bolus dose results in higher initial 
midazolam concentrations in a patient post bariatric surgery than in a morbidly obese 
patient. This indicates that, in comparison to morbidly obese patients, a lower intrave­
nous bolus dose may be anticipated in patients post bariatric surgery, as after a intrave­
nous bolus dose, midazolam effect is primarily determined by the initial concentrations. 
For an continuous intravenous infusion, a lower steady state concentration is reached in 
a bariatric patient due to the almost doubled midazolam clearance value compared to 
morbidly obese patients. So to reach a similar steady state concentration in a bariatric 
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patient a higher mg/h dose seems necessary. In this respect, it is important to realise that 
a post­bariatric surgery patient does not only need a higher dose than before surgery 
but also may need a higher dose in mg/h than a non­obese patient given the differences 
in clearance values (Figure 4). Furthermore, the steady state concentration is reached 2.5 
times faster in a bariatric surgery patient compared to a morbidly obese patient. Finally, 
a midazolam oral tablet will result in increased Cmax and earlier Tmax in a bariatric patient.
Finally, the influence of bariatric surgery on midazolam systemic clearance found in 
this study may be extrapolated to other drugs which are also primarily metabolised by 
CYP3A, as midazolam is considered a CYP3A probe substrate 23. While the extrapolation 
potential depends on many factors, including extraction ratio and physico­chemical 
properties of the drug, it may be speculated that other major CYP3A substrates may 
show a similar effect of bariatric surgery on systemic clearance.
In conclusion, in this cohort study in morbidly obese patients, systemic clearance was 
1.7 times higher one year after bariatric surgery, which may potentially result from an 
increase in hepatic CYP3A activity per unit of liver. Even though mean oral transit time 
was found to be faster, oral bioavailability remained unchanged, which considering the 
increased systemic clearance implies an increase in the midazolam fraction escaping 
intestinal first pass metabolism after an oral administration. In patients after a bariatric 
surgery, these alterations will result in lower midazolam steady state concentrations 
and in higher and earlier peak concentrations after oral administration in comparison to 
morbidly obese patients before bariatric surgery.
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esM 1 A Normalised prediction distribution errors plots of the final pharmacokinetic model of midazolam 
concentrations in 20 morbidly obese patients before bariatric surgery.
177
esM 1 B Normalised prediction distribution errors plots of the final pharmacokinetic model of midazolam 
concentrations in 18 patients whom returned one year after bariatric surgery.
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AbstrACt
This study aimed to describe the pharmacokinetics of midazolam and its CYP3A medi­
ated metabolite 1­OH­midazolam in morbidly obese patients receiving oral and intrave­
nous midazolam before (n=20) and one year after weight loss surgery (n=18), thereby 
providing insight into the influence of weight loss surgery on CYP3A activity in the gut 
wall and liver.
In a semi­PBPK model in which different blood flow scenarios were evaluated, intrinsic 
hepatic clearance of midazolam (CLint H) was 1.5 times higher compared to morbidly 
obese patients before surgery (p<0.01). Midazolam gut wall clearance (CLint G) was slightly 
lower in patients after surgery (p>0.05), with low values for both groups.
The results of the semi­PBPK model suggest that in patients after weight loss surgery 
CYP3A hepatic metabolizing capacity seems to recover compared to morbidly obese 
patients, while CYP3A mediated intrinsic gut wall clearance was low for both popula­
tions and showed large inter individual variability.
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IntroduCtIon
Weight loss surgery or bariatric surgery is widely and increasingly applied to treat 
morbid obesity (body mass index > 40 kg/m2)1, 2, 3. This type of surgery may profoundly 
affect drug pharmacokinetics, as the procedure reduces the stomach to a small pouch 
and, in case of a Roux­ and Y­gastric bypass (RYGB), 75­150 cm of the initial part of the 
small intestines including the duodenum is bypassed 4, 5. In addition, patients lose on 
average 32% of their body weight within 1 year 6, which may affect clearance and the 
distribution of drugs as well 7.
Previously, we showed in a population PK analysis that plasma clearance (CL) of the 
cytochrome P450 3A (CYP3A) substrate midazolam is 1.7 times increased in patients 
after a weight loss procedure in comparison to morbidly obese patients, while oral 
bioavailability (Ftotal) was unaltered 8. Similar results have been reported before for RYGB 
patients in comparison with age­ gender­ and BMI matched control patients 9. While it is 
well known that CYP3A resides both in the gut and in the liver, these analyses that use 
total oral bioavailability (Ftotal) as parameter do not allow for a distinction between the 
contribution of pre­systemic gut and pre­systemic liver metabolism. More specifically, 
oral bioavailability (Ftotal) may be deduced to its individual contributors, which are the 
fraction absorbed (Fa), the fraction escaping gut wall metabolism (FG) and the fraction 
escaping first pass hepatic metabolism (FH). As midazolam is a highly soluble and perme­
able drug, Fa is assumed to be equal to 1 in morbidly obese patients before and after 
surgery 10, 11. Keeping in mind the reported increase in midazolam systemic plasma clear­
ance after a weight loss surgery 9, 12, FH is expected to decrease after weight loss surgery. 
So, given the unchanged total bioavailability (Ftotal) identified in these patients 12, it may 
be hypothesized that the midazolam fraction escaping gut wall (FG) increases one year 
after weight loss surgery (Supplementary information 1). In theory, such an increase in 
FG upon weight loss surgery may be attributed to the 75­150 cm bypass of the small 
intestine during an RYGB surgery 4 potentially causing reduced (intrinsic) CYP3A clear­
ance in the gut.
Knowledge on the exact influence of a weight loss surgery on hepatic and gut wall 
CYP3A clearance is important because approximately 30% of all clinically used drugs are 
metabolised via this enzyme 13. To fully characterise the influence of weight loss surgery 
on CYP3A mediated drug metabolism in both the gut wall and the liver, a semi physio­
logically­based pharmacokinetic (semi­PBPK) model taking into account these distinct 
processes needs to be applied to both midazolam and the CYP3A mediated metabolite 
1­OH­midazolam concentrations obtained after oral and intravenous administration in 
these populations 14, 15. Such a semi­PBPK model consists of a compartment represent­
ing the gut wall, the portal vein and the liver, and an empirical compartment model 
for midazolam and 1­OH midazolam, representing the rest of the body. The model is 
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parameterized on the basis of intrinsic clearance (CLint) for both the gut and the liver, 
blood flow (Q) and fraction unbound (fu) in the blood or gut wall. In this model, intrinsic 
midazolam clearance in the liver or gut wall represents the capacity of the liver or gut 
wall to metabolize midazolam into 1­OH­midazolam and therefore represents CYP3A 
activity in these respective organs.
In this study we aimed to describe both midazolam and its CYP3A mediated me­
tabolite 1­OH­midazolam in morbidly obese patients before and one year after weight 
loss surgery after both oral and intravenous administration using a semi­PBPK model, 
ultimately to evaluate how the intrinsic CYP3A activity in the gut wall and liver are af­
fected by weight loss surgery and (loss of ) body weight. In addition, the results are used 
to explore to what extent these results may affect other CYP3A substrates used after 
weight loss surgery.
Methods
study design and patients
In this study, data are used from a prospective observational cohort study in 20 morbidly 
obese patients at the day of laparoscopic weight loss surgery of whom 18 patients were 
studied again one year later (NTC01519726, EudraCT 2011­003293­93). Study design 
and characteristics have been described before and are repeated briefly below 12.
In the study, morbidly obese patients undergoing a laparoscopic gastric bypass or 
sleeve surgery were eligible for inclusion. Patients were excluded if they used CYP3A 
inducing or inhibiting medication 16, used products containing grapefruit, wild grape, 
banpeiyu, pomegranate, star fruit or black berry with in two weeks before the study, were 
pregnant, gave breastfeeding or suffered from renal insufficiency (eGFR MDRD4  <60 
mL/min). Before participation, all patients gave written informed consent. One year 
after the weight loss procedure 18 of the 20 patients were restudied using the same 
study design. At both occasions, patients received 7.5 mg oral and 5 mg intravenous 
midazolam separated by 160 ± 48 minutes. Per patient and occasion, a mean of 22 blood 
samples were collected to measure both midazolam and 1­OH midazolam concentra­
tions. Plasma concentrations were measured using a method described before 17. For 
1­OH midazolam, the lower limit of quantification was 0.9 ng/ml and intra assay and 
inter assay coefficients of variation were 6.3% and 4.5%.
The study was approved by the local human research and ethics committee 
(NL35861.100.11) and was conducted according to the principles of the Declaration of 
Helsinki (version 22­10­2008) and in accordance with the Medical Research Involving 
Human Subjects Act (WMO) of the Netherlands.
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Population pharmacokinetic modelling
Population pharmacokinetic modelling was performed using NONMEM 7.3 18 ADVAN 6 
and (PsN version 3.6.2), Pirana (version 2.9.0) and R (version 3.1.2) to visualize the data. 
Different structural models were tested to fit the midazolam and 1­OH­midazolam data 
from morbidly obese patients before and after weight loss surgery.
First, a regular population pharmacokinetic (PK) model was applied with a two­
compartment model for 1­OH­midazolam, a three compartment model for midazolam 
and a transit compartment model for midazolam oral absorption in which oral absorp­
tion rate (Ka) was set equal to the transit compartment rate (Ktr) (Intermediate model, 
Figure 1a). This model was based on earlier work on the pharmacokinetics of midazolam 
not involving the 1­OH­midazolam metabolite 12.
Second, a semi physiologically based pharmacokinetic (semi­PBPK) model was ap­
plied to describe the data (Semi­PBPK model, Figure  1b). The structural semi­ PBPK 
model was adopted from Yang et al. (2003) and Frechen et al. (2013) and consisted of a 
compartment representing the gut wall, the portal vein and the liver, and an empirical 
compartment model for midazolam and 1­OH midazolam, representing the rest of the 
body 14, 15. In order to reduce runtimes, midazolam and 1­OH­midazolam were assumed 
to reach an instant equilibrium in the gut wall, portal vein and liver compartment which 
resulted in a simplified semi­PBPK model (Supplemental information 2). For midazolam, 
a three compartment model was used and for midazolam oral absorption a transit com­
partment model in which the oral absorption rate was equalized to the transit compart­
ment rate (Ktr) 19 was used. For 1­OH­midazlam, a two compartment model was applied.
In the semi­PBPK model, hepatic (EH) and the gut wall extraction (EG) of midazolam 
were defined as the input for the liver and gut wall compartment of the 1­OH­midazolam 
model, respectively. Hepatic extraction of midazolam (EH) and 1­OH­midazolam (EH, 1­OH) 
was defined by the well­stirred model:
EH = 
CLint,H × fu (Eq. 1)
QH,B + (CLint,H × fuB)
where CLint,H is the intrinsic hepatic clearance based on unbound blood concentrations, 
fuB is the unbound concentration in blood and QH,B is the hepatic blood flow.
The fraction escaping hepatic metabolism (FH) was defined as:
FH = 1 − EH (Eq. 2)




















figure 1 Schematic representation of the 
intermediate population pharmacoki­
netic model (a) and semi­PBPK model (b) 
for midazolam and its 1­OH­midazolam 
metabolite (1­OH). B=blood; CLint= in­
trinsic clearance; E= extraction ratio; G= 
gut wall; F= bioavailability; fa= fraction 
absorbed into the gut wall; fu= fraction 
unbound; H= hepatic; HA= hepatic artery; 
Ka= oral absorption rate; Ktrantsits= transit 
compartment rate; Q is blood flow (Qvilli, 
QPV, QHA, QH) or intercompartmental clear­
ance (Q1 and Q2); PV = portal vein.
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QGut + (CLint,G × fuG)
where Clint,G is the intrinsic gut wall clearance based on unbound blood concentrations, 





where, Qvilli is the villous blood flow and CLperm, is a term defining the permeability of the 
drug through the enterocytes in the gut wall. The fraction escaping gut wall metabolism 
was defined as:
FG = 1 − EG (Eq. 5)




QVilli × (CLint,G,1OH + fuG,1OH)
Systemic plasma clearance (CLH) was derived from the hepatic midazolam intrinsic clear­
ance and hepatic blood flow using 21:
CLH =
QH,B × fuB × CLint,H
(Eq. 7)
QH,B + fuB × CLint,H /(CB / CP)
In which CB/CP is the blood to plasma ratio.
Values used for the drug parameters are listed in Table 1. The fraction of midazolam ab­
sorbed (Fa) was fixed to 1 and it was assumed that no protein binding occurred in the gut 
wall (Table 1). As midazolam is an intermediate extraction ratio drug (EH= ~0.4 22, 23, 24), for 
the hepatic blood flow (QH) three different scenarios were explored including QH based 
on allometric scaling (scenario 1)25, QH based on a model for cardiac output in obese and 
morbidly obese patients (scenario 2)26, 27 and a QH that was the same before and after 
weight loss surgery (scenario 3), see Table 1.
Discrimination between different structural models was made by comparison of 
the objective function value (OFV, i.e. ­2 log likelihood [­2LL]). A p­value below 0.05, 
representing a decrease of 3.84 in the OFV between nested models for one degree of 
freedom, was considered statistically significant. In addition, goodness­of­fit plots 
(observed versus individual­predicted concentrations, observed versus population­
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predicted concentrations, conditional weighted residuals versus time and conditional 
weighted residuals versus population­predicted concentrations plots) of midazolam 
and 1­OH­midazolam were used for diagnostic purposes. Furthermore, the confidence 
interval of the parameter estimates, the correlation matrix and visual improvement 
of the individual plots were used to evaluate the models. The internal validity of the 
population pharmacokinetic model was assessed by the bootstrap re­sampling method 
using 500 replicates.
For the statistical model, the individual parameter estimate (empirical bayes estimate 
or post hoc value) of the ith individual was modelled according to:
θi = θmean × eηi (Eq. 8)





Allometric scaling of the 
hepatic blood flow 25
scenario 2
hepatic blood flow as a 
fraction of cardiac output 26, 27
scenario 3
one hepatic blood 
flow for all individuals
Midazolam
 fa 123
 B:P 0.66 23, 42
 fuG 1
 fuB 0.0303 42
 CLperm (L/min) 0.177 20
1-OH-midazolam
 B:P 1
 fuG, 1­OH 1 20
 fuB, 1­OH 0.106 43
 CLperm 1
Blood flows
Cardiac output (L/min) ­ (9119– EXP(9.164 + 
­2,9*10­2 * TBW + 3.91*10­4 * 
TBW2 + ­1.91*10­6 * TBW3) /1000
7
Qhepatic (L/min) 3.75 * TBW0.75 0.25 * CO 27 0.25 * CO 27
Qhepatic artery 0.25 * Qhepatic 27 0.25 * Qhepatic 27 0.25 * Qhepatic 27
Qportal vein 0.75 * Qhepatic 27 0.75 * Qhepatic 27 0.75 * Qhepatic 27
Qsmall intestine 0.4 * Qhepatic 27 0.1 * CO 20, 27 0.4 * Qhepatic 27
Qmucosal 0.80 * Qsmall intestine 20 0.80 * Qsmall intestine 20 0.80 * Qsmall intestine 20
Qvilli 0.60 * Qmucosal20 0.60 * Qmucosal 20 0.60 * Qmucosal 20
B:P = blood to plasma ratio; CO= cardiac output; fa = fraction absorbed in the gut wall; fub = fraction un­
bound in blood; fuG  =  fraction unbound in gut wall; CLperm  =  parameter representing the permeability 
through the enterocyte; Q= blood flow; TBW= total body weight.
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where θmean is the population mean, and ηi is a random variable for the ith individual with 
a mean of zero and variance of ω2, assuming log­normal distribution in the population. 
For residual variability, resulting from assay errors, model misspecifications and other 
unexplained sources, a proportional error model was used. The jth observed midazolam 
concentration of the ith individual (Yij) is described by:
Yij = Cpred,ij × (1 + εij) (Eq. 9)
where Cpred,ij is the individual predicted midazolam concentration of the ith individual at 
the jth time, and εij is a random variable with a mean of zero and variance of σ2.
Data below the limit of quantification of the bio­analysis assay were provided by the 
lab and included in the data set. Data below the limit of detection, defined as 30% of the 
lower limit of quantification, were deleted from the data set (5.7% for midazolam and 
8.9% for 1­OH­midazolam) 28.
Based on our earlier pharmacokinetic analysis for midazolam, body weight on 
midazolam central and peripheral volume of distribution for morbidly obese patients 
and a separate parameter estimate for midazolam oral absorption rate and inter­
compartmental clearance in morbidly obese and weight loss patients were included in 
the model 8. After inclusion of these midazolam covariates, the influence of weight loss 
surgery was evaluated for midazolam gut wall and hepatic intrinsic clearance (CLint). The 
binary covariate before/after weight loss surgery was plotted independently against the 
individual post hoc values and eta estimates of midazolam intrinsic clearance estimates 
to visualize potential relations. The covariate ‘before/after weight loss surgery’ was 
tested by means of a separate parameter or using the following equation:
Pi = Pp × ZCOV (Eq. 10)
where Pi and Pp represent individual and population parameter estimate, Z the estimated 
factor of increase or decrease for the patients subgroup with COV equalling one.
Potential covariates were separately entered into the model and statistically tested 
(p<0.05) by use of the OFV and, if applicable, the 95% confidence interval of the addi­
tional parameter. In addition, if applicable, it was evaluated whether the inter­individual 
variability (eta) in the parameter concerned decreased upon inclusion of the covariate 
on the parameter and whether the trend in the eta versus covariate plot had resolved.
simCYP simulations
The influence of weight loss surgery on mean systemic plasma clearance values of other 
CYP3A substrates was evaluated using the morbidly obese population in the SimCYP 
software and manipulation of the value for CYP3A hepatic abundance 29, 30. For each 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2a shows the goodness­of­fit plots of the midazolam and 1­OH­midazolam 
plasma concentrations of both morbidly obese and weight loss patients on the basis 
of the regular population PK model as shown in Figure 1a (Intermediate model). These 
goodness­of­fit plots show that after the oral dose, midazolam concentrations were 
over­predicted, while midazolam concentrations after the intravenous dose were under­
predicted (Figure 2a). In contrast, 1­OH­midazolam concentrations after oral dose were 
under­predicted by the model, while 1­OH­midazolam concentrations after intravenous 
dose were over­predicted. The obvious misspecification of midazolam and its 1­OH­
midazolam metabolite concentrations indicate the presence of substantial presystemic 



































































































































figure 3 Box and whisker plots of eta and post hoc parameter estimates before addition of covariate ef­
fects for intrinsic hepatic (CLint, H, left panels, shrinkage of 1%) and gut wall (CLint, G, right panels, shrinkage of 
21%) midazolam clearance in morbidly obese patients before (black) and after weight loss surgery (grey).
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semi­PBPK model including both pre­systemic midazolam metabolism at gut wall and 
hepatic level was applied (Figure 1b and Supplementary information 3). The goodness­
of­fit plots of the semi­PBPK model showed a substantial improvement in the prediction 
of midazolam and 1­OH­midazolam concentrations after both oral and intravenous 
dose (Figure 2b).
Upon these findings, the semi­PBPK model was further explored for covariates, tak­
ing into account the different QH scenarios for obesity (see Methods and Table 2).The 
influence of weight loss surgery on midazolam intrinsic gut wall (CLint, G) and hepatic 
clearance (CLint, H) was evaluated by visual inspection of eta versus covariate plots. Fig­
ure 3 shows a trend of higher CLint, H and slightly lower CLint, G in weight loss patients in 
comparison to morbidly obese patients (Figure 3, upper panels). A separate parameter 
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QH scenario 2
QH= 1.9 QH= 1.3
QH scenario 3
















figure 4 Box and whisker plots of calculated midazolam plasma clearance (equation 7, upper panels), FH 
(equation 1 and 2, middle panels) and FG (equation 3 and 5, lower panels) for morbidly obese (black) and 
weight loss patients (grey) for three different blood flow scenarios (QH in L/min, Table 1). Per scenario the 
value for hepatic blood flow (QH) is shown for the median morbidly obese (144 kg) and median weight loss 
patient (98 kg) of the studied populations.
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CLint,H morbidly obese (L/min) Intrinsic hepatic clearance morbidly obese 16.8 (14%) 16.9 (2.4)
CLint,H weight loss patients(L/min) Intrinsic hepatic clearance weight loss patients 25.5 (15%) 25.4 (4.2)
CLint,G (L/min) Intrinsic gut wall clearance 0.0199 (35%) 0.0207 (0.007)
Ka morbidly obese=Ktr (min­1) Oral absorption rate 0.126 (10%) 0.126 (0.01)
Ka weight loss patients=Ktr (min­1) Oral absorption rate 0.242 (9%) 0.241 (0.02)
Vcentral weight loss patients (L) Central midazolam volume of distribution 66.9 (13%) 68.1 (8.7)
Vcentral morbidly obese = Vcentral, 144 kg *(1+X(TBW­144))
Vcentral, 144 kg (L) = Vcentral weight loss 
patients
Central midazolam volume of distribution for 
a 144 kg individual
66.9 (13%) 68.1 (8.7)
X Covariate effect of TBW on Vcentral 0.0435 FIX 0.0435 FIX
Vperi 1 weight loss patients (L) First peripheral volume of distribution 31.0 (19%) 32.0 (6.5)
Vperi 1 morbidly obese = Vperi 1, 144 kg *(TBW/144)Y
Vperi 1, 144 kg (L) = Vperi 1 weight loss 
patients
First peripheral volume of distribution 31.0 (19%) 32.0 (6.5)
Y Exponent of covariate function 3.93 FIX 3.93 FIX
Vperi 2 (L) = Vperi 1 * Z Second peripheral volume of distribution
Z 10.8 (13%) 11.1 (1.7)
Q1 (L/min) First inter­compartmental clearance 1.41 (15%) 1.35 (0.2)
Q2 (L/min) = Q1*A Second inter­compartmental clearance
A 3.22 FIX 3.22 FIX
1-OH-Midazolam
Vcentral, 1­OH (L) Central volume of distribution 41.7 (11%) 41.9 (4.7)
Vperi, 1­OH (L) Peripheral volume of distribution 16.4 (25%) 17.4 (4.4)
Q1­OH (L/min) Inter compartmental clearance 0.652 (23%) 0.65 (0.15)
CLint,H,1­OH(L/min) Intrinsic hepatic clearance 27.4 (9%) 27.2 (2.6)
CLint,G,1­OH(L/min) Intrinsic gut wall clearance 11.9 (180%) 4.7*1022 (7.3*1023)
Inter individual variability
Ka (%) Oral absorption rate 44 (20%) 43 (19%)
Vcentral (%) Central volume of distribution 63 (49%) 61 (38%)
Vperipheral 1 (%) First peripheral volume of distribution 113 (24%) 115 (49%)
CLint,H (%) Intrinsic hepatic clearance 48 (21%) 47 (20%)
CLint,G (%) Intrinsic gut wall clearance 493 (35%) 582 (168%)
Residual variability
Morbidly obese patients (%) 32.6 (18%) 32.2 (13%)
Weight loss patients (%) 23.7 (8%) 23.6 (7%)
 TBW= total body weight (kg)
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intrinsic hepatic clearance in weight loss patients (­7 ΔOFV, p<0.01 for all QH scenarios) 
and a small decrease in inter individual variability (53% (relative standard error, RSE, of 
19%) versus 48% (19%) for scenario 1). A separate parameter estimate for midazolam 
gut wall intrinsic clearance (CLint,G) did not significantly improve the model (­2 ΔOFV, 
p>0.05 for all QH scenarios). The two highest values for CLint G (see Figure 3, lower row, 
right plot) are two morbidly obese individuals for which the duration in between oral 
and intravenous midazolam dose was only 43 and 50 minutes as compared to a mean 
of 171 ± 57 minutes for the other 18 morbidly obese patients. In addition, it seems that 
also these two individuals substantially contribute to the uncertainty of the parameter 
for intrinsic gut wall clearance of 1­OH­midazolam (CLint G 1­OH). Upon exclusion of these 
two individuals CLint G 1­OH this parameters changes from 11.9 (180%) L/min to 6.7 (40%) 
L/min. However, exclusion of the two individuals resulted in the same final covariate 
model, and therefore for the final model all individuals were kept in the data.
Overall, the different QH scenarios (see Methods) resulted in slightly different hepatic 
intrinsic clearance estimates (16.9 (13%), 17.1 (13%) and 12.6 (16%) L/min for morbidly 
obese patients and, 25.6 (16%), 25.7 (16%) and 18.9 (21%) L/min for weight loss patients 
for scenario 1, 2 and 3 respectively), while the observed covariate trend between mor­
bidly obese patients and weight loss patients was identical for the different scenarios. 

























Midazolam Cyclosporine Alprazolam Triazolam
figure 5 Box and whisker plots of simulated baseline systemic plasma clearances for the SimCYP morbidly 
obese patient population (dark grey boxes) and percentage change from baseline when hepatic CYP3a 
abundance is increased by 1.5 times for the morbidly obese population in the SimCYP simulator (light grey 
boxes) for four CYP3A substrates.
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narios. These QH scenarios were tested to evaluate the influence of QH in the parameters 
of the model because there is no consensus yet on the exact changes in QH upon morbid 
obesity and subsequent weight loss surgery. While there is no persuasive argument for 
choosing one QH scenario above another, the final parameter estimates and bootstrap 
results (98% successful) of scenario 1 are presented in Table 2 and goodness­of­fit plots 
of the this final model are shown in Figure 2b.
The different scenarios for hepatic blood flow slightly influenced the calculated values 
for midazolam plasma clearance, FH and FG, even though the differences between the 
morbidly obese patients and weight loss patients per scenario remained quite similar 
(Figure 4). In general for weight loss patients, higher midazolam plasma clearance (up­
per row, a median increase of 1.28, 1.34 and 1.33, for scenario 1, 2 and 3, respectively) 
and lower FH (middle row, median decrease of 0.84, 0.83 and 0.88, respectively) was 
observed. FG seems to be close to one for weight loss patients, while the morbidly obese 
patient group exhibits large inter individual variability (lower row).
Finally, the influence of weight loss surgery on hepatic CYP3A activity was further 
explored using the SimCYP simulator 29. Based on the findings for hepatic intrinsic 
midazolam clearance of the semi­PBPK model, CYP3A abundances in the liver of the 
‘morbidly obese population’ was 1.5 times increased and plasma clearance values for 
midazolam, cyclosporine, alprazolam and triazolam were simulated. Figure 5 shows that 
this increase in CYP3A abundance resulted in a 1.22 increase of midazolam plasma clear­
ance and a median 1.41, 1.37 and 1.30 increase of plasma clearance for CYP3A substrates 
cyclosporine, alprazolam and triazolam, respectively.
dIsCussIon
In this study we aimed to characterize the pharmacokinetics of both midazolam and 
its primary CYP3A mediated metabolite 1­OH­midazolam after oral and intravenous 
administration in morbidly obese patients before and one after weight loss surgery, 
ultimately to evaluate how intrinsic CYP3A activity in the gut wall and liver are affected 
by weight loss surgery. We found that midazolam and 1­OH­midazolam concentrations 
could not be described by a regular compartmental model (Figure  1a, Figure  2a) be­
cause of presystemic formation of the CYP3A mediated metabolite 1­OH midazolam for 
which a semi­PBPK model (Figure 1b, Figure 2b) was needed. Using this model, it was 
found that midazolam intrinsic hepatic clearance (CLint,H) was 1.5 times higher in patients 
after weight loss surgery, independent of the QH scenarios used. In addition, intrinsic 
midazolam gut wall clearance (CLint,G) showed a trend towards lower values in patients 
after surgery (p>0.05).
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Intrinsic hepatic midazolam clearance (CLint,H) represents the capacity of the liver to 
metabolize midazolam into 1­OH­midazolam and therefore represents hepatic CYP3A 
activity. The estimated CLint, H for weight loss patients (25.6, 25.7 and 18.9 L/min for sce­
nario 1, 2 and 3, respectively) was in close agreement with the value reported for healthy 
volunteers using a very similar semi­PBPK model (27.3 (24.3­30.7) L/min) 15. However, 
for morbidly obese patients, CLint,H was lower (16.9, 17.1 and 12.6 L/min for scenario 1, 2 
and 3, respectively), indicating that hepatic CYP3A activity is reduced in morbidly obese 
patients in comparison to healthy volunteers but normalizes one year after weight loss 
surgery. While this recovery of CYP3A activity in the liver upon weight loss surgery has 
not been reported before, the reduced hepatic CLint due to morbid obesity is supported 
by in vitro studies showing that human livers samples with steatosis show reduced 
CYP3A activity in comparison to liver samples without steatosis 31, 32. Comparing the 
observed 1.5 times increase in CLint,H  after a weight loss surgery with reported values 
for midazolam plasma clearance from earlier reports on weight loss surgery patients, it 
appears that this value closely resembles the previously reported 1.7 times increase in 
midazolam plasma clearance (CLplasma) 8, 9 However, when calculating midazolam plasma 
clearance on the basis of midazolam CLint,H using equation 7, we only find 1.28 increase 
(scenario 1 and Figure 4). Also, when increasing hepatic CYP3A abundance by 1.5 times 
in the morbidly obese population of the SimCYP simulator, midazolam plasma clearance 
only increased 1.22 times. This implies that the increase in midazolam plasma clearance 
after a weight loss surgery cannot be solely attributed to a normalization or recovery of 
hepatic CYP3A activity. Therefore, it may be suggested that another non­CYP3A related 
process may be involved. This other process may be hepatic blood flow (QH) or perfu­
sion 33. In the case of patients after weight loss surgery, potentially an improvement in 
hepatic microcirculation function (i.e. liver perfusion) due to a reduction in fatty liver, 
may result in a more pronounced increase in midazolam systemic plasma clearance 
value of 1.7 34, 35. For morbidly obese patients, the reduced hepatic CYP3A activity (1.5 
reduced CLint,H ) may be compensated by an increase in hepatic blood flow in comparison 
to healthy volunteers resulting in similar plasma midazolam systemic plasma clearance 
value compared to healthy volunteers 17, 36. As such, both changes in CYP3A and liver 
blood flow and/or perfusion contribute to the overall effects observed in midazolam 
plasma clearance in morbidly obese and weight loss patients compared to healthy 
volunteers.
It seems that information on the hepatic blood flow and perfusion in patients after 
weight loss surgery is crucial to understand the results and to support the above 
described hypothesis that hepatic blood flow or perfusion improves after weight loss 
surgery. Also, for morbidly obese patients information on hepatic blood flow and perfu­
sion is scarce. For this reason, we considered in our analysis different hepatic blood flow 
scenarios (Table 1, Figure 4), while a choice for any of these or other hepatic blood flow 
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scenarios cannot be justified. Scenario 1, in which the hepatic blood flow equation by 
Brown et al. was used, seems to lead to rather large values for morbidly obese patients 
(QH = 3.7 L/min at 144 kg) 25. At first sight, scenario 2 seems more plausible for morbidly 
obese patients, as hepatic blood flow values are derived from the cardiac output func­
tion by Young et al. in which data of morbidly obese patients were included as well 26, 
however the QH values for weight loss patients may be considered too low (QH = 1.3 L/
min at 98 kg), while in healthy volunteers QH is generally considered to be 1.6 L/min 25. 
Scenario 3, assuming a similar blood flow across all body weights, may not be so un­
realistic considering the fact that the calculated plasma clearance values are in good 
agreement with actual results found in our earlier study (Figure 4) 8, 9. Future research 
should elucidate how hepatic blood flow is affected by morbid obesity and weight loss 
surgery to be able to further improve predictions on how CYP3A mediated hepatic drug 
clearance is affected.
Midazolam intrinsic gut wall clearance, CLint,G, was low in both patient groups in 
comparison to results from healthy volunteers that were obtained using a similar semi­
PBPK model (i.e. 0.0199 (35%) versus 0.45 (0.98­0.52) L/min, respectively) 15. As a result, 
the derived values for FG were near 1 for both patient groups (Figure 4). In addition, a 
trend for a lower CLint,G for weight loss patients could be observed (Figure 3). This result 
may be attributed to the 75­150 cm bypass of relatively CYP3A rich initial part of the 
intestines, which is similar to the mechanism that may explain the increase in FG for 
controlled release formulation for highly permeable CYP3A substrates 37. However, the 
trend of lower CLint,G for weight loss patients was not statistically significant. This may 
in part be due to the high inter individual variability in CLint,G observed for both groups. 
For morbidly obese patients, the relatively low CLint,G estimate is in line with the increase 
in midazolam oral bioavailability (Ftotal) in comparison to healthy volunteers reported 
earlier (0.60 (13%) versus 0.28 (7%), p<0.01) 17.
To further investigate the consequences of 1.5 times increased hepatic CYP3A intrinsic 
clearance for other drugs, the SimCYP simulator was used in which the 1.5 increase in 
hepatic CYP3A abundance in the morbidly obese population was mimicked. For the 
CYP3A substrates cyclosporine, alprazolam and triazolam plasma clearance was 1.30­
1.41 times increased as opposed to 1.22 for midazolam. This difference in impact on 
plasma clearance between the drugs may be explained by the difference in extraction 
ratio of the substrates. Midazolam is considered an intermediate extraction ratio drug 
(EH= ~0.4 22, 23, 24), while cyclosporine, alprazolam and triazolam are low extraction ratio 
drugs (EH= 0.05­0.25 38, 39, 40). From these simulations, it can be concluded that the sys­
temic plasma clearance of low extraction ratio CYP3A substrates is increased by at least 
1.3 times after weight loss surgery, while, due to the lack of knowledge on how hepatic 
blood flow is affected by weight loss surgery, no definite conclusions can be drawn for 
CYP3A substrates with median and higher extraction ratios. Finally, these exploratory 
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extrapolations should be interpreted with caution, as it has been shown that the in vivo 
clearance of in CYP3A probes may correlate poorly 41.
We conclude that a semi­PBPK model taking into account both gut wall and liver 
processes, adequately describes midazolam and CYP3A mediated 1­OH­midazolam con­
centrations after both oral and intravenous administration in morbidly obese patients 
before and after a weight loss surgery. Using this model it was revealed that in patients 
one year after weight loss surgery CYP3A hepatic intrinsic metabolizing capacity is 
recovered in comparison to morbidly obese patients before weight loss surgery, while 
CYP3A mediated gut wall intrinsic clearance seems to be lower.
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table 1 Calculated values for FG and FH using literature values for intravenous midazolam clearance (CLiv) 











Morbidly obese patients (n=20, 144 kg) 1
 QH,B= 2.6 L/min (scenario 1 2) 0.385 0.56 0.78 0.72
 QH,B= 1.9 L/min (scenario 2 3) 0.385 0.56 0.69 0.81
 QH,B= 1.75 L/min (scenario 3) 0.385 0.56 0.67 0.84
 Mean 0.385 0.56 0.71 ± 0.06 0.79 ± 0.06
Bariatric patients (n=18, 98 kg) 1
 QH,B= 2.0 L/min (scenario 1 2) 0.647 0.56 0.50 1.13
 QH,B= 1.3 L/min (scenario 2 3) 0.647 0.56 0.25 2.26
 QH,B= 1.75 L/min (scenario 3) 0.647 0.56 0.44 1.27
Mean 0.647 0.56 0.39 ± 0.13 1.55 ± 0.61
Healthy volunteer studies (n=38) 4, 5, 6
 QH,B= 1.6­1.9 L/min from references 0.49 ± 0.04 0.31 ± 0.03 0.60 ± 0.06 0.52 ± 0.1
 QH,B= 1.6 L/min (scenario 1 2) 0.49 ± 0.04 0.31 ± 0.03 0.53 0.58
 QH,B= 1.2 L/min (scenario 2 3) 0.49 ± 0.04 0.31 ± 0.03 0.37 0.83
 QH,B= 1.75 L/min (scenario 3) 0.49 ± 0.04 0.31 ± 0.03 0.57 0.54
 Mean 0.49 ± 0.04 0.31 ± 0.03 0.52 ± 0.10 0.62 ± 0.14
Calculated FG and FH values based on literature clearance and oral bioavailability values
Total oral bioavailability of a drug, Ftotal, was defined as
Ftotal = Fa · FG · FH
in which, Fa is the fraction of drug absorbed into the gut wall and assumed to be equal 
to 1 for midazolam, FG is the fraction of drug or metabolite escaping gut wall metabo­
lism and FH is the fraction of drug or metabolite escaping hepatic metabolism. Using 
the ‘well­stirred’ liver model the value for midazolam FH can derived from intravenous 
plasma clearance (CLiv)7, assuming negligible extrahepatic clearance:
FH = 1 –
CLiv
QH,B × (CB / CP)
in which QH,B is the hepatic blood flow and CB/CP is the midazolam blood­to­plasma ratio 
(0.66)4. The value for QH,B were be determined using different models for cardiac output 
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and/or hepatic blood flow 2, 3, 8. For morbidly obese patients and bariatric patients the 
hepatic blood flow was calculated based on the median body weights, 144 kg and 98 kg.
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A quAsI-steAdY stAte sIMPlIfICAtIon of A seMI-PhYsIoloGICAl 
AbsorPtIon Model
the original model
A semi­physiological absorption model for the midazolam pharmacokinetics was origi­
nally described by Frechen et al. 1 with the following differential equations for gut wall, 
portal vein, liver, central, shallow peripheral and the deep peripheral compartments, 
respectively.
Appendix: A quasi-steadystate simplication of a
semiphysiological absorption model
The original model
A semiphysiological absorption model for the midazolam pharmacokinetics was originally described
by Frechen et al (2013) with the following dierential equations for gut wall, portal vein, liver, central,
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Where Ax denote amounts in compartments x, V denote compartment volumes (physiological or
empirical),Q denotebloodowsor empirical inter-compartmental clearances and I(t) is the time-dependent
input function into the gut wall compartment.
The hepatic bioavailability was described with the well-stirred model of hepatic blood clearance:
FH ,mdz =
QH
QH + CL int ,H ,mdzf uB ,mdz
(2)
Where CL int ,H ,mdz is the intrinsinc hepatic clearance and f uB ,mdz is themidazolam unbound fraction
in blood.
The intestinal bioavailability was described with the “Qgut” model, which inherits its structure from
the well-stirred model of hepatic blood clearance:
FG ,mdz =
QGUT
QGUT + CL int ,G ,mdzf uG ,mdz
(3)
1
Where Ax denote amounts in compartments x, V denote compartment volumes (physi­
olog cal or empirical), Q deno e blood flows or empirical inter­compartmental clear­
ances and I(t) is the time­dependent input function into the gut wall compartment.
The hepatic bioavailability was described with the well­stirred model of hepatic blood 
clearance:
Appendix: A quasi-ste dystate simplication of a
semiphysiological absorption model
The original model
A semiphysiological absorption model for the midazolam pharmacokinetics was originally described
by Frechen et al (2013) with the following dierential equations for gut wall, portal vein, liver, central,
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Where Ax denote amounts in compartments x, V denote compartment volumes (physiological or
empirical),Q denotebloodowsor empirical inter-compartmental clearances and I(t) is the time-dependent
input function into the gut wall compartment.
The hepatic bioavailability was described with the well-stirred model of hepatic blood clearance:
FH ,mdz =
QH
QH + CL int ,H ,mdzf uB ,mdz
(2)
Where CL int ,H ,mdz is the intrinsinc hepatic clearance and f uB ,mdz is themidazolam unbound fraction
in blood.
The intestinal bioavailability was described with the “Qgut” model, which inherits its structure from
the well-stirred model of hepatic blood clearance:
FG ,mdz =
QGUT
QGUT + CL int ,G ,mdzf uG ,mdz
(3)
1
Where CLint,H,mdz is the intrinsinc hepatic clearance and fuB,mdz is the midazolam nbound 
fraction in blood.
The intestinal bioav ila ility was described with the “Qgut” model, which inherits its 
structure from the well­stirred model of hepatic blood clearance1:
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by Frechen et al (2013) with the following dierential equations for gut wall, portal vein, liver, central,
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Where Ax denote amounts in compartments x, V denote compartment volumes (physiological or
empirical),Q denotebloodowsor empirical inter-compartmental clearances and I(t) is the time-dependent
input function into the gut wall compartment.
The hepatic bioavailability was described with the well-stirred model of hepatic blood clearance:
FH ,mdz =
QH
QH + CL int ,H ,mdzf uB ,mdz
(2)
Where CL int ,H ,mdz is the intrinsinc hepatic clearance and f uB ,mdz is themidazolam unbound fraction
in blood.
The intestinal bioavailability was described with the “Qgut” model, which inherits its structure from
the well-stirred model of hepatic blood clearance:
FG ,mdz =
QGUT
QGUT + CL int ,G ,mdzf uG ,mdz
(3)
1
Where CLint,G,mdz is the intrinsinc intestinal clearance and fuB,mdz is the midazolam unbound 
fraction in gut. The QGUT is a hybrid parameter of enterocytic villous blood flow and drug 
permeability CLperm:
Where CL int ,G ,mdz is the intrinsinc intestinal clearance and f uG ,mdz is the midazolam unbound frac-
tion in gut. The QGUT is a hybrid parameter of enterocytic vill us blood ow and drug permeability
CLperm :
QGUT =
Qv i l l iCLperm
Qv i l l i + CLperm
(4)
Furthermore, the metabolite pharmacokinetics was modeled with the following equations for the
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The original authors (Frechen et al, 2013) reported that the choice of physiological compartment
volumes (gut wall, portal vein and liver) had minimal inuence on the parameter estimates and the
objective function value of the model. Therefore, the volumes were xed to one liter in the original
analysis.
The organ volumes mainly represent an additional delay in the orally administered drug reaching
the central compartments of the midazolam and 1-OH-metabolite. This can be readily seen from their
respective equations. The organ volumes do not aect the bioavailability fractions, which alreadymake
use of the quasi-steadystate approximation by the use of the well-stirred models.
Therefore, the nding of the original authors that the volume of the physiological compartments
has little eect onparameter estimates and theobjective function, is an indication that thephysiological
compartmentswere only adding negligible delay for the drug to reach the centralmidazolam and 1-OH-
midazolam compartments. Further, all of these physiological compartments are well-perfused, which
further encourages the conclusion that the delay provided by them is negligible.
Therefore, as no observations are available from these physiological compartments, theirmain func-
tion is to explainwhich fraction of the dose ends up in themidazolam compartment, andwhich fraction
ends up as a metabolite because of rst-pass metabolism.
Model reduction by quasi-steadystate approximation
Quasi-steadystate approximation is a technique commonly used in systems biology (Reference: Mathe-
matical modeling in systems biology, Brian Ingalls). It involves assuming that one of the compartments
or states in the system exists in an equilibriumwith regard to other components of the system; in other
words, we set dAx/dt ≈ 0. Then, the amounts in compartment x can be calculated analytically, and this
compartment can be omitted from the system of dierential equations.
The rst reduction was to assume quasi-steadystate in the gut wall, for both midazolam and the
metabolite. For the parent, this leads to
2
Furthermore, the metabolite pharmacokinetics was modeled with the following equa­
tions for the gut wall, portal vein, liver, central and peripheral metabolite compartments.
ere L int ,G , dz is t e i tri si c i testi al cleara ce a f G , dz is t e i az la frac-
ti i . T e GUT is a y ri ara eter f e ter cytic villo s l  a r er ea ility
Lper :
GUT
v i l l i Lper
v i l l i Lper
(4)
F rt er re, t e eta lite ar ac ki etics as ele it t e f ll i e ati s f r t e
t all, rtal vei , liver, ce tral a eri eral eta lite c art e ts.
d G , e t
dt
v i l l iEG , dz G , dz
G
v i l l iEG , e t G , e t
G
v i l l iFG , e t G , e t
G
d PV , e t
dt
v i l l iFG , e t G , e t
G
PV c , e t
c , e t
PV PV , e t
PV
d H , e t
dt
HEH , dz H , dz
H
PV PV , e t
PV
HA c , e t
c , e t
HEH , e t H , e t
H
HFH , e t H , e t
H
d c , e t
dt
FH , e t H H , e t
H
HA P 1, e t
c , e t
1, e t p1, e t
p1, e t
d p1, e t
dt
1, e t c , e t
c , e t
1, e t p1, e t
p1, e t
(5)
T e ri i al a t rs (Frec e et al, 2 13) re rte t at t e c ice f ysi l ical c art e t
v l es ( t all, rtal vei a liver) a i i al i  e ce t e ara eter esti ates a t e
jective f cti val e f t e el. T eref re, t e v l es ere xe t e liter i t e ri i al
a alysis.
T e r a v l es ai ly re rese t a a iti al elay i t e rally a i istere r reac i
t e ce tral c art e ts f t e i az la a 1- - eta lite. T is ca e rea ily see fr t eir
res ective e ati s. T e r a v l es t a ect t e i availa ility fracti s, ic alrea y ake
se f t e asi-stea ystate a r xi ati y t e se f t e ell-stirre els.
T eref re, t e  i f t e ri i al a t rs t at t e v l e f t e ysi l ical c art e ts
as little e ect ara eter esti ates a t e jective f cti , is a i icati t at t e ysi l ical
c art e ts ere ly a i e li i le elay f r t e r t reac t e ce tral i az la a 1- -
i az la c art e ts. F rt er, all f t ese ysi l ical c art e ts are ell- erf se , ic
f rt er e c ra es t e c cl si t at t e elay r vi e y t e is e li i le.
T eref re, as servati s are availa le fr t ese ysi l ical c art e ts, t eir ai f c-
ti is t ex lai ic fracti f t e se e s i t e i az la c art e t, a ic fracti
e s as a eta lite eca se f rst- ass eta lis .
l i i- i i
asi-stea ystate a r xi ati is a tec i e c ly se i syste s i l y ( efere ce: at e-
atical eli i syste s i l y, ria I alls). It i v lves ass i t at e f t e c art e ts
r states i t e syste exists i a e ili ri it re ar t t er c e ts f t e syste ; i t er
r s, e set d x/dt . T e , t e a ts i c art e t x ca e calc late a alytically, a t is
c art e t ca e itte fr t e syste f i ere tial e ati s.
T e rst re cti as t ass e asi-stea ystate i t e t all, f r t i az la a t e
eta lite. F r t e are t, t is lea s t
2
The original authors 2 reported that the choice of physiological compartment volumes 
(gut wall, portal vein and liv r) had minimal influence on the parameter st mat s and 
the objective function value of the model. Therefore, the volumes were fixed to one liter 
in the original analysis.
Th  organ volumes mainly r present an additional delay in the orally administered 
drug reaching the central compartments of the midazolam and 1­OH­metabolite. This 
can be readily seen from their respective equations. The organ volumes do not affect the 
bioavailability fractions, which already make use of the quasi­steadystate approxima­
tion by the use of the well­stirred models.
Therefore, the finding of the original authors that the volume of the physiological 
compartments has little effect on parameter estimates and the objective function, is an 
indic tion that the physiological co partments were only adding negligible delay for 
the drug to reach the central midazolam and 1­OH­midazolam compartments. Further, 
all of these physiological compartments are well­perfused, which further encourages 
the conclusion that the delay provided by them is negligible.
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Therefore, as no observations are available from these physiological compartments, 
their main function is to explain which fraction of the dose ends up in the midazolam 
compartment, and which fraction ends up as a metabolite because of first­pass metabo­
lism.
Model reduction by quasi-steady state approximation
Quasi­steady state approximation (QSSA) is a technique commonly used in systems biol­
ogy3. It involves assuming that one of the compartments or states in the system exists 
in an equilibrium with regard to other compartments or states of the system; in other 
words, we set dAx/dt ≈ 0. Then, the amounts in compartment x can be calculated analyti­
cally, and this compartment can be omitted from the system of differential equations.
The first reduction was to assume quasi­steadystate in the gut wall, for both mid­
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Then, using these approximations for the gut wall drug amounts, we can calculate the amounts in
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With these solutions for portal vein compartment, we can calculate the quasi-steadystate amounts
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With these solutions for portal vein compartment, we can calculate the quasi-steadystate amounts
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And for the metabolite in the liver compartment:
G
t
I(t) v i l l i
FG , dz G , dz
G




v i l l i/ G
( )
f r t e eta lite i t e t all
G , e t
t
v i l l iEG , dz G , dz
G
v i l l iEG , e t G , e t
G
v i l l iFG , e t G , e t
G
G , e t G , dzEG , dz
(7)
T e , si t ese a r xi ati s f r t e t all r a ts, e ca calc late t e a ts i
t e rtal vei f r t e are t
PV , dz
t
v i l l iFG , dz G , dz
G
PV c , dz
c , dz
PV PV , dz
PV
PV , dz
Qv i l l i
VGW
FG , dz G , dz
QPV
Vc ,mdz c , dz
PV/ PV
(8)
f r t e eta lite i t e rtal vei
PV , e t
t
v i l l iFG , e t G , e t
G
PV c , e t
c , e t
PV PV , e t
PV
PV , e t
Qv i l l i
VGW
FG , e t G , e t
QPV
Vc ,met c , e t
PV/ PV
( )
it t ese s l ti s f r rtal vei c art e t, e ca calc late t e asi-stea ystate a ts
i t e liver f r t e are t:
H , dz
t
PV PV , dz
PV
HA c , dz
c , dz
HEH , dz H , dz
H




Vc c , dz
QPV
VPV PV , dz
H/ H
(1 )
f r t e eta lite i t e liver c art e t:
H , e t
t
HEH , dz H , dz
H
PV PV , e t
PV
HA c , e t
c , e t
HEH , e t H , e t
H
HFH , e t H , e t
H
H , e t
QHA
Vc ,met c , e t
QPV
VPV PV , e t
QH
VH
EH , dz H , dz
H/ H
(11)
3Finally, we can use these definitions to rewrite the original model in reduced form for 





















































Model reduction into a compartmental model
It is possible to further reduce themodel denedwith the quasi-steadystate approximations. First, using
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And for the metabolite:
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Mod l reduction i o a compartmental model
It is possible to further reduce the model defined with the quasi­steady state approxi­
mations. First, usi g the defined approximations we ca  simpl fy that the midazolam 
concentration in the liver is
7 | 208





















































Model reduction into a compartmental model
It is possible to further reduce themodel denedwith the quasi-steadystate approximations. First, using























I(t)FG ,mdz + QHAc ,mdz/Vc ,mdz
QH/VH
(14)




























( I(t)Fg+QHAc/VcQH/VH ) EH ,mdz
QH/VH
=
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Substituting the quasi­steady state approximations, we get the following expressions 
for the parent and metabolite central compartment differential equations:
Substituting the quasi-steadystate approximations, we get the following expressions for the parent
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(18)
It is possible to rewrite the original model without most of the blood ows; the only blood ows
necessary are either QGUT or QH , in order to dierentiate between the hepatic and intestinal ­rst-pass
metabolism.
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It is possible to rewrite the original model without most of the blood ows; the only blood ows
necessary are either QGUT or QH , in order to dierentiate between the hepatic and intestinal ­rst-pass
metabolism.
5
It is possible to rewrite the original model without most of the blood flows; the only 
blood flows n cessary are either QGUT or QH, in order to differ ntiate between the hepatic 
and intestinal first­pass metabolism. Further, as the volumes (V) of the gut wall, portal 
vein and liver cancel themselves out, fixing them to arbitrary values will have no effect 
on model prediction after quasi­steady state approximations.
dAc ,mdz
dt
=FG ,mdzFH ,mdz I(t) −
















































A simulation was conducted based on parameter estimates of an intermediate model, to verify that
the quasi-steadystate approximation does not cause signicant bias in the results. For the purposes
of the simulation, the parameters outlined in Table 1 were used. The simulation results showed that the
quasi-steadystate approximation produces only aminimal discrepancy to the predictedmidazolam and




A simulation was conducted based on parameter estimates of an intermediate model, 
to verify that the quasi­steady state approximation does not cause significant bias in the 
results. For the purposes of the simulation, the parameters outlined in Table 2 were used. 
The simulation results showed that the quasi­steady state approximation produces only 
a minimal discrepancy to the predicted midazolam and 1­OH­midazolam concentra­
tions (Figure 1).
table 2 Physiological and model­related parameters used in the simulation
Pk Parameter value
I(t) 0.15 · e−0.02min
−1t mg/min
Intrinsic gut wall clearance 0.02 L/min
Intrinsic gut wall clearance (1­OH) 0.0 L/min
Distribution volume (central) 40 L
Intrinsic hepatic clearance 25 L/min
Distribution volume (shallow peripheral) 100 L
Inter­compartmental clearance (shallow) 0.9 L/min
Distribution volume (deep peripheral) 50 L
Inter­compartmental clearance (deep) 0.2 L/min
Distribution volume (central, 1­OH) 65 L
Intrinsic hepatic clearance (1­OH) 3 L/min
Distribution volume (peripheral, 1­OH) 40 L























figure 1 A comparison of simulated concentrations from the original model (solid lines) and the reduced 
model (dashed lines). Black lines indicate midazolam concentrations and grey lines indicate 1­OH­midazol­
am concentrations.
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$PROBLEM MDZ+1­OH in Morbidly Obese and Bariatric pts
$INPUT ID TIME AMT RATE DROP DV PLAS CMT MDV BQL TAD TADI OBES TBW LOSS LBW 





COMP=(CENTRAL) ;2 Midazolam blood conc.
COMP=(PERIP) ;3
COMP=(PER2) ;4














Q= TVQ*EXP(ETA(2)) ; clearance blood to periph comp (L/min)
IF(OBES.EQ.1) TVV6=THETA(3)*(TBW/127)**THETA(20)
IF(OBES.EQ.2) TVV6=THETA(3)




KA= TVKA*EXP(ETA(11)) ; min­1
KTR=KA
F1= THETA(5)*EXP(ETA(4)) ; FA (fraction absorbed)
ALAG1= THETA(6)*EXP(ETA(5)) ; lag time (min)
V12=THETA(17)*V6
Q12=THETA(18)
VPV= 1 ; portal vein compartment fixed to 1 L.
IF(OBES.EQ.1) TCH= THETA(7)
IF(OBES.EQ.2) TCH= THETA(23)
CLH= TCH*EXP(ETA(6)) ; intrinsic hepatic clearance (unbound)
FUB= THETA(8) ; fraction unbound in blood
QH= 3.75*TBW**0.75/60 ; in L/min (according to Brown et al. 1997)
QPV= 0.75*QH ; portal vein blood flow (75% from blood flow of liver) from Williams et 
al. 1989
QHA= 0.25*QH ; hepatic artery blood flow (25% from liver blood flow) Williams et al. 
1989
VH= 1 ; fixed to 1 L.
CLG= THETA(9)*EXP(ETA(7)) ; intrinsic intestinal clearance (unbound)
FUG= 1 ; fixed to 1, acc to Yang et al. 2007
QIN= 0.4*QH ; intestial blood flow, acc to Williams et al. 1989
QMU= 0.8*QIN ; mucosa blood flow, according to Yang et al. 2007
QVI= 0.6*QMU ; villous blood flow, acc to Yang et al. 2007
VGW= 1 ; Volume of Gut wall fixed to 1 L.
; 1-OH-MDZ parameters
VMET=THETA(10)*EXP(ETA(8)) ; volume of central 1­OH cmt
CLHM=THETA(11)*EXP(ETA(9)) ; intrinsic hepatic clearance of 1­OH
FUBM=THETA(12) ; fraction unbound in blood of 1­OH
CLGM=THETA(13)*EXP(ETA(10)) ; intrinsic gut clearance of 1­OH
FUGM=THETA(14) ; fraction unbound in gut of 1­OH
VPER=THETA(15)
QPER=THETA(16)
BP=0.66 ; blood:plasma ratio
CLPL= (QH*FUB*CLH)/(QH+(FUB*CLH/BP)) ; calculated plasma clearance
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; hepatic extraction parent
EH= (CLH*FUB)/(QH+(CLH*FUB))
FH= 1­EH
; gutwall extraction, QG= “Qgut” parent




; hepatic extraction 1­OH­MDZ
EHM= (CLHM*FUBM)/(QH+(CLHM*FUBM))
FHM= 1­EHM





























DADT(3)=K56*A(2) ­K65*A(3) ; 1st periperal cmt
DADT(4)=K512*A(2) ­K125*A(4) ; 2nd periph
DADT(5)=FHM*(QH/VH)*AHM ­(QPV/VMET)*A(5)­ (QHA/VMET)*A(5) ­K1011*A(5) 
+K1110*A(6) ; centralM











IPRED=F ; individual prediction
Y1=IPRED*(1+ERR(1)) ; Morbidly obese patients
Y2=IPRED*(1+ERR(2)) ; Bariatric surgery patients
Y=Y1*COM1+Y2*COM2






(0, 40) ;1, V5 (L)
(0, 1.3) ;2, Q
(0, 100) ;3, V6 (L)
(0, 0.1) ;4, KA MO
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1 FIX ;5, FA (fraction absorbed fixed to 1)
0 FIX ;6, ALAG1
(0, 20) ;7, CLH MO
0.033 FIX ;8, Fraction unbound in blood (FUB)
(0, 0.01) ;9, CLG intrinsic gut wall clearance
(0, 65) ;10, VMET Volume of metabolite 1­OH­MDZ
(0, 3) ;11, CLHM intrinsic hepatic clearance of 1­OH
0.106 FIX ;12, FUBM Fraction unbound in blood 1­OH (Mandema et al.)
(0, 5) ;13, CLGM intrinsic gut clearance of 1­OH
1 FIX ;14, FUGM fraction unbound in gut of metabolite 1­OH
(0, 40) ;15, VPER
(0, 0.3) ;16, QPER
(0, 7) ;17, V12
(0, 0.5) ;18, Q12
0.1766 FIX ;19, CLperm
3.93 FIX ;20, TBW pow V6
0.0435 FIX ;21, TBW lin V5
(0, 0.2) ;22, KA BA
(0, 30) ;23, CLH BA
3.22 FIX ;24, fQ BA
$OMEGA ; perc. standrd dev. van interind.var(eta)
0.2 ; 1, V5
0 FIX ; 2, Q
0.5 ; 3, V6
0 FIX ; 4, F1
0 FIX ; 5, ALAG1
0.05 ; 6, CLH
0.9 ; 7, CLG
0 FIX ; 8, VMET Volume of metabolite 1­OH­MDZ
0 FIX ; 9, CLHM
0 FIX ; 10, CLGM
0.2 ; 11, KA
$SIGMA ; residuele (error/epsilon)
0.07 ; MO
0.04 ; BA








Chap te r  8
Concepts and applications for evidence­based 
dosing in morbidly obese patients before and 






The prevalence of morbid obesity (body mass index, BMI> 40 kg/m2) is increasing across 
the globe 1­2. The physiological changes associated with morbidly obese patients may 
impact the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs and thus drug 
exposure and effects. Therefore (clinical) studies guiding evidence­based dosing in the 
morbidly obese population are needed, particularly in view of the increased risk of (mor­
bidly) obese patients to develop serious comorbidities including cancer, diabetes type 
2, cardiovascular diseases, etc. 3. Currently, knowledge to what extent these physiologic 
changes influence absorption, metabolism, distribution, elimination and ultimately 
efficacy and safety of drugs is largely unknown. While until today studies on drug phar­
macokinetics in obesity predominantly included overweight (BMI 25­30 kg/m2) and 
moderately obese patients (BMI 30­40 kg/m2), there is a strong need for pharmacokinetic 
studies in morbidly obese patients. In the end, the influence of (morbid) obesity on the 
PK­PD relationship should be characterized to guide dosing in this population.
Furthermore, as a result of an increase in the number of morbidly obese patients, also 
the number of patients who undergo weight loss or bariatric surgery is increasing 4. Bar­
iatric surgery or weight loss surgery is considered the most effective treatment option 
for morbid obesity 5­6 and results, among other factors, in long term weight loss, remis­
sion of type 2 diabetes and overall mortality 6­7. Bariatric patients present physicians 
and pharmacists with many challenges regarding safe and effective drug therapy, as 
bariatric procedures may impact a drug’s pharmacokinetics both due to the anatomical 
changes made to the gastro­intestinal tract and the induced loss in body weight. On 
average, bariatric patients lose a mean of 32% of total body weight 0.5­2 years after the 
bariatric procedure 6. For these reasons, also for the bariatric patient population, insight 
into changes in PK and PD that can be expected and evidence­based dosing recom­
mendations are needed.
As a first step, Chapter 2 provides an overview of findings reported in pharmacokinetic 
studies in both obese and non­obese subjects which are sorted by the metabolic or 
elimination pathway of the drug 8. This overview shows that the impact of obesity on 
drug metabolism and elimination seems to depend on the metabolic or elimination 
pathway primarily involved in the clearance of a drug. It was shown that Cytochrome 
P450 3A (CYP3A) metabolized drugs have lower total (oral) clearance values, while clear­
ance of drugs primarily metabolized by uridine diphosphate glucuronosyltransferase 
(UGT), glomerular filtration and/or tubular­mediated mechanisms, xanthine oxidase, 
N­acetyltransferase or CYP2E1 appears higher in obese versus non­obese patients.
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Furthermore, in Chapter 3 an overview of the impact of obesity on each aspect of a 
drug’s pharmacokinetics as well as perspectives for future research into the influence 
of obesity on pharmacokinetics are summarized 9. This overview shows that (morbid) 
obesity may substantially impact the distribution of drugs, while the magnitude and 
direction of change are difficult to predict based on the lipophilicity of the drug alone. 
Relative to the influence of obesity on distribution, the impact of (morbid) obesity on 
clearance may be smaller and more predictable based on the elimination pathway in­
volved (Chapter 2). Finally, Chapter 3 shows that very little is known about the influence 
of (morbid) obesity on oral absorption and bioavailability, while from a small number of 
studies it seems that oral drug absorption may be altered.
Given the lack of information on drug absorption, distribution and clearance in morbidly 
obese and bariatric surgery patients, we decided to study two different drugs in these 
populations in this thesis. First, we studied cefazolin subcutaneous tissue penetration 
in morbidly obese patients undergoing bariatric surgery. In addition, we evaluated the 
impact of both morbid obesity and bariatric surgery on the pharmacokinetics of CYP3A 
substrate midazolam after semi­simultaneous oral and intravenous administration.
Influence of morbid obesity on cefazolin pharmacokinetics
Cefazolin is a first generation cephalosporin antibiotic which is widely applied for the 
prevention of surgical site infections during many types of surgical interventions, includ­
ing bariatric surgery 10. Cefazolin is eliminated by glomerular filtration and active tubular 
excretion 11. Studies report more surgical wound infections in morbidly obese patients, 
while cefazolin plasma concentrations seem to reach adequate levels in morbidly obese 
patients 12­13. Yet, for morbidly obese patients it was unknown whether adequate levels 
of cefazolin were reached at the target site, which in this case is the interstitial space 
fluid (ISF) of the subcutaneous adipose tissue around the surgical wounds (abdomen). 
Therefore, in Chapter 4 we aimed to measure and compare unbound cefazolin concen­
trations in the ISF of the subcutaneous adipose tissue of morbidly obese and non­obese 
patients. The results were used to quantify the influence of morbid obesity on cefazolin 
pharmacokinetics in the subcutaneous adipose tissue taking into account protein bind­
ing of this drug 14.
After a 2 gram cefazolin intravenous bolus dose, total and unbound cefazolin plasma 
concentrations were collected in nine morbidly obese (141 ± 22 kg, 107­175 kg) and 
7 non­obese patients (86 ± 13 kg, 72­109 kg). In addition, using clinical microdialysis, 
unbound cefazolin ISF concentrations of the abdominal adipose tissue were collected 
until 4 hours after dosing. It was found that unbound cefazolin subcutaneous tissue 
penetration, defined by the unbound AUC ratio (fAUCtissue/fAUCplasma) was lower in mor­
bidly obese compared with non­obese patients (0.70 (0.67­0.83) versus 1.02 (0.85­1.41), 
p<0.05). Measured cefazolin concentrations were best described by a two­compartment 
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population PK model with saturable protein binding. The covariate analysis showed that 
central volume of distribution increased linearly with body weight and that cefazolin 
distribution from the central to the subcutaneous compartment decreased with body 
weight in a non­linear manner. Based on the final covariate population PK model, Monte 
Carlo simulations were performed indicating that a dose of 2 g cefazolin given prior to 
incision will be sufficient to prevent wound infections with pathogens for which the 
minimal inhibitory concentration (MIC) is 1 mg/L for a duration of 240 minutes. In con­
trast, the probability of target attainment for morbidly obese versus non­obese patients 
for MIC values of 2 and 4 mg/L is reduced (Chapter 4 , Table 3 and Figure 4).
In conclusion, this study showed that cefazolin distribution to the ISF of the subcu­
taneous adipose tissue is reduced in morbidly obese versus non­obese patients, that 
cefazolin tissue distribution reduces with increasing body weight and that dose adjust­
ments are required in this patient group (see Appendix I).
Influence of morbid obesity and weight loss surgery on the pharmacokinetics 
of CYP3A substrate midazolam
According to the literature review in Chapter 2 decreased CYP3A mediated clearance 
in obese individuals may be expected. Therefore, in Chapter 5 we aimed to study the 
pharmacokinetics of midazolam in morbidly obese patients versus non­obese healthy 
volunteers after semi­simultaneous oral and intravenous administration 15. Midazolam 
is a widely applied drug for short­term and long­term sedation for procedures or at the 
intensive care unit. It is primarily metabolized by CYP3A into 1­OH­midazolam and as 
such considered a probe substrate for CYP3A activity 16.
In a clinical study, 20 morbidly obese patients with a mean body weight of 144 kg 
(range 112–186 kg) and mean body mass index 47 kg/m2 (range 40–68 kg/m2) partici­
pated in the study. All patients received a midazolam 7.5 mg oral and 5 mg intravenous 
dose separated by 159 ± 67 minutes. In addition, data from 12 healthy volunteers were 
available for a population pharmacokinetic (PK) analysis using NONMEM. In the final 
PK model, it was found that in morbidly obese patients the population mean clearance 
(relative standard error %) was similar (0.36 (4%) L/min), while oral bioavailability was 
higher in comparison to healthy volunteers (60% (13%) versus 28% (7%), p<0.001). 
Furthermore, we found that central and peripheral volumes of distribution increased 
substantially with body weight (both p<0.001).
In conclusion, in morbidly obese patients, systemic plasma clearance of midazolam is 
unchanged, while oral bioavailability is increased. Given the large increase in volumes 
of distribution, dose adaptations for intravenous midazolam should be considered 
(see Appendix I). Further research should elucidate the exact physiological changes at 
intestinal and hepatic level contributing to our observations of unchanged midazolam 
clearance and increased oral bioavailability in morbidly obese patients.
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Besides the influence of morbid obesity on the pharmacokinetics on CYP3A substrate 
midazolam, the influence of bariatric surgery and its associated weight loss was evalu­
ated. For his purpose, the patients from the study in Chapter 5 were invited to participate 
at a second study occasion one year after the bariatric procedure. The outcomes of these 
investigations are reported in Chapter 6 17.
Of the 20 morbidly obese adult patients (144 ± 22 kg) who participated in the study 
of Chapter 5, 18 patients participated (mean loss of 45 ± 10 kg) one year after surgery. 
At both study occasions, patients received 7.5 mg oral and 5 mg intravenous midazolam 
separated by 160 ± 48 minutes. Using population pharmacokinetic modeling, it was 
found that, one year after bariatric surgery, systemic clearance of midazolam was higher 
(0.65 (7%) versus 0.39 (11%) L/min, p<0.01, respectively). This increase in clearance after 
bariatric surgery could not be attributed to the decrease in body weight as the body 
weight model was inferior to the bariatric surgery model (p<0.05). In addition, mean oral 
transit time was faster (23 (20%) versus 51 (15%) minutes, p<0.01), while oral bioavail­
ability was unchanged (0.54 (9%)). Central and peripheral volumes of distribution were 
overall lower in patients one year after bariatric surgery (p<0.05).
Concluding, in this cohort study in morbidly obese patients undergoing bariatric 
surgery, systemic clearance (CL) was 1.7 times higher one year after bariatric surgery, 
which may potentially result from an increase in hepatic CYP3A activity per unit of 
liver weight. Although oral transit time was found to be faster, oral bioavailability (F) 
remained unchanged, which considering the increased systemic clearance (CL) implies 
an increase in the fraction escaping intestinal first pass metabolism (FG).
Based on the results of Chapter 6, it was hypothesized that the midazolam fraction 
escaping gut wall metabolism (FG) is increased in patients after bariatric surgery in com­
parison with morbidly obese patients before bariatric surgery. Knowledge on the exact 
influence of a bariatric procedure on hepatic and gut wall CYP3A activity, and therefore 
the fraction escaping hepatic metabolism (FH) and FG, may be of value for many other 
drugs, as approximately 30% of all clinically used drugs are metabolised via CYP3A 18. 
Therefore, in Chapter 7 we aimed to describe the pharmacokinetics of both midazolam 
and its CYP3A mediated metabolite 1­OH­midazolam in morbidly obese patients before 
and one year after bariatric surgery after both oral and intravenous administration 19. 
A semi­physiologically based PK (Semi­PBPK) model taking into account gut wall and 
hepatic first pass metabolism was required for this analysis. The results of the model 
were used to explore to what extent these results may affect other CYP3A substrates.
Using a semi­PBPK model, it was found that for bariatric patients midazolam intrinsic 
hepatic clearance (CLint hepatic) was 1.5 times higher (p<0.01) in comparison to morbidly 
obese patients before surgery, resulting in a decrease in FH of midazolam in patients 
after bariatric surgery. In contrast, intrinsic midazolam gut wall clearance (CLint gut wall) 
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showed a trend towards lower values in bariatric patients, while for both patients groups 
values were considered low. As a result, FG was close to one both for patients before and 
after for weight loss surgery, while especially the morbidly obese patient group exhib­
ited large inter individual variability. Simulations of increased hepatic CYP3A abundance 
by 1.5 times showed a plasma clearance increase of 1.30­1.41 for low extraction ratio 
CYP3A substrates such as cyclosporine, alprazolam and triazolam using the SimCYP 
simulator 20. For the medium extraction ratio CYP3A substrate midazolam, this resulted 
in only a 1.22 increase in plasma clearance.
As this factor of 1.22 is lower than the factor of 1.7 identified in Chapter 6, the results of 
Chapter 7, in combination with the results from Chapter 5 and 6, have been summarized 
in Figure 1. In this figure, plasma clearance (CLplasma) values and intrinsic blood clearance 
values at the level of the gut wall (CLint gut wall) and liver (CLint hepatic) are compared to values 
for healthy volunteers and bariatric patients from the perspective of the morbidly obese 
patient. From this figure, it may be concluded that the increase in midazolam plasma 

















Potentially an increase in hepatic 
blood flow compensates reduced 
hepatic CYP3A activity in morbidly 
obese patients, resulting in 
unchanged values for plasma 
clearance.
The lower midazolam intrinsic gut wall 
clearance in morbidly obese patients 
may be due to increased villous blood 
flow and/or increased intestinal 
permeability.
This increase may be due to an 
increase in previously reduced 
hepatic CYP3A metabolism and 
possibly also an increase in liver 
blood flow and/or perfusion.





metabolism is found,  
potentially because of 
lower inflammatory 
status of the liver 24.
A trend towards lower intrinsic gut 
wall clearance is possibly due to the 




figure 1 An overview of results on midazolam plasma clearance (CLplasma (L/min)), intrinsic blood clearance 
at the level of the gut wall (CLint gut wall (L/min)) and intrinsic blood clearance at the level of the liver (CLint hepatic 
(L/min)) in morbidly obese patients in comparison to healthy (non­obese) volunteers and bariatric patients. 
The results are taken from Chapters 5, 6 and 7 and literature 22­24. The grey arrows indicate the direction of 
comparison.
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hepatic CYP3A activity (that is related to morbid obesity), but that at the same time 
another non­CYP3A related process is involved in an increase in midazolam plasma 
clearance (Chapter 6) 17. This other process may be an increase in hepatic blood flow (QH) 
or hepatic perfusion 21. An increase in QH in morbidly obese patients in comparison with 
healthy volunteers may also explain the similar midazolam plasma clearance in morbidly 
obese patients in comparison with healthy volunteers, despite reduced hepatic CYP3A 
activity related to morbid obesity (Chapter 5 and Figure 1) 15.
In conclusion, a semi­PBPK model was identified that adequately described midazolam 
and CYP3A mediated 1­OH­midazolam concentrations after both oral and intravenous 
administration. Using this model it was found that in patients one year after bariatric 
surgery CYP3A hepatic intrinsic metabolizing capacity is increased in comparison to 
morbidly obese patients before bariatric surgery. However, CYP3A mediated gut wall 
intrinsic clearance shows a trend towards lower values in bariatric patients, probably as 
a results of the 75­150 cm bypass of the initial part of the small intestine.
PersPeCtIves
how to get to evidence-based dosing in morbidly obese or bariatric patients
In this thesis, two drugs have been studied using well­designed clinical trials resulting 
in evidence­based dosing recommendations for morbidly obese and bariatric patients 
(see Appendix I). However, to establish evidence­based dosing for morbidly obese 
patients before and after weight loss surgery for every clinically used drug separately, 
as we did in this thesis, will be time and cost consuming. Hence, an intriguing ques­
tion is how we can accelerate and facilitate this process. One way would be to evaluate 
whether the PK models that were developed for specific drugs as we did in this thesis 
may contain information that can be considered system specific information for this 
population. Such system specific information may potentially be used for predictions 
for other (unstudied) drugs.
This concept has been explored earlier for both UGT2B7 glucuronidation and renal 
elimination in neonates and children 25­31. These studies showed that the covariate func­
tion for a population characteristic (e.g. body weight) derived for one so called model 
drug was predictive for the changes in clearance of another drug cleared through the 
same pathway. For changes in clearance of the UGT2B7 substrate zidovudine in young 
infants, the same influence of body weight was found as for the UGT2B7 substrate 
morphine and potentially other substrates of UGT2B7 28­29, 32. Also, for drugs cleared via 
glomerular filtration, it was found that the covariate model for amikacin clearance in the 
heterogeneous group of preterm and term neonates was able to describe the clearance 
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of other glomerularly filtrated drugs such as netilmicin, vancomycin, tobramycin, and 
gentamycin across this population 27, 30.
For obese patients, we tended to apply a similar approach for which the literature 
overview of Chapter 2 was written. In fact, this overview showed coherent trends of 
the influence of obesity on the different classes of clearance pathway. However, the 
observed trends should be prospectively evaluated before they can be used to predict 
the impact of obesity on an unstudied drug. This particularly applies to morbidly obese 
individuals, because the studies in the review predominantly included overweight and 
obese patients as opposed to morbidly obese patients.
In this thesis, we found for cefazolin (Chapter 4) which is mainly eliminated by glo­
merular filtration (GFR) and active tubular excretion 11, that there was no influence of 
body weight on clearance. Also for the CYP3A substrate midazolam (Chapter 5), no 
effect of morbid obesity on clearance was found in comparison to healthy volunteers. A 
crucial question in this respect is whether these results can be applied to other renally 
cleared and CYP3A metabolized drugs, respectively. The review in Chapter 2 shows that 
of the ten studies involved in glomerularly filtrated drugs, six studies show a significant 
increase in clearance and four studies show no difference, indicating that the influence 
of morbid obesity on glomerular filtration may not be straightforward to predict. This 
in line with studies reporting that both GFR hyperfiltration and impairment may be 
present in the general morbidly obese patient population, with impairment reported 
particularly upon a prolonged state of morbid obesity 33­35. As such it seems that our 
findings for cefazolin are in agreement with literature as we report unchanged cefazolin 
clearance in a morbidly obese patient group that was relatively young (mean age 40 
years) with normal creatinine concentrations at inclusion of the study.
The lack of difference in clearance of the CYP3A substrate midazolam between 
morbidly obese patients and non­obese volunteers (Chapter 5) seems to be in contrast 
with the results of the review of Chapter 2 in which several studies showed significantly 
lower oral clearance (CL/F) of CYP3A mediated drugs. However, as we found a higher 
midazolam oral bioavailability (F) in morbidly obese patients in comparison to healthy 
volunteers (60 versus 28%, respectively), indeed a lower CL/F for midazolam in morbidly 
obese patients can be reported. Using a more sophisticated approach in Chapter 7 (us­
ing semi­PBPK model for midazolam and 1­OH midazolam), a lower CYP3A metabolizing 
capacity of the liver was found in morbidly obese patients in comparison to non­obese 
healthy volunteers from the literature. This reduced CYP3A activity in morbidly obese 
patients is in good agreement with results of in vitro and animal studies showing re­
duced CYP3A protein expression and activity 36­39. Despite this reduced CYP3A activity in 
the liver, similar plasma clearance values for morbidly obese and non­obese individuals 
were found (Figure 1, Chapter 5&7). As a consequence, it is hypothesized that another 
process (e.g. liver blood flow, liver perfusion and/or size of the liver) compensates for this 
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reduction in hepatic CYP3A metabolizing capacity. It therefore seems that for the success 
of between drug extrapolation per pathway information on obesity­related changes in 
liver blood flow, size and perfusion are needed. Future studies should therefore not only 
focus on the quantification of the influence of obesity on drug different metabolism 
and elimination pathways using model drugs, but also on the quantification of changes 
in liver blood flow, size and liver perfusion to be able to make better informed predic­
tions on how plasma clearance of an unstudied drug will change with obesity. In this 
respect, also the hepatic extraction ratio of a drug may play a role 40, as plasma clearance 
of low extraction ratio drugs are more sensitive to changes in metabolizing activity of 
the involved enzyme system and high extraction ratio and drugs are more sensitive to 
changes in the blood flow (Chapter 7, Figure 5).
The studies reported in this thesis show that particularly the volume of distribution 
of the two drugs studied are impacted by morbid obesity. Jain et al. showed that the 
influence of obesity on hydrophilic drugs may be predicted based on the Log P value, 
while for (highly) lipophilic drugs no such trends can be observed 41. As the change in 
distribution volume for the two drugs studied in this thesis were responsible for the pro­
posed dose adaptations for morbidly obese patients (Appendix I), concepts to predict 
the influence of obesity on volume of distribution are needed. Volume of distribution is 
determined by drug characteristics, including protein binding, transporter dependency, 
the ability to cross tissue membranes, binding within blood and tissues and partition­
ing into fat 40. In addition, volume of distribution is determined by systemic properties 
of which in particular blood volume, adipose tissue volume, cardiac output and tissue 
perfusion are impacted by obesity 21, 42­43. Theoretically, when the influence of obesity on 
the systemic parameters governing volume of distribution are known and drug charac­
teristics are known, it should be possible to predict the change in volume of distribution 
for a specific drug in a specific obese individual. Huisinga et al. have proposed such a 
model for estimating volume of distribution at steady state (Vss) based on the concept 
that adipose tissue volume equals total body weight (TBW) minus lean body weight 
(LBW) 44:
VSS = VS,ref × ( (1–R) × LBW +R× TBW – LBW )LBWref TBWref – LBWref
in which LBW is the lean body weight (estimated by the formula of Janmahasatian et 
al. 45), ’ref’ indicates the reference individual (a non­obese healthy volunteer age 20­50 
years) and R denotes the adipose­to­total volume of distribution ratio of the reference 
individual which can be estimated from clinical data 44. A drawback of this model seems 
that the value R comprises all drug characteristics and needs to be determined for each 
drug individually. Therefore, the applicability of this model is unclear at this point and 
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should be subject of future studies. Alternatively, physiological models in which drug 
characteristics regarding drug distribution can be defined (e.g. log D, ionization at pH 
7.4, protein binding, tissue partition coefficients, etc.) seem more promising as opposed 
to a single drug parameter. Currently, several software packages of such physiologically 
based pharmacokinetic (PBPK) models are available, including SimCYP© 20, 46, which 
deserve to be explored for their predictive value to estimate volume of distribution in 
(morbidly) obese individuals.
The PBPK software package SimCYP© also proved capable of to mimicking observed 
clearance values in (morbidly) obese patients for 6 out of 8 compounds in 60­100% of 
the simulations using the ‘obese’ and ‘morbidly obese’ population of this program 47. 
However, for 2 compounds (phenytoin and clorzoxazone) clearance predictions were 
in good agreement for only 20% of the simulations 47, implying that these models need 
further information, in particular as the exact influence of (morbid) obesity on some 
physiologic parameters (e.g. hepatic blood flow and perfusion) remains unclear. While 
this approach seems very promising for predicting the pharmacokinetics of unstudied 
drugs in (morbidly) obese patients, in our opinion close collaboration with groups 
performing clinical trials in morbidly obese patients are important to further inform and 
improve the predictability of these PBPK models.
These concepts for predicting pharmacokinetics in (morbidly) obese patients may 
also be applied for patients after weight loss (bariatric) surgery. For this population, the 
type of bariatric surgery, time after bariatric surgery and decrease in body weight should 
be considered. Darwich et al. have aimed to predict the disposition of drugs in patients 
after different types of bariatric surgeries using an adjusted advanced drug absorption 
and metabolism (ADAM) model combined with a PBPK model 48. On the basis of this 
model, the authors were able to adequately predict the trends in oral drug exposure 
of atorvastatin and cyclosporine (CYP3A substrates) following a Roux­and Y­gastric 
bypass surgery 48. However, this model did not yet include a recovery of hepatic CYP3A 
metabolizing capacity as indicated by the Chapters 6 and 7. This further underlines 
the need to perform clinical trials on (model) drugs to inform PBPK models which can 
then be applied to predict the influence of morbid obesity and bariatric surgery on 
unstudied drugs. In addition to the recovery of intrinsic hepatic CYP3A metabolizing 
capacity, knowledge on the change in physiologic parameters due to the reduction in 
body weight (e.g. cardiac output, liver perfusion, adipose tissue volume, etc.) is needed 
to further enhance the applicability and predictability of such a PBPK model for patients 
after weight loss surgery.
In conclusion, on the basis of these concepts the process of getting to evidence­based 
dosing recommendations for all clinically used drugs for the morbidly obese and bar­
iatric surgery patient population may be accelerated and as such it seems that further 
study on these concepts are justified.
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tips and tricks for the design and analysis of studies in morbidly obese and 
bariatric surgery individuals
While additional clinical trials in morbidly obese before and after weight loss surgery are 
evidently needed, this section aims to emphasize on methods and techniques for future 
clinical research that ultimately aim to guide dosing in morbidly obese patients before 
and after weight loss surgery.
First, for future studies it is recommended to measure and quantify the clinical effects 
(pharmacodynamics, PD) in addition to pharmacokinetics (PK), as in the end it is the 
clinical effect that will determine the optimal dose for the individual morbidly obese 
or bariatric patient. In this thesis, the pharmacodynamics of both the drugs that were 
studied for the PK, have been measured. For cefazolin, the clinical desired effect is the 
prevention of surgical wound infections. Due to the nature of this clinical endpoint, 
large trials will be needed to measure the effect of a single cefazolin dose. Therefore, 
we have evaluated the cefazolin concentrations which are expected to correlate most 
closely with its antibacterial effect, i.e. the subcutaneous tissue ISF concentrations, in 
addition to unbound and total cefazolin plasma concentrations (Chapter 4). To date, 
clinical microdialysis is the only sampling technique that allows for measurement of 
free, active concentrations in virtually any tissue such as ISF 49­50. In addition, clinical 
microdialysis has been shown to be a safe, reproducible, and an ethically acceptable 
technique for studying tissue drug distribution in human 51­52. Alternative methods for 
measuring tissue concentration include tissue biopsies or blister fluid techniques 53­54. A 
draw back of these alternative methods is that they do not easily allow for continuous 
measurements. Furthermore, tissue biopsies are homogenized which prevents the mea­
surement of inter­ and intra­ cellular concentration separately, while for antimicrobial 
agents only the inter cellular concentration is of interest, as this fraction is expected to 
exert an antimicrobial effect. In addition, the blister fluid technique may be quite painful 
for each blister made for each measurement 55. In contrast, in case of clinical microdialy­
sis, the insertion of the microdialysis membrane may be considered moderately painful 
as well, but is only performed once at insertion. After insertion no pain was experienced 
until the end of the study. So, in the study of Chapter 4, clinical microdialysis facilitated 
insight into cefazolin target site penetration in morbidly obese patients. It is emphasized 
that these measurements in the ISF proved crucial for conclusions regarding cefazolin 
dosing in this patient population as plasma concentrations proved relatively similar 
while subcutaneous tissue distribution and concentrations were largely reduced in 
morbidly obese patients in comparison to non­obese patients 12, 14.
For the midazolam study of Chapter 6, sedation scores were recorded from midazolam 
oral dose administration until 160 ± 48 minutes after dosing. In Figure 2, the Richmond 
Agitation and Sedation Scale (RASS) scores are shown for morbidly obese patients be­
fore (occasion 1) and one year after bariatric surgery (occasion 2). For occasion 1, 10 out 
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of 19 morbidly obese patients were sedated to some extent (score ­1 and/or ­2), while 
9 out of 19 patients showed no sign of sedation (RASS = 0). One year later, 16 out of 18 
patients showed some level of sedation (score ­1 to ­4), while only 2 patients showed 
no level of sedation. Moreover, sedation was deeper after bariatric surgery (maximum 
of ­4 reported in 4 patients) compared to before bariatric surgery (maximum of ­2 in 2 
patients) and seemed to occur slightly faster. The sedation levels versus times profiles 
suggest that the midazolam concentration­time profile is indicative of its sedative effect 
in morbidly obese patients before and after bariatric (Figure 2). However, it should be 
noted that the less deep sedation levels observed in morbidly obese patients before 
bariatric surgery may also be the result of anxiety related to the surgical procedure that 
may be experienced by these patients while one year after surgery no surgical procedure 





























Morbidly obese patients (n=20)
Bariatric patients (n=18)
figure 2 Midazolam concentration versus time (upper panel) and Richmond Agitation Sedation Scale 
(RASS) scores over time(lower panel) after a 7.5 mg oral midazolam dose in 20 morbidly obese patients 
before (black lines) and 18 patients one year after bariatric surgery (grey dotted lines) from the study de­
scribed in Chapter 6.
8 | 234
was scheduled. In conclusion, for both of the drugs studied in this thesis, drug effects 
have been measured in addition to pharmacokinetic profiles, which may provide a more 
profound basis for dose recommendations in morbidly obese and bariatric surgery 
patients.
Second, it is recommended to evaluate the pharmacokinetics after both oral and 
intravenous administration in order to estimate the influence of morbid obesity or 
bariatric surgery for each PK parameter separately (i.e. oral bioavailability (F), clearance 
(CL) and volume of distribution (V)). In studies in which the drug is administrated orally, 
only the apparent clearance (CL/F) and volume of distribution (V/F) can be determined, 
while studies on intravenous administered drug result in estimates of CL and V and not 
of F. In particular because the majority of pharmacotherapy is given orally, knowledge 
on how F or CL are each impacted by morbid obesity or bariatric surgery is essential for 
the extrapolation of the results to other drugs as described in 8.2.1.. For this reason in 
Chapter 5 and 6, a semi­simultaneous oral­intravenous dosing design was applied. Ear­
lier, it had been shown that this semi­simultaneous dosing design method is a reliable 
and accurate for estimating oral bioavailability (F) and systemic clearance (CL) in a single 
person, on a single occasion 56­59. Alternatively, the stable isotope method for determin­
ing oral bioavailability in a single person on a single occasion may be applied 60. How­
ever, the preparation of the labeled drug and the determination of the labeled drug in 
the samples may be expensive and labor intensive. In conclusion, a semi­simultaneous 
dosing design allows for separate estimation of both CL and F (Chapter 5 and 6) and 
therefore also of hepatic and gut wall CYP3A mediated metabolism (Chapter 7).
Third, when designing a clinical trial the choice of control or reference group de­
termines the type of results and conclusions that can be drawn from the trial. In this 
thesis, different types of control groups have been used: non­obese (never been obese) 
patients undergoing a Toupet fundoplication laparoscopic procedure (Chapter 4), 
healthy (never been obese) volunteers (Chapter 5) and the same patients (who were 
morbidly obese at the time) one after year a bariatric surgery (Chapters 6 and 7). Besides 
the specific advantages and drawbacks of each type of control group, it can be expected 
that comparing two groups does not allow for estimation of a continuous covariate 
function, but rather a binary function (‘obese/non­obese’), to describe the influence 
of overweight or obesity, while in fact the overweight itself (normal weight to super 
obese) may be expected to be a continuous parameter. For instance, when analysing 
midazolam PK in morbidly obese patients versus healthy volunteers (Chapter 5) a large 
difference in oral bioavailability (F) was found, which was defined by a binary covariate, 
‘obese/non­obese’. Whether and how midazolam F changes with increasing degree of 
overweight or obesity remains unclear as no midazolam concentrations in individuals 
in between healthy volunteer and morbidly obese were available. Following this, it can 
be expected that the predictability of midazolam oral bioavailability by this particular 
8 | 235
covariate model is low, while a model based on the full range of overweight/obesity as 
well as different types of obesity (e.g. type of body shape), may result in more predictive 
PK functions. That is why, for future studies it is proposed to include the full spectrum 
of body weights ranging from normal weight (BMI 20­25 kg/m2) to super obese patients 
(BMI>60 kg/m2) individuals, facilitating the development of more predictive covariate 
models.
Fourth, besides population pharmacokinetic modelling, which allows for the quanti­
fication of covariate effects (body weight, overweight, weigh loss and bariatric surgery), 
semi­physiologically based pharmacokinetic (semi­PBPK) modelling has been applied in 
Chapter 7 (Figure 3). This model allowed for estimation of CYP3A meditated metabolism 
at the level of the gut wall and liver separately using the Qgut and well­stirred liver model, 
respectively 61­63 and was described earlier by Frechen et al. and Yang et al. for non­obese 
individuals 24, 64. Apart from the gut wall, the portal vein and the liver, the volumes and 
intercompartmental clearances (blood flows) representing the rest of the body were 
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figure 3 Schematic representation of the semi­PBPK model for midazolam and its 1­OH­midazolam me­
tabolite (1­OH). B=blood; CLint= intrinsic clearance, CLH= plasma clearance; E= extraction ratio; G= gut wall; 
F= bioavailability; fa= fraction absorbed into the gut wall; fu= fraction unbound; H= hepatic; HA= hepatic 
artery; Ka= oral absorption rate, Ktrantsits= transit compartment rate; Q is blood flow (Qvilli, QPV, QHA, QH) or 
intercompartmental clearance (Q1 and Q2); PV = portal vein. Taken from Chapter 7.
8 | 236
lumped into an empirical three compartment population PK model. In addition, further 
simplification of the model was performed assuming quasi steady state approximation 
as outlined in Supplement 2 of Chapter 7 65. This model simplification allowed omitting 
setting values for the organ volumes of the gut wall, liver and portal vein, while giving 
approximately the same model prediction (Supplement 2 of Chapter 7). Ultimately, this 
model only requires knowledge on hepatic and villous blood flow and protein bind­
ing of the population studied to estimate midazolam clearance at the level of the gut 
wall and liver. For future projects, semi­PBPK modeling may be applied to estimate 
intrinsic metabolizing capacity in special patient populations providing insight at what 
level (blood flow, protein binding, intrinsic metabolic capacity, etc.) drug clearance is 
impacted by obesity or bariatric surgery and thus enhancing the extrapolation potential 
of the results.
Finally, in future trials physiological parameters should be collected in order to under­
stand the observed changes in the pharmacokinetics and to enhance the applicability 
of PBPK models. The conversion of the influence of obesity on CYP3A activity in the 
liver to plasma clearance of midazolam and other CYP3A substrates as reported in the 
Chapters 6 and 7, show the relevance of obesity related changes in the physiology of the 
obese individual. For instance, hepatic blood flow is an important physiological param­
eter involved in the clearance of many medium and high hepatic extraction rate drugs 
(e.g. midazolam). Yet, it is still unclear whether and how hepatic blood flow changes 
with obesity and bariatric surgery. It has been reported that cardiac output increases 
with (morbid) obesity 66 and that the percentage of cardiac output going to the hepatic 
blood flow is similar to (predicted) normal weight individuals 21. Furthermore, studies on 
the pharmacokinetics of propofol, a high extraction ratio drug and therefore considered 
a marker of hepatic blood flow 67, indicate a 0.75 allometric increase in hepatic blood 
flow with body weight 68­69. In contrast, a study in animals shows that hepatic blood flow 
and perfusion (hepatic microcirculation) reduce with the degree of fatty infiltration in 
the liver, a condition which is highly associated with (morbid) obesity 70­71. Moreover, 
data on hepatic blood flow values in bariatric patients are non existent. This lack of infor­
mation prevents a full understanding of the change in midazolam clearance observed 
in bariatric patients in comparison to morbidly obese patients (Chapter 7). Therefore, 
we recommend that in future clinical trials in morbidly obese and/or bariatric patients 
physiological parameters should be measured in order to enlarge the predictability 
and extrapolation potential of the results from clinical trials to other (unstudied) drugs. 
Lastly, it should be noted that the collection of such physiologic parameters may not be 
easy, as not all methods (e.g. Flo Trac/Vigileo™ for measuring cardiac output) have been 
validated in the (morbidly) obese population and may therefore be inappropriate.
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In conclusion, the most efficient way towards evidence­based dosing in morbidly obese 
and bariatric patients is to perform optimally designed clinical trials in morbidly obese 
and bariatric patients, to investigate how system specific properties (e.g. CYP3A activity) 
can be inferred from these trials and to evaluate whether these system specific proper­
ties may predict the impact of obesity and weight loss surgery on other (unstudied) 
drugs. The clinical studies should be designed to include the complete range overweight 
to super obese patients (BMI 25 – 100+ kg/m2) and in case of bariatric surgery, various 
types of bariatric surgery and periods after the bariatric procedure. Within these clinical 
trials one should aim to collect data on concentration­time profiles (pharmacokinetic 
data, PK), clinical effects (pharmacodynamic data, PD) as well as physiological param­
eters (e.g. blood flows, protein binding, etc.). Finally, PBPK(­PD) models which allow for 
the integration of pharmacokinetic and physiologic parameters and possibly also phar­
macodynamic parameters for the obese and bariatric patients population should be 
further developed to improve prediction of the impact of obesity and bariatric surgery 
on unstudied drugs. With this thesis we hope to have contributed to this relevant topic.
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ConCePten en toePAssInGen voor het doseren vAn GeneesMIddelen 
oP bAsIs vAn WetensChAPPelIjke onderbouWInG In MorbIde obese 
PAtIënten vóór en nA een MAAGverkleInInGsoPerAtIe
AChterGrond en IntroduCtIe
In Nederland en wereldwijd is er een toename van mensen met obesitas of morbide 
obesitas (zeer ernstig overgewicht) 1­2. Obesitas wordt gedefinieerd als een body mass 
index (BMI) groter dan 30 kg/m2 en bij een BMI groter dan 40 kg/m2 spreekt men van 
morbide obesitas.
Obesitas en morbide obesitas kunnen veranderingen teweeg brengen in de sa­
menstelling en functies van het lichaam. Deze veranderingen kunnen vervolgens van 
invloed zijn op twee processen die bepalend zijn voor de werking van geneesmiddelen: 
de farmacokinetiek (PK) en de farmacodynamiek (PD). De farmacokinetiek beschrijft de 
absorptie (opname), verdeling, metabolisme (afbraak) en uitscheiding van het genees­
middel en daarmee het verloop van de geneesmiddelconcentratie in het lichaam over 
de tijd. De farmacodynamiek beschrijft het effect en werking van het geneesmiddel op 
het lichaam.
Doordat (morbide) obesitas de blootstelling (farmacokinetiek) en effecten (farma­
codynamiek) van geneesmiddelen kunnen veranderen, wordt er mogelijk teveel of te 
weinig van een bepaald geneesmiddel toegediend wanneer de standaard dosering 
(voor niet­obese patiënten) wordt gebruikt. Om deze reden en het feit dat mensen met 
(morbide) obesitas een verhoogd risico hebben op het ontwikkelen van verschillende 
gerelateerde aandoeningen zoals kanker, diabetes type 2 en cardiovasculaire aandoe­
ningen 3, zijn er voor obese en morbide obese patiënten doseeradviezen nodig die 
gebaseerd zijn op wetenschappelijk onderbouwing.
Op dit moment is de invloed van morbide obesitas op de absorptie, verdeling, 
metabolisme en uitscheiding (farmacokinetiek) van geneesmiddelen grotendeels on­
bekend. De studies die reeds zijn uitgevoerd en gepubliceerd, vonden met name plaats 
in mensen met overgewicht (BMI 25­30 kg/m2) en obese patiënten (BMI 30­40 kg/m2), 
waardoor er een sterke behoefte is aan farmacokinetiek onderzoek in morbide obese 
patiënten. Uiteindelijk zal ook de invloed van morbide obesitas op de farmacokinetiek­
farmacodynamiek (PK­PD) relatie bestudeerd moeten worden om de juiste geneesmid­
deldosering in deze populatie te bepalen.
Door de toename van morbide obesitas, neemt ook het aantal bariatrische (gewichtsre­
ducerende) operaties toe 4. Een bariatrische operatie, of ook wel een maagverkleining 
genoemd, wordt beschouwd als de meest effectieve behandeling van morbide obesi­
9 | 246
tas 5­6. Deze operatieve ingreep resulteert onder andere in langdurig gewichtverlies, het 
verdwijnen van diabetes type 2 en langere overleving 6­7. Er worden veel verschillende 
typen maagverkleiningsoperatie uitgevoerd, waarvan de Roux­ and Y gastric bypass en 
de sleeve gastrectomy de meest voorkomende zijn (circa 75% wereldwijd 4). Bij een Roux­ 
and Y gastric bypass wordt de maag tot de grootte van ongeveer een ei gereduceerd en 
het eerste deel van de dunne darm (75­150 cm) wordt omgelegd. Bij een gastric sleeve 
operatie wordt de maag tot een buis gereduceerd, maar vindt er geen omlegging van 
de darm plaats 8­9. Voor artsen en apothekers roept deze steeds groter wordende groep 
bariatrische patiënten veel vragen en onduidelijkheid op omtrent veilige en effectieve 
geneesmiddeltherapie, aangezien deze typen operatie van sterke invloed kunnen zijn 
op de farmacokinetiek van een geneesmiddelen. Immers, de operaties hebben zowel 
een aanpassing van het maag­darmkanaal als een groot gewichtverlies tot gevolg. 
Gemiddeld verliest iemand na een maagverkleiningsoperatie 32% van zijn totale 
lichaamsgewicht binnen 0,5­2 jaar na de ingreep 6. Om deze redenen is er een sterke 
vraag naar informatie over de veranderingen in de farmacokinetiek en –dynamiek van 
geneesmiddelen en naar wetenschappelijk onderbouwde doseeradviezen bij patiënten 
met een maagverkleining.
Als een eerste stap in de richting van wetenschappelijk onderbouwde doseeradviezen 
voor mensen met (morbide) obesitas, wordt in hoofdstuk 2 van dit proefschrift een 
overzicht gepresenteerd van alle gerapporteerde farmacokinetiek studies in zowel 
(morbide) obese als niet­obese individuen. Deze studies zijn gesorteerd per afbraak 
(metabole) of eliminatie route van het onderzochte geneesmiddel 10. Dit overzicht laat 
zien dat de invloed van obesitas op de klaring (uitscheidingssnelheid, CL) van een ge­
neesmiddel, afhangt van de belangrijkste afbraak of eliminatie route die betrokken is bij 
de uitscheiding van dat geneesmiddel. Geneesmiddelen die bijvoorbeeld via het enzym 
systeem Cytochroom P450 3A (CYP3A) worden gemetaboliseerd hebben een lagere 
orale klaring (CL/F) in obese individuen. Echter, geneesmiddelen die bijvoorbeeld door 
uridine diphosfaat glucuronosyltransferase (UGT), glomerulaire filtratie of het CYP2E1 
systeem afgebroken of uitgescheiden worden hebben juist een hogere geneesmiddel­
klaring in obese individuen dan in niet­ obese individuen.
In hoofdstuk 3 wordt een overzicht gegeven van de invloed van obesitas op de 
orale absorptie (opname), verdeling, en klaring (afbraak en/of uitscheiding) van een 
geneesmiddel en worden aanwijzingen voor toekomstig onderzoek op dit gebied 
samengevat 11. Dit hoofdstuk wijst op het feit dat het verdelingsvolume van een genees­
middel zeer sterk beïnvloed kan worden door (morbide) obesitas, waarbij de grootte 
en richting van verandering met toenemende obesitas niet goed te voorspellen is op 
basis van alleen de lipofiliciteit (mate van vetoplosbaarheid) van een geneesmiddel. In 
vergelijking met de invloed van (morbide) obesitas op het verdelingsvolume, lijkt het 
9 | 247
erop dat de invloed van (morbide) obesitas op de klaring van een geneesmiddel kleiner 
is en voorspelbaar per metabole of eliminatie route (zie Hoofdstuk 2). Tenslotte wordt 
uit Hoofdstuk 3 duidelijk dat er weinig bekend is over de invloed van (morbide) obesitas 
op de orale absorptie snelheid (Ka) en de biologische beschikbaarheid (F) van genees­
middelen, terwijl een beperkt aantal studies laat zien dat de orale absorptie mogelijk 
veranderd is.
Gezien het tekort aan kennis over orale absorptie, verdeling en klaring van genees­
middelen in morbide obese patiënten en patiënten na een bariatrische operatie en het 
gebrek aan wetenschappelijk onderbouwde doseeradviezen voor deze patiëntengroe­
pen, hebben wij in dit proefschrift twee verschillende geneesmiddelen bestudeerd in 
deze patiëntengroepen. Ten eerste hebben we de onderhuidse weefselpenetratie van 
cefazoline in morbide obese patiënten tijdens een bariatrische ingreep onderzocht. Ten 
tweede hebben we de invloed van zowel morbide obesitas als een bariatrische ingreep 
op de farmacokinetiek van het geneesmiddel midazolam, dat via het CYP3A enzym 
systeem wordt gemetaboliseerd, onderzocht na orale en intraveneuze toediening.
De geneesmiddelconcentratie­tijd gegevens uit deze onderzoeken werden ge­
analyseerd met populatie farmacokinetiek modellen (met behulp van het software 
programma NONMEM 12) 13. Met deze analyse methode kunnen op basis van de ge­
zamenlijke concentratie­tijd gegevens de farmacokinetische parameters (Ka, F, V, CL) 
geschat worden. Daarbij kan een inschatting van de interindividuele variabiliteit per 
parameter gemaakt worden, waardoor de invloed van covariaten, zoals bijvoorbeeld 
lichaamsgewicht, mate van obesitas, etc., op elk van de farmacokinetiek parameters 
bepaald kunnen worden.
Invloed vAn MorbIde obesItAs oP de fArMACokInetIek vAn 
CefAzolIne
Het geneesmiddel cefazoline is een eerste generatie cefalosporine antibioticum dat 
wordt gebruikt bij veel verschillende operaties, waaronder bariatrische ingrepen, om 
ontsteking (infectie) van operatiewonden te voorkomen 14. Cefazoline wordt uitgeschei­
den door glomerulaire filtratie en actieve tubulaire excretie in de nieren 15.
Onderzoek toont aan dat morbide obese patiënten meer wondinfecties krijgen na een 
operatie, terwijl de cefazoline concentraties in het bloedplasma adequate spiegels lijken 
te bereiken 16­17. Of cefazoline ook adequate spiegels bereikt op de plek van werking is 
onduidelijk. De plek van werking is in dit geval de interstitiële vloeistof (ISF) van het 
onderhuidse vetweefsel rondom de operatiewondjes (buik). Om dit in kaart te brengen, 
stelden we ons in hoofdstuk 4 als doel om ongebonden cefazoline concentraties in 
het ISF van het onderhuidse vetweefsel van morbide obese patiënten en niet­obese 
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patiënten te meten en te vergelijken. De resultaten werden gebruikt om de invloed van 
morbide obesitas op de farmacokinetiek van cefazoline in het onderhuidse vetweefsel te 
kwantificeren, waarbij rekening werd gehouden met de eiwitbinding van cefazoline 18.
Na intraveneuze toediening van 2 gram cefazoline werden bloedplasma monsters 
verzameld en werden totaal en ongebonden cefazoline concentraties gemeten in 9 
morbide obese patiënten (141 ± 22 kg, 107­175 kg) en 7 niet­obese patiënten (86 ± 13 
kg, 72­109 kg). Met behulp van klinische microdialyse werd ongebonden cefazoline in 
het ISF van het onderhuidse vetweefsel van de buik verzameld tot 4 uur na de intrave­
neuze toediening van cefazoline. Er werd gevonden dat de onderhuidse weefselpene­
tratie van ongebonden cefazoline, aangeduid als de ratio van de oppervlakte onder de 
ongebonden concentratie­tijd curven (AUCs), fAUCweefsel/fAUCplasma, lager was in morbide 
obese patiënten in vergelijking met niet­obese patiënten (0.70 (0.67­0.83) versus 1.02 
(0.85­1.41), p<0.05).
De cefazoline concentraties in plasma en onderhuids weefsel over de tijd werden het 
best beschreven met behulp van een twee­compartimenten populatie farmacokine­
tiek model met verzadigbare eiwitbinding. De analyse van de invloed van covariaten 
wees uit dat het centrale verdelingsvolume lineair toenam met lichaamsgewicht en 
dat de cefazoline verdeling van het centrale naar het onderhuidse weefsel afnam met 
toenemend lichaamsgewicht op een non­lineaire wijze. Op basis van dit populatie 
farmacokinetiek model werden Monte Carlo simulaties uitgevoerd. Deze simulaties 
lieten zien dat een cefazoline dosis van 2 gram (toegediend vóór de operatie) tot en 
met 240 minuten na toediening voldoende is om ontsteking van operatiewondjes door 
pathogenen, voor welke een minimale inhibitoire concentratie (MIC) van 1 mg/L gelden 
(Nederland), te voorkomen. Het percentage morbide obese patiënten die gedurende 
240 minuten onderhuidse ongebonden cefazoline concentraties boven hogere MIC 
waarden (bijvoorbeeld 2 of 4 mg/L) halen, nam sterk af in vergelijking met niet­obese 
patiënten (Tabel 3 en Figuur 4 van Hoofdstuk 4).
Op basis van deze studie kan worden geconcludeerd dat de verdeling van cefazoline 
naar het onderhuidse vetweefsel in morbide obese patiënten is afgenomen in vergelij­
king met niet­obese patiënten, dat de weefselpenetratie van cefazoline afneemt met 
toenemend gewicht en dat er aanpassingen in de dosering nodig zijn voor morbide 
obese patiënten (zie het doseeradvies voor cefazoline in Appendix I).
Invloed vAn MorbIde obesItAs en een MAAGverkleInInGsoPerAtIe oP 
de fArMACokInetIek vAn het CYP3A substrAAt MIdAzolAM
Het literatuuroverzicht van Hoofdstuk 2 geeft aan dat CYP3A gemedieerde klaring 
mogelijk lager is in individuen met (morbide) obesitas. Om dit nader te onderzoeken, 
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had hoofdstuk 5 tot doel om de farmacokinetiek van midazolam in morbide obese 
patiënten versus niet­obese gezonde vrijwilligers na orale en intraveneuze toediening 
te onderzoeken 19.
Midazolam is een veelgebruikt geneesmiddel voor sedatie bij korte ingrepen of op 
de intensive care afdeling. Het wordt voor het overgrote deel door het CYP3A enzym 
in 1­OH­midazolam omgezet en wordt om deze reden als ‘probe substraat’ voor de 
activiteit van het CYP3A enzym systeem beschouwd 20. Het CYP3A enzym bevindt zich 
zowel in de lever als in de darmwand waardoor het bij zowel de klaring (via de lever) als 
de orale biologische beschikbaarheid (via de darmwand) van midazolam betrokken is.
In deze klinische studie namen 20 morbide obese patiënten met een gemiddeld 
lichaamsgewicht van 144 kg (minimum ­ maximum, 112–186 kg) en een gemiddeld BMI 
van 47 kg/m2 (minimum ­ maximum, 40–68 kg/m2) deel. Alle patiënten kregen 7,5 mg 
orale midazolam dosis en een 5 mg intraveneuze dosis toegediend met een interval 
van 159 ± 67 minuten. Daarbij was er data van 12 gezonde vrijwilligers beschikbaar 
voor een gezamenlijke populatie farmacokinetiek analyse met behulp van NONMEM. 
Het uiteindelijke populatie farmacokinetiek model liet zien dat er geen verschil is in de 
klaring (CL) van midazolam in morbide obese patiënten versus gezonde vrijwilligers 
(0.36 (4 %) L/min), terwijl de orale biologische beschikbaarheid (F) hoger was in morbide 
obese patiënten in vergelijking met gezonde vrijwilligers (60 % (13 %) versus 28 % (7 %), 
p<0.001). Verder toonde deze studie aan dat de centrale en perifere verdelingsvolumes 
van midazolam substantieel toenamen met lichaamsgewicht (beide p<0.001).
Op basis van deze resultaten, kan worden geconcludeerd dat midazolam klaring 
onveranderd is in morbide obese patiënten, terwijl de orale biologische beschikbaar­
heid is verhoogd. Vanwege de grote toename van het verdelingsvolume van midazolam 
in morbide obese patiënten, moet er rekening worden gehouden met een aanpassing 
van de intraveneuze toediening van midazolam (zie het doseeradvies in Appendix I). 
Toekomstig onderzoek moet aantonen welke fysiologische veranderingen in de lever en 
darm bijdragen aan onze observaties ten aanzien van, respectievelijk, de onveranderde 
klaring en verhoogde biologische beschikbaarheid van CYP3A substraat midazolam in 
morbide obese patiënten.
Naast de invloed van morbide obesitas op de farmacokinetiek van het CYP3A substraat 
midazolam, is de invloed van een bariatrische operatie, en het daarmee gepaard gaande 
verlies in lichaamsgewicht, onderzocht. Voor dit doel zijn de morbide obese patiënten 
uit de studie van Hoofdstuk 5 één jaar nu hun bariatrische ingreep uitgenodigd om deel 
te nemen aan het tweede deel van het onderzoek. De uitkomsten van dit tweede deel 
zijn gerapporteerd in hoofdstuk 6 21.
Van de 20 morbide obese patiënten (144 ± 22 kg), die deelnamen aan de studie in 
Hoofdstuk 5, namen 18 patiënten (gemiddeld gewichtsverlies van 45 ± 10 kg) opnieuw 
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deel aan het onderzoek één jaar na de operatie. De patiënten kregen opnieuw een 7,5 
mg tablet midazolam en een 5 mg intraveneuze dosis toegediend met een interval van 
gemiddeld 160 ± 48 minuten. Met behulp van populatie farmacokinetiek modelleren 
werd gevonden dat de plasmaklaring (CL) van midazolam een jaar naar de bariatrische 
operatie, hoger was in vergelijking met ervoor (0.65 (7%) versus 0.39 (11%) L/min, 
respectievelijk, p<0.01). Verder werd gevonden dat de gemiddelde orale opname duur 
(orale absorptie) van midazolam sneller was na een bariatrische operatie (23 (20%) 
versus 51 (15%) minuten, p<0.01) en dat de orale biologische beschikbaarheid (F) on­
veranderd was (0.54 (9%)) in vergelijking met vóór de operatie. Het centrale en perifere 
verdelingsvolume van midazolam waren over het algemeen lager in patiënten na een 
bariatrische ingreep dan vóór de ingreep (p<0.05).
Uit deze studie kan geconcludeerd worden dat patiënten na een bariatrische ingreep 
een 1,7 keer verhoogde midazolam klaring (CL) hebben in vergelijking met vóór de 
ingreep. Dit kan mogelijk verklaard worden door een toename van activiteit van het 
CYP3A enzym systeem en/of een verbetering van de lever doorbloeding. Verder kan 
worden geconcludeerd dat hoewel de orale opname duur sneller was, de biologische 
beschikbaarheid (F) van midazolam onveranderd was na een bariatrische ingreep. Deze 
laatste uitkomst in combinatie met een verhoogde klaring (CL) wijst mogelijk op een 
verhoging van de fractie van de midazolam dosis die ontsnapt aan het CYP3A metabo­
lisme in de darmwand (FG).
Op basis van de uitkomsten van Hoofdstuk 6 wordt verondersteld dat de fractie van 
de midazolam dosis die ontsnapt aan het CYP3A metabolisme in de darmwand (FG) 
verhoogd is in patiënten na een bariatrische operatie in vergelijking met morbide 
obese patiënten vóór een dergelijke operatie. Kennis omtrent de precieze invloed van 
een bariatrische ingreep op de CYP3A activiteit in de lever en darmwand (en dus op 
de fractie van een geneesmiddel dat ontsnapt aan het lever (FH) en darmwand meta­
bolisme (FG ), respectievelijk) kan van grote waarde zijn voor andere geneesmiddelen, 
aangezien ongeveer 30% van alle geneesmiddelen via het CYP3A enzym systeem 
worden gemetaboliseerd 22. Om deze reden hadden we in hoofdstuk 7 het doel om de 
farmacokinetiek van zowel midazolam als zijn CYP3A metaboliet, 1­OH­midazolam, na 
orale en intraveneuze toediening te beschrijven in morbide obese patiënten vóór en na 
een bariatrische operatie 23.
Voor deze studie werd een semi­fysiologisch gebaseerd farmacokinetiek (semi­PBPK) 
model toegepast. In dit model werd met het CYP3A omzetting van midazolam naar 
1­OH­midazolam in zowel de darmwand als in de lever rekening gehouden. Met het 
semi­PBPK model werd gevonden dat intrinsieke leverklaring (CLint lever) in patiënten na 
een bariatrische ingreep 1,5 keer hoger is in vergelijking met morbide obese patiënten 
vóór de operatie (p<0.01). Dit leidt tot een lagere FH van midazolam voor bariatrische 
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patiënten. Daarentegen liet de intrinsieke midazolam klaring in de darmwand (Clint 
darmwand) een trend van lagere waarden zien in bariatrische patiënten in vergelijking met 
morbide obese patiënten. Hoewel vermeld moet worden dat de CLint darmwand  voor beide 
groepen erg laag was. Deze lage CLint darmwand waarden resulteerden in FG waarden van 
bijna 1 voor beide patiënten groepen, terwijl met name de morbide obese patiënten 
grote inter­individuele variabiliteit lieten zien.
De resultaten van dit model zijn vervolgens gebruikt om inzicht te krijgen in hoeverre 
deze uitkomsten ook van toepassing zijn op andere CYP3A substraat geneesmiddelen met 
behulp van simulaties met het software pakket SimCYP 24. In de morbide obese patiënten 
populatie van het software pakket SimCYP werd de CYP3A hoeveelheid in de lever 1,5 
vergroot, om de gevonden 1,5 keer verhoogde intrinsieke midazolam leverklaring na te 
bootsen. Voor de CYP3A substraten ciclosporine, alprazolam en triazolam (alle drie met 
een lage lever extractie ratio) resulteerde dit in een verhoging van de plasmaklaring tus­
sen de 1,30­1,41. Voor midazolam (met een middelmatig lever extractie ratio geneesmid­
del) resulteerde deze verhoging in slechts een 1,22 keer toename van de plasmaklaring. 
Deze factor van 1,22 is lager dan de 1,7 keer verhoogde plasma klaring welke we vonden 
in Hoofdstuk 6. Dit kan verklaard worden door het feit dat de klaring van midazolam niet 
alleen door de activiteit van het CYP3A enzym systeem in de lever wordt bepaald, maar 
ook door een ander proces (bijvoorbeeld de mate van bloedstroom door de lever).
De resultaten van Hoofdstuk 7 in combinatie met de uitkomsten van Hoofdstuk 5 en 6 
zijn samengevat in Figuur 1. In dit figuur worden de midazolam plasma klaring (CLplasma) 
en de intrinsieke bloedklaringen van de lever (CLint lever) en de darmwand (Clint darmwand) van 
morbide obese patiënten (middelste kolom) vergeleken met die van gezonde vrijwilligers 
(linker kolom) en patiënten één jaar na een bariatrische operatie (rechter kolom). Het figuur 
laat zien dat de verhoging van de midazolam plasma klaring (CLplasma) na een bariatrische 
operatie niet alleen verklaard wordt door een normalisatie van de eerder verlaagde CYP3A 
activiteit in de lever (vanwege morbide obesitas), maar dat er ook een niet­CYP3A gere­
lateerd proces bijdraagt aan deze verhoging in de midazolam plasma klaring (Hoofdstuk 
6) 25. Dit andere proces zou een verhoogde bloedstroom door de lever (QH) of verhoogde 
doorbloeding van de lever kunnen zijn. Een verhoogde lever bloedstroom in morbide 
obese patiënten in vergelijking met gezonde vrijwilligers kan mogelijk ook de gelijke 
midazolam plasma klaring in deze beide groepen verklaren (Hoofdstuk 5 en Figuur 1) 19.
Op basis van de studie in Hoofdstuk 7 kan worden geconcludeerd dat een semi­PBPK 
model midazolam en 1­OH­midazolam concentraties over de tijd adequaat kan beschrij­
ven na zowel orale als intraveneuze dosis. Met behulp van dit model werd aangetoond 
dat in bariatrische patiënten de intrinsieke metabole CYP3A capaciteit van de lever 
hoger is dan in morbide obese patiënten vóór de operatie. De CYP3A capaciteit van de 
darmwand, daarentegen, liet in bariatrische patiënten een trend van lagere waarden 
zien, mogelijkerwijs door de 75­150 cm omlegging van het eerste deel van de darm.
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PersPeCtIeven en ConClusIes
In dit proefschrift zijn twee geneesmiddelen bestudeerd in morbide obese patiënten 
en patiënten na een bariatrische operatie door middel van de uitvoer van adequate 
klinische studies. Deze studies hebben geleid tot wetenschappelijk onderbouwde do­
seeradviezen voor cefazoline en midazolam in deze patiëntengroepen (zie Appendix I).
Het zal zeer tijdrovend en kostbaar zijn om op deze wijze voor elk geneesmiddel 
afzonderlijk wetenschappelijk onderbouwde doseeradviezen te ontwikkelen. Daarom is 
het een interessante vraag hoe we dit proces kunnen versnellen. Een methode is om te 
inventariseren of de farmacokinetiek modellen die we per geneesmiddel hebben ontwik­
keld, informatie bevatten die specifiek is voor de onderzochte populatie, zogenaamde 
systeem specifieke informatie (bijvoorbeeld een veranderde CYP3A activiteit in de lever 
in patiënten met toenemende obesitas). Dergelijk systeem specifieke informatie kan 
vervolgens gebruikt worden voor het voorspellen van de farmacokinetiek voor andere 
(nog niet onderzochte) geneesmiddelen (die bijvoorbeeld ook via het CYP3A enzym 

















Een afname in CYP3A activiteit in de 
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wordt mogelijk gecompenseerd door 
een toename in de lever bloedstroom. 
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onveranderde plasma klaring.
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de verhoogde bloedstroom door de 
darm villi en/of verhoogde
doorlaatbaarheid van de darm.
Deze verhoging wordt verklaard door 
een toename van eerder verlaagde
CYP3A activiteit in de lever en
mogelijk ook door een verhoging van 








metabolisme in de 
lever gevonden, 
mogelijk door de 
lagere
inflammatoire
status van de lever 
28.
Een trend richting lagere intrinsieke klaring
van midazolam in de darmwand is mogelijk





figuur 1 Een overzicht van de resultaten van midazolam plasmaklaring (CLplasma (L/min)), intrinsieke bloe­
dklaring in de darmwand (CLint darmwand (L/min)) en intrinsieke bloedklaring in de lever (CLint lever (L/min)) in 
morbide obese patiënten in vergelijking met (niet­obese) gezonde vrijwilligers en bariatrische patiënten. 
Dit zijn de resultaten uit Hoofdstuk 5, 6 en 7 26­28. De grijze pijlen geven de richting van vergelijking aan.
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voor UGT2B7 glucuronidering en renale (nier) klaring in kinderen 29­35. In Hoofdstuk 
2 hebben we voor obese patiënten geprobeerd eenzelfde aanpak toe te passen met 
behulp van een literatuuroverzicht. Dit overzicht wijst inderdaad op coherente trends 
qua invloed van obesitas per metabole of eliminatie route.
In dit proefschrift vonden we geen invloed van lichaamsgewicht op de klaring van 
cefazoline (Hoofdstuk 4), wat voornamelijk via glomerulaire filtratie en actieve tubulaire 
excretie in de nieren wordt uitgescheiden 15, 18. Deze bevindingen komen overeen met 
de algemene trend voor glomerulaire filtratie uit het literatuuroverzicht van Hoofdstuk 
2, waarin glomerulaire filtratie een kleine verhoging of geen verandering laat zien onder 
invloed van obesitas.
Wat betreft midazolam suggereert het overzicht van Hoofdstuk 2 dat het genees­
middelmetabolisme via CYP3A in de lever is verlaagd in patiënten met obesitas. Dit is 
met name gebaseerd op de orale klaring waarden (CL/F) van CYP3A geneesmiddelen 
gevonden uit eerdere studies in obese versus niet­obese patiënten. In de studie van 
Hoofdstuk 5 met het CYP3A substraat midazolam, vonden we geen verschil in mida­
zolam klaring (CL) tussen morbide obese patiënten en gezonde vrijwilligers, maar wel 
een hogere biologische beschikbaarheid (F) in morbide obese patiënten (60 versus 28% 
respectievelijk). Dit resulteert dus inderdaad in een sterk afgenomen orale klaring (CL/F) 
van midazolam in morbide obese patiënten, zoals gesuggereerd in het overzicht van 
Hoofdstuk 2. Onze resultaten komen overeen met eerder studies en dus kunnen we 
stellen dat uitkomsten voor één geneesmiddel voorspellend lijken te zijn voor andere 
geneesmiddelen die dezelfde klaring route hebben (zie ook Hoofdstuk 7).
In tegenstelling tot de resultaten voor klaring (CL), werd er een sterke invloed van 
lichaamsgewicht gevonden op het verdelingsvolume (V) van cefazoline en midazolam 
(Hoofdstuk 4 en 5) in morbide obese patiënten. Om de invloed van obesitas op het 
verdelingsvolume van een geneesmiddel beter op voorhand te kunnen voorspellen, 
lijken fysiologische gebaseerde farmacokinetiek modellen van grote waarde te kunnen 
zijn. In fysiologische gebaseerde farmacokinetiek (PBPK) modellen wordt rekening ge­
houden met de eigenschappen van een geneesmiddel (o.a. log D, eiwitbinding, weefsel 
partitie coëfficiënten, etc.) en die van het systeem (bijvoorbeeld de bloedstroom door 
de organen en de organengroottes in het lichaam van een morbide obese patiënt). Op 
dit moment zijn er verschillende software pakketten beschikbaar met dergelijke PBPK 
modellen, onder andere SimCYP 24, 36, en de voorspellende waarde van deze modellen 
op het gebied van het verdelingsvolume in morbide obese patiënten dient onderzocht 
te worden. Dergelijk concepten en PBPK modellen kunnen ook worden toegepast voor 
patiënten die een bariatrische operatie hebben ondergaan. Hoewel er al enkele stap­
pen in deze richting zijn gemaakt 37 is er nog een groot tekort aan kennis en informatie 
rondom deze patiënten. Daarom zal deze integrale aanpak in nauwe samenwerking 
moeten plaatsvinden met groepen die klinische studies in morbide obese patiënten en 
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bariatrische patiënten uitvoeren. Op die manier kunnen de PBPK modellen van meer 
informatie worden voorzien, waardoor het voorspellend vermogen van deze modellen 
wordt verbeterd.
In de toekomst blijft het uitvoeren van klinische studies naar geneesmiddelendose­
ringen in morbide obese patiënten en bariatrische patiënten dus essentieel. Op basis 
van onder andere onze ervaringen met de verschillende onderzoeken in dit proefschrift 
komen we tot een aantal adviezen voor toekomstige klinische studies in morbide obese 
en bariatrische patiënten.
Ten eerste is het belangrijk dat er naast geneesmiddel concentraties (farmacokine­
tiek) ook gegevens over klinische effecten (farmacodynamiek) worden verzameld. Ten 
tweede adviseren we de fysiologische eigenschappen in kaart te brengen van zowel 
obese als bariatrische patiënten (hartminuut volume, bloedstromen door organen, etc.), 
zodat PBPK modellen kunnen worden verbeterd. Ten derde adviseren we om, indien 
mogelijk, de farmacokinetiek en farmacodynamiek van een geneesmiddel na zowel 
orale als intraveneuze toediening te bestuderen. Daardoor kunnen de klaring (CL), het 
verdelingsvolume (V) en de biologische beschikbaarheid (F) van een geneesmiddel 
onafhankelijk van elkaar bepaald worden waardoor deze gegevens mogelijk ook voor 
andere geneesmiddelen kunnen worden gebruikt. Tenslotte adviseren we om in nieuwe 
studies in obese patiënten te streven naar een zo groot mogelijke variatie aan patiënten 
van overgewicht (BMI>25) tot en met super obesitas (BMI> 60) en, in het geval van ba­
riatrische patiënten, een zo groot mogelijke variatie in tijd na operatie (>1 maand ­ >10 
jaar) en type bariatrische operatie. Op deze manier zal de relatie tussen een covariaat, 
zoals lichaamsgewicht, ‘mate van obesitas’ of ‘type bariatrische ingreep’, op bijvoorbeeld 
het verdelingsvolume van een geneesmiddel beter in kaart kunnen worden gebracht. 
Op basis van deze concepten verwachten we sneller te komen tot wetenschappelijk 
onderbouwde doseeradviezen voor alle geneesmiddelen voor obese en bariatrische 
patiënten.
Kortom, de meest efficiënte weg naar wetenschappelijk onderbouwde doseeradviezen 
in morbide obese patiënten en patiënten na een bariatrische operatie is om goed op­
gezette klinische studies uit te voeren waarin wordt onderzocht of systeem specifieke 
eigenschappen van de populatie kunnen worden afgeleid. Vervolgens moet worden 
bestudeerd of deze systeem specifieke gegevens de invloed van morbide obesitas en 
een bariatrische operatie op andere geneesmiddelen kan voorspellen.
Om dit doel te bereiken dienen er klinische studies worden uitgevoerd met een wijd 
bereik aan patiënten: van overgewicht (BMI>25 kg/m2) tot en met super obesitas (BMI 
100+ kg/m2) en, in het geval van bariatrische patiënten, verschillende typen bariatrische 
ingrepen en verschillende periodes na een ingreep. Verder is het belangrijk dat er bin­
nen deze klinische onderzoeken geneesmiddelconcentraties over de tijd (farmacokine­
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tiek), klinische effecten (farmacodynamiek) en fysiologische parameters (bijvoorbeeld 
bloedstromen door organen, eiwit binding, etc.) worden gemeten. Tenslotte dienen er 
PBPK(­PD) modellen ontwikkeld te worden welke in staat zijn om de farmacokinetiek en 
fysiologische gegevens, en mogelijk ook de farmacodynamische gegevens te integreren. 
Dergelijke geïntegreerde modellen zullen de voorspelling van de invloed van (morbide) 
obesitas en bariatrische operatie op nog niet bestudeerde geneesmiddelen verbeteren 
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Based on the results of the studies in this thesis together with other relevant studies 
currently available in the literature, evidence­based dosing guidelines for morbidly 
obese patients and in case of midazolam also for bariatric patients can be composed. 
A dosing advice monograph consists of a discussion of the relevant available literature 
(evidence) and a proposed dosing advice. Then, these monographs should be discussed 
by an expert panel consisting of clinical pharmacologists, hospital pharmacists and 
medical specialists (expert opinion). After finishing this process, the final dosing advice 
can be included in the Informatorium Medicamentorum of the knowledge center of the 
Royal Dutch Society for Pharmacy (KNMP), which can be accessed by Dutch pharmacists 
and physicians. For the drugs studied in this thesis, monographs were prepared and are 
presented below in a summarized version.
I.1 CefAzolIn In MorbIdlY obese PAtIents
Advice
For prophylaxis in morbidly obese patients (BMI>40 kg/m2) in the Netherlands, 2 grams 
of cefazolin will lead to adequate subcutaneous ISF levels for a minimal inhibitory con­
centration (MIC) of 1 mg/L. Repeat this dose after 4 hours in case the surgical procedures 
lasts longer than 4 hours. This dosing advice is based on patients with a body weight 
range of 107 kg tot 175 kg (BMI 40 kg/m2 tot 57 kg/m2) 1.
discussion
This advice is based on Chapter 4 and three other studies on the pharmacokinetics and/
or pharmacodynamics of cefazolin in (morbidly) obese patients 1­4. To evaluate the influ­
ence of morbid obesity on cefazolin target site concentrations in Chapter 4 unbound 
cefazolin concentrations at the interstitial space fluid (ISF) of the subcutaneous adipose 
tissue were measured using microdialysis. It was found that cefazolin subcutaneous 
tissue penetration is reduced in morbidly obese patients in comparison to non­obese 
patients. Using Monte Carlo simulations it was shown that unbound ISF cefazolin will 
remain above 1 mg/L until 120 minutes post dose in morbidly obese patients (see Fig­
ure 4 in Chapter 4). However, in case higher MIC values apply (2 or 4 mg/L), unbound 
ISF cefazolin concentrations will drop below the MIC values faster than in non­obese 
patients and redosing or increasing the initial cefazolin dose may be necessary 1.
While it has been suggested before that a dose of 1 gram cefazolin as prophylaxis is 
inadequate for the prevention of surgical site infections in morbidly obese patients 4, 
Edmiston et al. measured active cefazolin concentrations in 3 patient groups (A=BMI 
40­50; B=BMI50­60 en C=BMI>60 kg/m2) after a cefazolin 2 gram intravenous dose and 
an additional dose after 3 hours in tissue biopsies at closure of the surgical wound. They 
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reported that 48.1%, 28.6% en 10.2% of the active cefazolin concentrations of Group A, B 
and C, respectively, reached an MIC > 8 μg/mg 3. However, these results cannot be easily 
extrapolated to the Dutch (and European) situation, while in the Netherlands generally 
an MIC90 of 1 mg/L is considered (MIC at which 90% of all s. aureus species is susceptible 
to cefazolin 1 mg/L). In addition, the American guideline advises a prophylactic cefazolin 
dose of 2 gram for patients  >80 kg and 3 grams for patients  >120 kg 5. This advice is 
mainly supported by studies applying MIC values of 4 and 8 mg/L and the consideration 
that cefazolin is inexpensive and well­tolerated. As mentioned before, due to the differ­
ent MIC values applied, this advice may not be applicable for the Dutch (and European) 
situation.
In conclusion, based on these studies a 2 gram cefazolin prophylactic dose is sufficient 
for morbidly obese patients in the Netherlands in case of an MIC of 1 mg/L. As these 
studies predominantly involved morbidly obese patients, it remains unclear how cefazo­
lin should be dosed in overweight and obese patients.
I.2 MIdAzolAM In obese And MorbIdlY obese PAtIents
Advice based on pharmacokinetic considerations only
First of all, midazolam half­life in (morbidly) obese patients strongly increases with body 
weight, which may cause midazolam effect to last longer. This is particularly important 
to consider for intravenous administration of midazolam.
­ Oral dose administration: Same dose as in non­obese adults (Figure 4 of Chapter 5).
­ Intravenous bolus dose: To reach the same maximum concentration as in non­obese 
health volunteers, for (morbidly) obese patients total body weight should be used 
(calculate dose based on mg/kg dose * total body weight) for a mg/kg dose that 
would be used in a non­obese patient, see Figure 1a
­ Intravenous continuous infusion: For a morbidly obese patient the body weight of a 
non­obese individual (i.e. 75 kg) can be used for an mg/kg dose that would be used 
for non­obese patients. To reach steady state concentration with in approximately 1 
hour, higher infusion rates should be applied, see Figure 1b.
discussion
In addition to the study of Chapter 5, one other study evaluated the pharmacokinetics of 
midazolam in (morbidly) obese patients after both oral and intravenous administration 7. 
In both studies parameters estimates for the obese and non­obese study population, for 
midazolam central volume of distribution (mean of 44 L vs 21 L in Brill et al. and 58 L 
vs 38 L in Greenblatt et al., respectively), total volume of distribution (322 L versus 78 
L 6 and 311 L vs 114 L7) and systemic clearance (0.36 vs 0.36 L/min 6 and 0.47 vs 0.53 L/
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min 7) were in good agreement. However, the estimates for oral bioavailability (F) differed 
between the studies. Brill et al. found an oral bioavailability of 60% versus 28% (p<0.001) 
and Greenblatt et al. of 42% versus 40% (p>0.05). This difference may be explained by the 
studied population, i.e. the mean body weight of the obese population of Greenblatt et 
al. was 117 ± 8 kg (n=20) in comparison to 144 ± 22 kg (n=20) for Brill et al.
Due to the substantial increase of volume of distribution with body weight, one should 
consider a strong increase in the midazolam half­life in (morbidly) obese patients which 
may cause midazolam effects to last longer than in non­obese patients. The increased 
half­life also significantly prolongs the time to reach the steady state concentration in 
(morbidly) obese patients. For this reason, for midazolam continuous infusion, initially 
higher infusion rates are advised based on dose simulations. For a 145 kg patient, higher 
infusion rates for a period of 8 hours are proposed to reach the steady state concentra­
tion with 1 hour (Figure 1). For non­obese healthy volunteers, a higher infusion rate for 
the duration of 2 hours is needed to reach steady state concentration within 1 hour.
Finally, it should be noted that the midazolam dosing advice is based on midazolam 
concentration­time data, while midazolam effects (sedation) have not been included in 
these studies. Although, no studies have looked into the concentration­effect relation­
ship for midazolam in (morbidly) obese patients, a clear concentration effect relation­







































figure 1 Simulated midazolam concentration time profiles for three morbidly obese patients of 112, 145 
and 186 kg and one non­obese healthy volunteer of 76 kg after receiving:
(a) a 0.1 mg/kg total body weight (TBW) intravenous bolus dose (the concentration at T=5 minutes is 247 
ng/ml for 76 kg; 236 ng/ml for 112 kg; 233 ng/ml for 145 kg; 229 ng/ml for 186 kg), (b) a continuous in­
travenous infusion of 2.5 mg/h (0,033 mg/kg/h*75kg) for the duration of 72 hours + a temporarily higher 
infusion rate to reach the steady state concentration within 1 hour (76 kg: 1h 7.5 mg/h, 1h 5 mg/h, 70h 2.5 
mg/h; 112 kg: 1h 15 mg/h, 2h 7.5 mg/h, 2h 5 mg/h, 67h 2.5 mg/h; 145 kg: 2h 15 mg/h, 2h 10 mg/h, 2h 7.5 
mg/h, 2h 5 mg/h, 64h 2.5 mg/h, 186 kg: 4h 15 mg/h, 3h 10 mg/h, 3h 7.5 mg/h, 2h 5 mg/h, 60h 2.5 mg/h). The 
simulations have be executed based on the population pharmacokinetic model by Brill et al.6
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I.3 MIdAzolAM In GAstrIC bYPAss PAtIents
Advice based on pharmacokinetic considerations only
­ Oral dose administration: The same total dose in mg as in non­obese adults. Be aware 
of a decreased time to maximum concentration (Tmax) and increased maximum con­
centration (Cmax) in comparison to morbidly obese and matched control patients. In 
addition, midazolam effect will have shorter duration due to increased midazolam 
systemic clearance of which the clinical relevance is unclear (see Figure 3 of Chapter 
6).
­ Intravenous bolus dose: Dose based on mg/kg total body weight (TBW). Be aware 
of more rapid decrease in effect due to increased midazolam systemic clearance in 
gastric bypass patients, see Figure 2a.
­ Intravenous continuous infusion: To reach a similar steady state concentration as in 
morbidly obese patients, a higher infusion rate should be applied since the level 
of the steady state concentration is determined by midazolam clearance (which is 
increased). In gastric bypass patients midazolam clearance was 1.68 times higher in 
comparison to morbidly obese and control patients (therefore, calculate the dose 
based on: mg/kg* 75 kg/hour *1.68), see Figure 2b.
discussion
Clinical studies into the PK of midazolam show that after a gastric bypass, oral absorp­
tion rate is increased, oral bioavailability is similar and systemic clearance substantially 
increases in comparison to morbidly obese and matched control patients 10­12. Based 
on these studies the above midazolam dosing advice is defined. There are several im­
portant factors which need to be considered when adjusting the midazolam dose for 
gastric bypass patients. Firstly, it is important to know exactly what type of bariatric 
surgery a patient underwent. There are several types of bariatric surgery (as described 
in the introduction of this thesis) of which each may have a different effect on the PK 
of midazolam (and thus a different consequence for dosing). The advice defined here 
is based on studies which predominantly included patients after a Roux­ and Y gastric 
bypass (RYGB). In the study described in Chapter 6 also two gastric sleeve patients were 
included 10, and therefore potentially, for this group the same midazolam dosing advice 
may be applied. Secondly, it should be noted that it remains unclear how the pharmaco­
kinetics of midazolam changes over the course of time after a gastric bypass procedure. 
Possibly, there is a difference in midazolam PK in patients shortly after versus 10 year 
after a gastric bypass procedure, because some sort of adaption may occur. The studies 
included in this monograph investigated patients on average 1­1.9 year after a gastric 
bypass and no further studies are currently available. Finally, this midazolam dosing 
advice is based on two studies in which midazolam PK was compared with morbidly 
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obese patients before the surgery 10 and matched control individuals 11. Until now, no 
studies have directly compared midazolam PK in gastric bypass patients with non­obese 
































200 Morbidly obese patient (145 kg) 10
Bariatric patient (98 kg) 10
Healthy volunteer (76 kg) 6
a b
figure 2 Simulated midazolam concentration­time profiles in a patient after a bariatric surgery, a 145 kg 
morbidly obese patients 10 and a healthy volunteer (76 kg) 6 after:
(a) an intravenous bolus dose of 0.1 mg/kg (7.5 mg for a healthy volunteer, 14.5 mg for a morbidly obese 
patients of 145 kg and 9.8 mg/kg for a bariatric patients of 98 kg). At T=5 minutes post dose midazolam 
concentrations are: 247 ng/ml, 194 ng/ml en 175 ng/ml, respectively. (b) a continuous intravenous infusion 
during 72 hours with temporarily higher infusion rates to quickly reach steady state concentration. (Bar­
iatric patient: 1h 15 mg/h, 1h 10 mg/h, 70h 4.2 mg/h; healthy volunteer of 76 kg: 1h 7.5 mg/h, 1h 5 mg/h, 
70h 2.5 mg/h; morbidly obese patient of 145 kg: 2h 15 mg/h, 2h 10 mg/h, 2h 7.5 mg/h, 2h 5 mg/h, 64h 2.5 
mg/h). Simulations have been executed based on the population PK models from Brill et al. 6, 10.
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